Helix (HLIX) 10-K 30 Mar 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 24, 2020	Jun. 30, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	Helix TCS, Inc.
Entity Central Index Key	0001611277
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity File Number	000-55722
Entity Shell Company	false
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	DE
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		95,279,713
Entity Public Float			$ 18,528,165
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash	$ 652,524	$ 285,761
Accounts receivable, net	1,879,722	1,184,923
Prepaid expenses and other current assets	737,159	409,800
Costs & earnings in excess of billings	257,819	42,869
Total current assets	3,518,224	1,923,353
Property and equipment, net	805,679	349,518
Intangible assets, net	14,395,287	18,604,078
Goodwill	53,716,207	39,913,559
Deposits and other assets	1,172,600	146,990
Promissory note receivable	75,000
Total assets	73,682,997	60,937,498
Current liabilities:
Accounts payable and accrued liabilities	3,263,146	1,702,713
Advances from related parties		45,250
Billings in excess of costs	164,663	155,192
Deferred rent		2,937
Notes payable, current portion	24,805	24,805
Obligation pursuant to acquisition	50,000	201,667
Convertible notes payable, net of discount	832,492	187,177
Convertible notes payable, net of discount - related party	1,584,360
Due to related party		32,489
Contingent consideration		908,604
Warrant liability	715,259	896,171
Promissory notes	300,000
Total current liabilities	6,934,725	4,157,005
Long-term liabilities:
Notes payable, net of current portion	433,087	51,554
Convertible notes payable, net of current portion and discount	385,000
Other long-term liabilities	783,230
Total long-term liabilities	1,601,317	51,554
Total liabilities	8,536,042	4,208,559
Shareholders’ equity:
Common stock; par value $0.001; 200,000,000 shares authorized; 93,608,619 shares issued and outstanding as of December 31, 2019; 72,660,825 shares issued and outstanding as of December 31, 2018	93,608	72,660
Additional paid-in capital	100,906,143	82,831,014
Accumulated other comprehensive (loss) income	(79,901)	17,991
Accumulated deficit	(35,787,679)	(26,207,510)
Total shareholders’ equity	65,146,955	56,728,939
Total liabilities and shareholders’ equity	73,682,997	60,937,498
Preferred Stock (Class A) [Member]
Shareholders’ equity:
Preferred stock value	1,000	1,000
Total shareholders’ equity	1,000	1,000
Preferred Stock (Class B) [Member]
Shareholders’ equity:
Preferred stock value	13,784	13,784
Total shareholders’ equity	$ 13,784	$ 13,784

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	93,608,619	72,660,825
Common stock, shares outstanding	93,608,619	72,660,825
Preferred Stock (Class A) [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued	1,000,000	1,000,000
Preferred stock, shares outstanding	1,000,000	1,000,000
Preferred Stock (Class B) [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	17,000,000	17,000,000
Preferred stock, shares issued	13,784,201	13,784,201
Preferred stock, shares outstanding	13,784,201	13,784,201

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue:
Total revenues	$ 15,292,100	$ 9,563,573
Cost of revenue	8,178,137	5,969,039
Gross margin	7,113,963	3,594,534
Operating expenses:
Selling, general and administrative	4,111,085	2,491,518
Salaries and wages	5,739,783	5,810,594
Professional and legal fees	2,682,626	2,263,212
Depreciation and amortization	4,778,334	3,086,531
Loss on impairment of Goodwill		664,329
Total operating expenses	17,336,828	14,316,184
Loss from operations	(10,222,865)	(10,721,650)
Other income (expenses):
Change in fair value of convertible note	496,790	450,216
Change in fair value of convertible note - related party	(283,453)	93,506
Change in fair value of warrant liability	3,812,977	1,641,398
Change in fair value of contingent consideration	(880,050)	(131,306)
(Loss) gain on issuance of warrants	(825,098)	91,778
Gain on reduction of obligation pursuant to acquisition		607,415
Interest expense	(1,695,149)
Other income	16,679	2,841
Other income	642,696	2,755,848
Net loss	(9,580,169)	(7,965,802)
Other comprehensive (loss) income:
Changes in foreign currency translation adjustment	(97,892)	17,991
Total other comprehensive (loss) income	(97,892)	17,991
Total comprehensive loss	(9,678,061)	(7,947,811)
Convertible preferred stock beneficial conversion feature accreted as a deemed dividend		(22,202,194)
Net loss attributable to common shareholders	$ (9,653,061)	$ (30,150,005)
Net loss per share attributable to common shareholders:
Basic	$ (0.12)	$ (0.56)
Diluted	$ (0.12)	$ (0.56)
Weighted average common shares outstanding:
Basic	80,206,895	53,777,343
Diluted	80,206,895	53,777,343
Security and guarding [Member]
Revenue:
Total revenues	$ 5,022,436	$ 4,889,472
Systems installation [Member]
Revenue:
Total revenues	783,192	499,138
Software [Member]
Revenue:
Total revenues	$ 9,486,472	$ 4,174,963

Consolidated Statements of Shar

Consolidated Statements of Shareholders’ Equity - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]	Preferred Stock (Class A) [Member]	Preferred Stock (Class B) [Member]	Total
Balance Beginning at Dec. 31, 2017	$ 28,771	$ 18,741,114		$ (18,241,708)	$ 1,000	$ 13,784	$ 542,961
Balance Beginning (in shares) at Dec. 31, 2017	28,771,402				1,000,000	13,784,201
Beneficial conversion feature of Series B convertible preferred stock		22,202,194					22,202,194
Deemed dividend on conversion of Series B convertible preferred stock to common stock		(22,202,194)					(22,202,194)
Issuance of common stock per stock subscription agreements	$ 3,949	3,351,269					3,355,218
Issuance of common stock per stock subscription agreements (in shares)	3,949,997
Issuance of common stock resulting from convertible note conversion	$ 206	174,794					175,000
Issuance of common stock resulting from convertible note conversion (in shares)	205,974
Issuance of restricted common stock	$ 115	134,850					134,965
Issuance of restricted common stock (in shares)	115,000
Reduction in Additional Paid-In Capital due to Security Grade acquisition settlement agreement		(340,039)					(340,039)
Restricted common stock issued as part of BioTrack acquisition	$ 38,185	57,513,848					57,552,033
Restricted common stock issued as part of BioTrack acquisition(in shares)	38,184,985
Restricted common stock issued as part of Engeni acquisition	$ 367	388,335					388,702
Restricted common stock issued as part of Engeni acquisition (in shares)	366,700
Issuance of common stock to employees under Stock Incentive Plan	$ 515	915,968					916,483
Issuance of common stock to employees under Stock Incentive Plan (in shares)	514,945
Grant of an option to purchase common stock		629,200					629,200
Issuance of common stock resulting from inducement of consulting agreement	$ 200	251,800					252,000
Issuance of common stock resulting from inducement of consulting agreement (in shares)	200,000
Issuance of restricted common stock resulting from an investor relation consulting agreement	$ 125	126,875					127,000
Issuance of restricted common stock resulting from an investor relation consulting agreement (in shares)	125,000
Issuance of warrants pursuant to consulting agreement		943,000					943,000
Issuance of common stock resulting from exercise of stock options	$ 227						227
Issuance of common stock resulting from exercise of stock options (in shares)	226,822
Share-based compensation expense							3,002,648
Foreign currency translation			17,991				17,991
Net loss				(7,965,802)			(7,965,802)
Balance Ending at Dec. 31, 2018	$ 72,660	82,831,014	17,991	(26,207,510)	$ 1,000	$ 13,784	56,728,939
Balance Ending (in shares) at Dec. 31, 2018	72,660,825				1,000,000	13,784,201
Issuance of common stock per investment unit agreements	$ 1,422	66,247					67,669
Issuance of common stock per investment unit agreements (in shares)	1,421,889
Issuance of common stock resulting from convertible note conversion	$ 1,031	675,710					676,741
Issuance of common stock resulting from convertible note conversion (in shares)	1,031,315
Issuance of common stock resulting from cashless exercise of stock options	$ 110	(110)
Issuance of common stock resulting from cashless exercise of stock options (in shares)	109,931
Issuance of common stock in satisfaction of contingent consideration	$ 733	1,787,921					1,788,654
Issuance of common stock in satisfaction of contingent consideration(in shares)	733,300
Issuance of common stock resulting from convertible note PIK interest (paid)	$ 187	132,663					132,850
Issuance of common stock resulting from convertible note PIK interest (paid) (in shares)	186,988
Restricted common stock issued as part of Tan Security acquisition	$ 250	709,750					710,000
Restricted common stock issued as part of Tan Security acquisition (in shares)	250,000
Issuance of common stock resulting from exercise of stock options	$ 79	26,534					26,613
Issuance of common stock resulting from exercise of stock options (in shares)	78,644
Restricted common stock issued as part of the Green Tree acquisition	$ 16,766	12,892,845					12,909,611
Restricted common stock issued as part of the Green Tree acquisition (in shares)	16,765,727
Share-based compensation expense	$ 370	1,783,569					1,783,939
Share-based compensation expense (in shares)	370,000
Foreign currency translation			(97,892)				(97,892)
Net loss				(9,580,169)			(9,580,169)
Balance Ending at Dec. 31, 2019	$ 93,608	$ 100,906,143	$ (79,901)	$ (35,787,679)	$ 1,000	$ 13,784	$ 65,146,955
Balance Ending (in shares) at Dec. 31, 2019	93,608,619				1,000,000	13,784,201

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (9,580,169)	$ (7,965,802)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,778,334	3,086,531
Accretion of debt discounts	1,354,689
Loss on issuance of warrants	825,098
Provision for doubtful accounts	357,749
Share-based compensation expense	1,783,939	3,002,648
Change in fair value of convertible notes, net of discount	(496,790)	(450,216)
Change in fair value of warrant Liability	(3,812,977)	(1,533,398)
Change in fair value of convertible notes, net of discount - related party	283,453	(93,506)
Change in fair value of contingent consideration	880,050	131,306
Loss on impairment of goodwill		664,329
Gain on reduction of obligation pursuant to acquisition		(607,415)
Gain on reduction of contingent consideration	(100,000)
Change in operating assets and liabilities:
Accounts receivable	(932,832)	(415,939)
Prepaid expenses and other current assets	(334,627)	(406,997)
Deposits and other assets	65,454	280,703
Due to related party	(32,489)	32,489
Costs & earnings in excess of billings	(214,950)	(2,022)
Accounts payable and accrued expenses	1,684,797	342,733
Deferred rent	(2,937)	(6,730)
Billings in excess of costs	9,471	135,001
Right of use assets and liabilities	65,875
Net cash used in operating activities	(3,418,862)	(3,806,285)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(1,044,457)	(155,559)
Purchase of domain names	(21,856)
Payments for business combination, net of cash acquired	(148,727)
Cash acquired as part of business combination		454,306
Payments for asset acquisition		(58,729)
Net cash (used in) provided by investing activities	(1,215,040)	240,018
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments pursuant to convertible notes payable - related party		(150,000)
Promissory note receivable	(75,000)
Payments pursuant to advances from related parties	(45,250)
Payments pursuant to notes payable	(18,467)	(27,836)
Payments pursuant to a promissory note	(280,000)	(250,000)
Payments pursuant to contingent consideration		(131,331)
Advances from related parties		(79,500)
Proceeds from notes payable		39,723
Proceeds from the issuance of a promissory note	580,000	250,000
Proceeds from the issuance of convertible notes payable	3,745,000
Proceeds from the issuance of common stock	1,306,313	3,355,445
Net cash provided by financing activities	5,212,596	3,006,501
Effect of foreign exchange rate changes on cash	(211,931)	(23,027)
Net change in cash	366,763	(582,793)
Cash, beginning of period	285,761	868,554
Cash, end of period	652,524	285,761
Supplemental disclosure of cash and non-cash transactions:
Cash paid for interest	40,625
Common stock issued pursuant to convertible notes payable	676,741
Debt discount for warrant liability	(1,594,936)
Equity issued pursuant to acquisition	13,619,611	57,940,735
Security Grade acquisition consideration settlement
Cash payable pursuant to acquisition	50,000
PIK interest payment of common stock	132,850
Common stock issued pursuant to contingent consideration as part of acquisition	1,788,654
Supplemental non-cash amounts of lease liabilities arising from obtaining right of use assets	1,485,511
Partial conversion of convertible note into common stock		$ 175,000

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2019
Description of Business [Abstract]
Description of Business	1. Description of Business Helix TCS, Inc. (the "Company" or "Helix") was incorporated in Delaware on March 13, 2014. Pursuant to the acquisition of the assets of Helix TCS, LLC, as discussed below, we changed our name from Jubilee4 Gold, Inc. to Helix TCS, Inc. effective October 25, 2015. Effective October 25, 2015, we entered into an acquisition and exchange agreement with Helix TCS, LLC. We closed the transaction contemplated under the acquisition and exchange agreement on December 23, 2015 and Helix TCS, LLC was merged into and with Helix. Effective October 1, 2015, for accounting purposes, as part of an acquisition amounting to a reorganization dated December 21, 2015, Helix Opportunities LLC exchanged 100% of Helix TCS, LLC and its wholly-owned subsidiaries, Security Consultants Group, LLC and Boss Security Solutions, Inc. to the Company in exchange for 20 million common shares and 1 million convertible preferred shares of the Company. The acquisition of Helix was treated as a recapitalization for financial accounting purposes. Jubilee4 Gold, Inc. is considered the acquiree for accounting purposes and their historical financial statements before the Acquisition Agreement were replaced with the historical financial statements of the Company. The common stock account of the Company continues post-merger, while the retained earnings of the acquiree is eliminated. Furthermore, on April 11, 2016, the Company acquired the assets of Revolutionary Software, LLC ("Revolutionary"). On March 3, 2018, Helix TCS, Inc. and its wholly owned subsidiary, Helix Acquisition Sub, Inc. ("BioTrackTHC Merger Sub"), entered into an Agreement and Plan of Merger (the "BioTrackTHC Merger Agreement") with Bio-Tech Medical Software, Inc. ("BioTrackTHC") and Terence J. Ferraro, as the representative of the BioTrackTHC stockholders, pursuant to which BioTrackTHC Merger Sub merged with and into BioTrackTHC (the "BioTrackTHC Merger"). On June 1, 2018 (the "BioTrackTHC Closing Date"), in connection with closing the BioTrackTHC Merger, the Company issued 38,184,985 unregistered shares of its common stock to BioTrackTHC stockholders, of which 1,852,677 shares were held back to satisfy indemnification obligations in the BioTrackTHC Merger Agreement, if necessary. The Company also assumed the Bio-Tech Medical Software, Inc. 2014 Stock Incentive Plan ("BioTrackTHC Stock Plan"), pursuant to which options exercisable in the amount of 8,132,410 shares of common stock are outstanding. As a result, BioTrackTHC stockholders owned approximately 48% of the Company on a fully diluted basis as of the BioTrackTHC Closing Date. On August 3, 2018 (the "Engeni Closing Date"), the Company and its wholly owned subsidiary, Engeni Merger Sub, LLC ("Engeni Merger Sub"), entered into an Agreement and Plan of Merger (the "Engeni Merger Agreement") with Engeni LLC ("Engeni US"), Engeni S.A ("Engeni SA"), Scott Zienkewicz, Nicolas Heller and Alberto Pardo Saleme (the Engeni US members), and Scott Zienkewicz, as the representative of the Engeni US members. Pursuant to the Engeni Merger Agreement, Engeni Merger Sub merged with and into Engeni US, with Engeni US surviving the merger as a wholly-owned subsidiary of the Company (the "Engeni Merger"). On the Engeni Closing Date, in connection with closing the Engeni Merger Agreement, the Company issued 366,700 shares of Company common stock to Engeni US members. Furthermore, the Company subsequently issued Engeni US members 733,300 shares of Company common stock on April 2, 2019. On April 1, 2019 ("Tan Security Closing Date"), the Company entered into a Membership Interest and Stock Purchase Agreement (the "Tan Security Acquisition Agreement") with Tan's International Security and Tan's International LLC (collectively, "Tan Security"). Pursuant to the Tan Security Acquisition Agreement, the Company purchased all membership interests and capital stock of Tan Security and collectively holds 100% of the interests of Tan Security (the "Tan Security Acquisition"). On February 5, 2019, the Company and its wholly owned subsidiary, Merger Sub, entered into an Agreement and Plan of Merger (the "Amercanex Merger Agreement") with Green Tree International, Inc. ("GTI") and Steve Janjic, as the representative of the GTI shareholders, pursuant to which Merger Sub merged with and into GTI (the "GTI Merger"). On September 10, 2019 (the "GTI Closing Date"), the Company closed the GTI Merger and entered into an Addendum No. 1 to the Amercanex Merger Agreement acknowledging and approving certain events that occurred since signing as well as implementing various related amendments to the Amercanex Merger Agreement. In connection with closing the GTI Merger, the Company issued 16,765,727 unregistered shares of Company common stock to GTI shareholders, of which 4,140,274 shares were held back to satisfy indemnification obligations in the Amercanex Merger Agreement, if necessary.

Going Concern Uncertainty, Fina

Going Concern Uncertainty, Financial Condition and Management's Plans	12 Months Ended
	Dec. 31, 2019
Going Concern Uncertainty, Financial Condition and Management's Plans [Abstract]
Going Concern Uncertainty, Financial Condition and Management's Plans	2. Going Concern Uncertainty, Financial Condition and Management's Plans The Company believes that there is substantial doubt about the Company's ability to continue as a going concern. The Company believes that its available cash balance as of the date of this filing will not be sufficient to fund its anticipated level of operations for at least the next 12 months. The Company believes that its ability to continue operations depends on its ability to sustain and grow revenue and results of operations as well as its ability to access capital markets when necessary to accomplish the Company's strategic objectives. The Company believes that the Company will continue to incur losses for the immediate future. The Company expects to finance future cash needs from the results of operations and, depending on the results of operations, the Company will need additional equity or debt financing until the Company can achieve profitability and positive cash flows from operating activities, if ever. At December 31, 2019, the Company had a working capital deficit of approximately $3,416,501, as compared to working capital deficit of approximately $2,233,652 at December 31, 2018. The increase of $1,182,849 in the Company's working capital from December 31, 2018 to December 31, 2019 was primarily the result of an increase in the Company's convertible notes payable, net of discount – related party and accounts payable and accrued expenses, partially offset by a decrease in contingent consideration and an increase in accounts receivable, net. The Company's future capital requirements for its operations will depend on many factors, including the profitability of its businesses, the number and cash requirements of other acquisition candidates that the Company pursues, and the costs of operations. The Company has been investing in expanding its operation in new states, its security service in Colorado and California, and upgrading the capabilities of BioTrackTHC. The Company's management has taken several actions to ensure that it will have sufficient liquidity to meet its obligations for the next twelve months, including growing and diversifying its revenue streams, selectively reducing expenses, and considering additional funding. Additionally, if the Company's actual revenues are less than forecasted, the Company anticipates that variable expenses will also decline, and the Company's management can implement expense reduction as necessary. The Company is evaluating other measures to further improve its liquidity, including the sale of equity or debt securities. Lastly, the Company may elect to reduce certain related-party and third-party debt by converting such debt into common shares. The Company's management believes that these actions will enable the Company to meet its liquidity requirements for the next twelve months. There is no assurance that the Company will be successful in any capital-raising efforts that it may undertake to fund operations during 2020 and beyond. The Company plans to generate positive cash flow from its Colorado and California security operations, BioTrackTHC and Engeni software operations to address some of the liquidity concerns. The Company also plans to generate positive cash flows from the acquisitions of Tan Security and Green Tree made during 2019. However, to execute the Company's business plan, service existing indebtedness and implement its business strategy, the Company anticipates that it will need to obtain additional financing from time to time and may choose to raise additional funds through public or private equity or debt financings, borrowings from affiliates or other arrangements. The Company cannot be sure that any additional funding, if needed, will be available on terms favorable to the Company or at all. Furthermore, any additional capital raised through the sale of equity or equity-linked securities may dilute the Company's current stockholders' ownership and could also result in a decrease in the market price of the Company's common stock. The terms of those securities issued by the Company in future capital transactions may be more favorable to new investors and may include the issuance of warrants or other derivative securities, which may have a further dilutive effect. The Company also may be required to recognize non-cash expenses in connection with certain securities it issues, such as convertible notes and warrants, which may adversely impact the Company's operating results and financial condition. Furthermore, any debt financing, if available, may subject the Company to restrictive covenants and significant interest costs. There can be no assurance that the Company will be able to raise additional capital, when needed, to continue operations in their current form.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, which include Helix TCS, LLC (“Helix TCS”), Security Consultants Group, LLC (“Security Consultants”), Boss Security Solutions, Inc. (“Boss Security”), Security Consultants Group Oregon, LLC (“Security Oregon”), Security Grade, BioTrackTHC (since June 1, 2018), Engeni US (since August 3, 2018), Tan Security (since April 1, 2019) and Green Tree International, Inc. (since September 10, 2019). Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Use of estimates includes the following: 1) allowance for doubtful accounts, 2) estimated useful lives of property, equipment and intangible assets, 3) intangibles impairment, 4) valuation of convertible notes payable and 5) revenue recognition. Actual results could differ from estimates. Cash Cash consists of checking accounts. The Company considers all highly-liquid investments purchased with a maturity of three months or less at the time of purchase to be cash equivalents. The Company has no cash equivalents as of December 31, 2019 or 2018. Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount, net of an allowance for doubtful accounts. The Company performs ongoing credit evaluations of its customers and adjusts credit limits based upon payment history and the customer’s current credit worthiness, as determined by the review of their current credit information; and determines the allowance for doubtful accounts based on historical write-off experience, customer specific facts and economic conditions. Management charges balances off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company determines when receivables are past due, or delinquent based on how recently payments have been received. Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. Allowance for doubtful accounts was $273,138 and $76,156 at December 31, 2019 and 2018, respectively. Long-Lived Assets, Including Definite Lived Intangible Assets Long-lived assets, other than goodwill and other indefinite-lived intangibles, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable through the estimated undiscounted future cash flows derived from such assets. Definite-lived intangible assets primarily consist of non-compete agreements and customer relationships. For long-lived assets used in operations, impairment losses are only recorded if the asset’s carrying amount is not recoverable through its undiscounted, probability-weighted future cash flows. The Company measures the impairment loss based on the difference between the carrying amount and the estimated fair value. When an impairment exists, the related assets are written down to fair value. Goodwill Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value-based test. Helix reviews goodwill for possible impairment annually during the fourth quarter, or whenever events or circumstances indicate that the carrying amount may not be recoverable. The impairment model prescribes a two-step method for determining goodwill impairment. However, an entity is permitted to first assess qualitative factors to determine whether the two-step goodwill impairment test is necessary. The qualitative factors considered by Helix may include, but are not limited to, general economic conditions, Helix’s outlook, market performance of Helix’s industry and recent and forecasted financial performance. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that a reporting unit’s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. In the first step, Helix determines the fair value of its reporting unit using a discounted cash flow analysis. If the net book value of the reporting unit exceeds its fair value, Helix then performs the second step of the impairment test, which requires allocation of the reporting unit’s fair value to all of its assets and liabilities using the acquisition method prescribed under authoritative guidance for business combinations with any residual fair value being allocated to goodwill. An impairment charge is recognized when the implied fair value of Helix’s goodwill is less than its carrying amount. Assumptions and estimates used in the evaluation of impairment may affect the carrying value of long-lived assets, which could result in impairment charges in future periods. Such assumptions include projections of future cash flows and the current fair value of the asset. It was determined that during the first quarter of 2018, the Company’s entire amount of goodwill attributable to the Security Grade acquisition was impaired. See Note 7 for a further discussion on the impairment. Accounting for Acquisitions In accordance with the guidance for business combinations, the Company determines whether a transaction or other event is a business combination, which requires that the assets acquired, and liabilities assumed constitute a business. Each business combination is then accounted for by applying the acquisition method. If the assets acquired are not a business, the Company accounts for the transaction or other event as an asset acquisition. Under both methods, the Company recognizes the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquired entity. In addition, for transactions that are business combinations, the Company evaluates the existence of goodwill or a gain from a bargain purchase. The Company capitalizes acquisition-related costs and fees associated with asset acquisitions and immediately expense acquisition-related costs and fees associated with business combinations. Business Combinations The Company accounts for its business combinations under the provisions of Accounting Standards Codification (“ASC”) Topic 805-10, Business Combinations (“ASC 805-10”), which requires that the purchase method of accounting be used for all business combinations. Assets acquired and liabilities assumed, including non-controlling interests, are recorded at the date of acquisition at their respective fair values. ASC 805-10 also specifies criteria that intangible assets acquired in a business combination must meet to be recognized and reported apart from goodwill. Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from the business combinations and are expensed as incurred. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date and any changes in fair value after the acquisition date are accounted for as measurement-period adjustments. Changes in fair value of contingent consideration resulting from events after the acquisition date, such as earn-outs, are recognized as follows: 1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or 2) if the contingent consideration is classified as a liability, the changes in fair value are recognized in earnings. The estimated fair value of net assets acquired, including the allocation of the fair value to identifiable assets and liabilities, was determined using established valuation techniques. The estimated fair value of the net assets acquired was determined using the income approach to valuation based on the discounted cash flow method. Under this method, expected future cash flows of the business on a stand-alone basis are discounted back to a present value. The estimated fair value of identifiable intangible assets, consisting of software and trade name acquired were determined using the relief from royalty method. The most significant assumptions under the relief from royalty method used to value software and trade names include: estimated remaining useful life, expected revenue, royalty rate, tax rate, discount rate and tax amortization benefit. The discounted cash flow method used to value non-compete agreements includes assumptions such as: expected revenue, term of the non-compete agreements, probability and ability to compete, operating margin, tax rate and discount rate. Management has developed these assumptions on the basis of historical knowledge of the business and projected financial information of the Company. These assumptions may vary based on future events, perceptions of different market participants and other factors outside the control of management, and such variations may be significant to estimated values. Revenue Recognition Under FASB Topic 606, Revenue from Contacts with Customers The security services revenue is generated from performing armed and unarmed guarding which is contracted for on an hourly basis. Revenues associated with these contracted services are recognized under time-based arrangements as services are provided. Additionally, the Company provides transportation security services, which are generally contracted for on a per-run basis and sometimes additional fees and surcharges are also billed to the client depending on the length of the run. Revenues associated with these services are recognized as the transportation service is provided. The Company also generates revenue from developing and licensing seed to sale cannabis compliance software to both private-sector and public-sector (government agencies) businesses that are involved in cannabis related operations. The Company also generates revenue from on-going training, support and software customization services. Occasionally, the Company will enter into systems installation arrangements. Installation jobs are estimated based on the cost of equipment to be installed, the number of hours expected to be incurred to complete the job and other ancillary costs. Revenue associated with these services are recognized over the arrangement period. Lastly, the Company generates monthly recurring revenues from Cannalytics, its business intelligence and data tool for commercial customers. Revenue is recognized monthly. Segment Information Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 280, Segment Reporting, establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is the Chief Executive Officer, who reviews the financial performance and the results of operations of the segments prepared in accordance with GAAP when making decisions about allocating resources and assessing performance of the Company. Asset information by operating segment is not presented since the chief operating decision maker does not review this information by segment. The reporting segments follow the same accounting policies used in the preparation of the Company’s consolidated financial statements. Expenses Cost of Revenue The cost of revenues is the total cost incurred to obtain a sale and the cost of the goods or services sold. Cost of revenues primarily consisted of hourly compensation for security personnel and employees involved in the creation and development of licensing software. Operating Expenses Operating expenses encompass selling general and administrative expenses, salaries and wages, professional and legal fees and depreciation and amortization. Selling, general and administrative expenses consist primarily of rent/moving expenses, advertising and travel expenses. Salaries and wages is composed of non-revenue generating employees. Professional services are principally comprised of outside legal, audit, information technology consulting, marketing and outsourcing services as well as the costs related to being a publicly traded company. Other Income Other income consisted of a gain on the change in fair value of convertible notes, gain on the change in the fair value of warrant liability, loss on the change in fair value of convertible notes – related party, loss on the change in fair value of contingent consideration, loss on issuance of warrants and interest expense. Property and Equipment Property and equipment are stated at cost and depreciated on a straight-line basis over their estimated useful lives. Useful lives are 3 years for vehicles and 5 years for furniture and equipment. Maintenance and repairs are expensed as incurred and major improvements are capitalized. When assets are sold, or retired, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is included in loss from operations. Contingencies Occasionally, the Company may be involved in claims and legal proceedings arising from the ordinary course of its business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred, and the amount can be reasonably estimated. If these estimates and assumptions change or prove to be incorrect, it could have a material impact on the Company’s consolidated financial statements. Contingencies are inherently unpredictable, and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. Advertising Advertising costs are expensed as incurred and included in selling, general and administrative expenses and amounted to $378,233 and $96,420 for the years ended December 31, 2019 and 2018, respectively. Foreign Currency The local currency is the functional currency for one entity’s operations outside the United States. Assets and liabilities of these operations are translated to U.S. dollars at the exchange rate in effect at the end of each period. Income statement accounts are translated at the average exchange rate prevailing during the period. Translation adjustments arising from the use of differing exchange rates from period to period are included as a component of other comprehensive loss within shareholders’ equity. Gains and losses from foreign currency transactions are included in net loss for the period. Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company has incurred net operating loss for financial-reporting and tax-reporting purposes. Accordingly, for Federal and state income tax purposes, the benefit for income taxes has been offset entirely by a valuation allowance against the related federal and state deferred tax asset for the years ended December 31, 2019 and 2018. Comprehensive Loss Comprehensive loss consists of consolidated net loss and foreign currency translation adjustments. Foreign currency translation adjustments included in comprehensive loss were not tax-effected as investments in international affiliates are deemed to be permanent. Distinguishing Liabilities from Equity The Company relies on the guidance provided by ASC Topic 480, Distinguishing Liabilities from Equity Once the Company determines that a financial instrument should not be classified as a liability, the Company determines whether the financial instrument should be presented between the liability section and the equity section of the balance sheet (“temporary equity”). The Company will determine temporary equity classification if the redemption of the financial instrument is outside the control of the Company (i.e. at the option of the holder). Otherwise, the Company accounts for the financial instrument as permanent equity. Initial Measurement The Company records its financial instruments classified as liability, temporary equity or permanent equity at issuance at the fair value, or cash received. Subsequent Measurement – Financial instruments classified as liabilities The Company records the fair value of its financial instruments classified as liabilities at each subsequent measurement date. The changes in fair value of its financial instruments classified as liabilities are recorded as other expense/income. Share-based Compensation The Company accounts for stock-based compensation to employees in conformity with the provisions of ASC Topic 718, Stock Based Compensation The Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC Topic 718, based upon the fair-value of the underlying instrument. The equity instruments are valued using the Black-Scholes valuation model. The measurement of stock-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense over the period which services are received. The Company calculates the fair value of option grants utilizing the Black-Scholes pricing model and estimates the fair value of the stock based upon the estimated fair value of the common stock. The amount of stock-based compensation recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. The resulting stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight- line basis over the requisite service period of the award. Fair Value of Financial Instruments ASC Topic 820, Fair Value Measurements and Disclosures ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC Topic 820 are described as follows: ● Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date. ● Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. ● Level 3 – Inputs that are unobservable for the asset or liability. Certain assets and liabilities of the Company are required to be recorded at fair value either on a recurring or non-recurring basis. Fair value is determined based on the price that would be received for an asset or paid to transfer a liability in an orderly transaction based on market participants. The following section describes the valuation methodologies that the Company used to measure, for disclosure purposes, its financial instruments at fair value. Convertible notes payable The fair value of the Company’s convertible notes payable, approximated the carrying value as of December 31, 2019 and 2018. Factors that the Company considered when estimating the fair value of its debt included market conditions and the term of the debt. The level of the debt would be considered as Level 2. Additional Disclosures Regarding Fair Value Measurements The carrying value of cash, accounts receivable, prepaid expenses, deposits, accounts payable and accrued liabilities, advances from shareholders and obligation pursuant to acquisition approximate their fair value due to the short-term maturity of those items. Earnings (Loss) per Share The Company follows ASC 260, Earnings Per Share Basic net loss per share is based on the weighted average number of common and common-equivalent shares outstanding. Potential common shares includable in the computation of fully-diluted per share results are not presented in the consolidated financial statements for the years ended December 31, 2019 and 2018 as their effect would be anti-dilutive. The anti-dilutive shares of common stock outstanding for years ended December 31, 2019 and 2018 were as follows: For the Years Ended 2019 2018 Potentially dilutive securities: Convertible notes payable 5,994,838 124,784 Convertible Preferred A Stock 1,000,000 1,000,000 Convertible Preferred B Stock 13,784,201 13,784,201 Warrants 5,113,058 3,418,184 Stock options 11,617,381 8,729,463 Reclassifications Certain reclassifications have been made to the prior period financial statements to conform to the current period financial statement presentation. These reclassifications had no effect on net earnings or cash flows as previously reported. Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-.02, Leases (Topic 842) The Company adopted the new standard on January 1, 2019 and used the modified retrospective approach with the effective date as the date of initial application. Consequently, prior period balances and disclosures have not been restated. The Company elected certain practical expedients, which among other things, allowed us to carry forward prior conclusions about lease identification and classification. Adoption of the standard resulted in the balance sheet recognition of additional lease assets and lease liabilities of approximately $1,500,000. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company currently has elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in separate lease and non-lease components for all our leases. For additional information regarding the Company’s leases, see Note 19 in the notes to condensed consolidated financial statements. In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception In February 2018, the FASB issued ASU 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220); Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (ASC 718): Improvements to Nonemployee Share-Based Payment Accounting In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (ASC 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact on the Company’s consolidated financial statements and related disclosures effective for public companies for the reporting periods beginning after December 15, 2019.

Revenue Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2019
Revenue Recognition [Abstract]
Revenue Recognition	4. Revenue Recognition Adoption of ASC 606 Revenue from Contracts with Customers The Company adopted the new revenue standard, ASC 606, using the modified retrospective method with respect to all non-completed contracts as of January 1, 2018. This method required retrospective application of the new accounting standard to all unfulfilled contracts that were outstanding as of January 1, 2018. The Company has determined that there were no adjustments required with respect to the adoption of ASC 606 with respect to any prior periods. Disaggregation of revenue For the Years Ended 2019 2018 Types of Revenues: Security and Guarding $ 5,022,436 $ 4,889,472 Systems Installation 783,192 499,138 Software 9,486,472 4,174,963 Total revenues $ 15,292,100 $ 9,563,573 The following is a description of the principal activities from which we generate our revenue. Security and Guarding Revenue Helix provides armed and unarmed guards, monitoring of security alarms and cameras, as well as armed transportation services. The guards are charged out at an hourly rate, as are the monitoring services, with invoices typically sent to clients shortly after each month-end for the previous month, with revenue being recognized over time. The customer simultaneously receives and consumes benefits provided by the Helix performance. Transportation services are typically invoiced on a per-run basis, with revenue being recognized at a point in time once the service has been completed. Systems Installation Revenue Security systems, including Internet Protocol camera, intrusion alarm systems, perimeter alarm systems, and access controls are installed for clients. Installation jobs are estimated based on the cost of the equipment, the number of man hours expected to complete the work, supplies, travel, and any other ancillary costs. The installation is typically invoiced with 60% of the total price immediately after signing and the balance upon completion of the installation service. The timing of these contracts is short-term in nature and less than 12 months in duration, and revenue is recognized over the term of the contracts, utilizing the cost-to-cost method. Software The Company generates revenue from developing and licensing seed to sale cannabis compliance software to both private-sector and public-sector (government agencies) clients that are involved in cannabis related operations. The Company also generates revenue from on-going training, support and software customization services. The private-sector software entails cultivation tracking, inventory management, point of sale and analytic reporting to assist businesses in meeting their compliance requirements and effectively managing their businesses. Customers within the private sector business are charged an initial one-time installation fee and the revenues associated with these services are recognized upon completion of installation and configuration at a point in time. After the installation and configuration of the software is completed, the customer is invoiced monthly and revenues associated with these services are recognized monthly over a period of time in which the customer continues to use the software and related services. The public-sector software assists government agencies in efficient oversight of cannabis related business under their jurisdiction. Revenues associated with governmental contracts are longer-term in nature and recognized upon completion of certain milestones over a period of time or on a completed-contract basis at a point in time. The Company considers the contract to be complete when all significant costs have been incurred and the customer accepts the project. Costs incurred prior to the customer accepting the project are deferred and reflected on the consolidated balance sheets as prepaid expenses and other current assets. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in accordance with ASC 606. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Generally, the Company’s contracts include a single performance obligation that is separately identifiable, and therefore, distinct. Under ASC 606, the allocation of transaction price is not necessary if only one performance obligation is identified. Significant Judgments Accounting for long-term contracts involves the use of various techniques to estimate total contract revenue, costs and satisfaction of performance obligation. The Company satisfies its performance obligations and subsequently recognizes revenue, at a point in time, as security and installation services are performed. There were no changes to the significant judgments used by the Company to determine the timing of satisfaction of the performance obligations under ASC 606. Costs to Obtain or Fulfill Contract The Company’s costs to fulfill or obtain contracts with customers primarily consist of commissions and legal costs. The Company provides sales team members with commissions at 0-6%. Although sales commissions are incremental in nature and are only incurred when a contract is obtained, there is no up-front commission paid on the satisfactory obtainment of a contract, resulting in no sales commissions being capitalized at December 31, 2019 and 2018. The Company also incurs legal costs relating to the drafting and negotiating of contracts with select customers. Because legal costs are not incremental in nature and are incurred regardless of whether a contract is ultimately obtained, there were no legal costs capitalized as of December 31, 2019 and 2018.

Business Combination

Business Combination	12 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
Business Combination	5. Business Combination Security Grade Acquisition On June 2, 2017, the Company entered into a Membership Interest Purchase Agreement (the "Agreement") in which the Company purchased all issued and outstanding Units of Security Grade Protective Services, Ltd. ("Security Grade"), which comprised of 800,000 Class A Units and 200,000 Class B Units. At closing, the Company delivered $800,000 in cash and 207,427 non-qualified stock options (the "Initial Stock Options"). Furthermore, provided that, within the first 60 days following the closing, no material customer identified in the Agreement terminates its contractual relationship with the Company and that all contracts with such material customers are in full force and effect without default or cancellation as of the 60 th st The merger is being accounted for as a business combination in accordance with ASC 805. The Company's allocation of the purchase price was calculated as follows: Base Price - Cash $ 2,100,373 Base Price - Stock Options 916,643 Contingent Consideration - Stock Options 916,643 Total Purchase Price $ 3,933,659 Weighted Average Useful Life Description Fair Value (in years) Assets acquired: Cash $ 14,137 Accounts receivable 53,792 Costs & earnings in excess of billings 96,898 Property, plant and equipment, net 27,775 Trademarks 25,000 10 Customer lists 3,154,578 5 Web address 5,000 5 Goodwill 664,329 Other assets 3,880 Total assets acquired $ 4,045,389 Liabilities assumed: Billings in excess of costs $ 23,967 Loans payable 18,414 Credit card payable and other liabilities 69,349 Total liabilities assumed 111,730 Estimated fair value of net assets acquired $ 3,933,659 The initial stock options are included as part of the purchase price. The Company determined the fair value of the contingent consideration to be $916,643 at June 2, 2017 and recorded it as a liability in its unaudited consolidated balance sheets. The Company satisfied their contingent consideration liability during the third quarter of 2017. During the year ended December 31, 2018, the Company reached settlement agreements with all six selling members. As a result of these settlements, a gain on reduction of obligation pursuant to acquisition in the amount of $607,415 has been recorded for the year ended December 31, 2018. BioTrackTHC Acquisition In connection with closing the BioTrackTHC Merger, the Company issued 38,184,985 unregistered shares of Company common stock to BioTrackTHC stockholders, of which 1,852,677 shares were held back to satisfy indemnification obligations in the BioTrackTHC Merger Agreement, if necessary. The Company also assumed the BioTrackTHC Stock Plan, pursuant to which options exercisable for 8,132,410 shares of Company common stock are outstanding so that the BioTrackTHC stockholders owned approximately 48% of the Company on a fully diluted basis as of the BioTrackTHC Closing Date. The BioTrackTHC Merger is being accounted for as a business combination in accordance with ASC 805. The Company's allocation of the purchase price was calculated as follows: Base Price - Common Stock $ 44,905,542 Base Price - Stock Options 12,646,491 Total Purchase Price $ 57,552,033 Weighted Average Useful Life Description Fair Value (in years) Assets acquired: Cash $ 448,697 Accounts receivable 128,427 Prepaid expenses 351,615 Property, plant and equipment, net 72,252 Goodwill 39,135,007 Customer list 8,304,449 5 Software 9,321,627 4.5 Tradename 466,081 4.5 Total assets acquired $ 58,228,155 Liabilities assumed: Accounts payable $ 223,581 Other liabilities 452,541 Total liabilities assumed 676,122 Estimated fair value of net assets acquired $ 57,552,033 Total acquisition costs for the BioTrackTHC merger incurred during the year ended December 31, 2018 was $116,624, and is included in selling, general and administrative expense in the Company's consolidated statements of operations. Engeni SA Acquisition On the Engeni Closing Date, in connection with closing the Engeni Merger Agreement, the Company issued 366,700 shares of Company common stock to Engeni US members. Furthermore, the Company may also issue Engeni US members 366,700 and 366,600 shares of Parent common stock upon the achievement of specific objectives. If applicable, the Company will pay Engeni US members the aggregate amount of $100,000, on a pro rata basis, if Engeni SA reaches financial breakeven on or before December 31, 2018, as determined by the Company's Chief Financial Officer and Scott Zienkewicz. The Engeni Merger is being accounted for as a business combination in accordance with ASC 805. During the first quarter of 2019, it was determined Engeni SA did not reach financial breakeven and therefore the contingent consideration of $100,000 was deemed by the Company not to be payable and was reduced to zero. In accordance with ASC 805-30-35-1, the Company recognized the change in the fair value of contingent consideration subsequent to the acquisition date in general and administrative expenses. The Company's allocation of the purchase price was calculated as follows: Base Price - Common Stock $ 388,702 Contingent Consideration - Common Stock 777,298 Total Purchase Price $ 1,166,000 Weighted Average Useful Life Description Fair Value (in years) Assets acquired: Cash $ 5,609 Accounts receivable and other assets 30,479 Property, plant and equipment, net 57,830 Software 449,568 3.3 Goodwill 778,552 Total assets acquired $ 1,322,038 Liabilities assumed: Accounts payable $ 56,038 Total liabilities assumed 56,038 Estimated fair value of net assets acquired $ 1,266,000 The Company determined the fair value of the contingent consideration to be $777,298 at August 3, 2018 and recorded it as a liability in its unaudited condensed consolidated balance sheets. On April 2, 2019, the Company satisfied their contingent consideration liability and issued 733,300 shares of the Company's common stock to Engeni US members. Tan's International Security On the Tan Security Closing Date, the Company entered into the Tan Security Acquisition Agreement. Pursuant to the Tan Security Acquisition Agreement, Helix purchased all membership interests and capital stock of Tan Security and collectively holds 100% of the interests of Tan Security. The purchase price of $100,000 in cash plus 250,000 shares of the Company's restricted common stock will be paid to Rocky Tan as follows: ● 250,000 shares of Helix Stock at closing. ● $25,000 at closing ● $25,000 on the 4-month anniversary of the Tan Security Closing Date ● $25,000 on the 8-month anniversary of the Tan Security Closing Date ● $25,000 on the 12-month anniversary of the Tan Security Closing Date The Tan Security Acquisition is being accounted for as a business combination in accordance with ASC 805. The Company has determined preliminary fair values of the assets acquired and liabilities assumed in the Tan Security Acquisition. These values are subject to change as we perform additional reviews of our assumptions utilized. The Company has made a provisional allocation of the purchase price of the Tan Security transaction to the assets acquired and the liabilities assumed as of the purchase date. The following table summarizes the provisional purchase price allocations relating to the Tan Security Acquisition: Base Price – Cash at closing $ 25,000 Base Price – Deferred cash payment (including $25,000 to be made on the 4,8 and 12-month anniversaries of closing) 75,000 Base Price – Common Stock 710,000 Total Purchase Price $ 810,000 Description Fair Value Assets acquired: Cash $ 2,940 Accounts receivable 7,635 Goodwill 821,807 Total assets acquired $ 832,382 Liabilities assumed: Accounts payable $ 12,526 Other liabilities 9,856 Total liabilities assumed 22,382 Estimated fair value of net assets acquired $ 810,000 Green Tree International, Inc. Pursuant to the Amercanex Merger Agreement, the Company issued to the GTI stockholders an amount of unregistered shares of the Company's common stock equal to $15 million, based on the average closing price of the Company's common stock over the forty-five (45) trading day period ending three (3) trading days prior to the GTI Closing Date. If revenues of GTI in the second 12 month period following the GTI Closing Date exceed $5 million and are less than or equal to $10 million, the Company shall issue to the GTI shareholders a number of unregistered Helix shares (whether issued or reserved for issuance) equal to the quotient of (a) $5 million divided by (b) Helix share price multiplied by the quotient of (c) the revenues of GTI in the second 12 month period following the GTI Closing Date less $5 million divided by (d) $5 million. To secure the indemnification obligations of the GTI shareholders to the Company under the GTI Merger Agreement, 4,140,274 of the Company shares issued to the GTI shareholders were held back and the Company is entitled to retain such number of the holdback shares as necessary to satisfy those indemnification obligations. 50% of the holdback shares that remain after satisfaction of any indemnification obligations will be released 12 months after the GTI Closing Date of the merger, and the remainder 24 months after the GTI Closing Date of the merger. Additionally, if in the first 12 months following the closing GTI generates less than $1.5 million of revenues, 100% of the holdback shares shall be returned to the Company. In connection with closing the GTI Merger on September 10, 2019, the Company issued 16,765,727 unregistered shares of its common stock to GTI stockholders. In connection with the GTI Merger, Steve Janjic joined the board of directors of the Company. The GTI Merger is being accounted for as a business combination in accordance with ASC 805. The Company has determined preliminary fair values of the assets acquired and liabilities assumed in the GTI Merger. These values are subject to change as we perform additional reviews of our assumptions utilized. The Company has made a provisional allocation of the purchase price of the GTI transaction to the assets acquired and the liabilities assumed as of the purchase date. The following table summarizes the provisional purchase price allocations relating to the GTI transaction: Base Price - Common Stock $ 12,909,611 Total Purchase Price $ 12,909,611 Description Fair Value Weighted Average Useful Life Assets acquired: Note Receivable, net $ 135,000 Property, Plant and Equipment, Net 12,142 Software 452,002 4.5 Goodwill 12,980,840 Total assets acquired $ 13,579,984 Liabilities assumed: Accounts Payable 43,717 Notes Payable 400,000 Other Liabilities 226,656 Total liabilities assumed: 670,373 Estimated fair value of net assets acquired: $ 12,909,611 Total acquisition costs for the GTI Merger incurred during the year ended December 31, 2019 was $83,324, and is included in selling, general and administrative expense in the Company's consolidated statements of operations. Unaudited Pro Forma Results GTI contributed revenues of $0 and a net loss of $73,644 for the period September 10, 2019 through December 31, 2019, included in the Company's consolidated statements of operations.

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	6. Property and Equipment, Net At December 31, 2019 and 2018, property and equipment consisted of the following: December 31, 2019 2018 Furniture and equipment $ 262,167 $ 264,659 Software equipment 561,964 - Vehicles 201,066 202,700 Total 1,025,197 467,359 Less: Accumulated depreciation (219,518 ) (117,841 ) Property and equipment, net $ 805,679 $ 349,518 Depreciation expense for the years ended December 31, 2019 and 2018 was $95,685 and $106,625, respectively.

Intangible Assets, Net and Good

Intangible Assets, Net and Goodwill	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net and Goodwill	7 . Intangible Assets, Net and Goodwill The following table summarizes the Company's intangible assets: December 31, 2019 Estimated Useful Life (Years) Gross Carrying Amount Assets Acquired Pursuant to Business Combination (2) Assets Acquired Accumulated Amortization Net Book Value Database 5 $ 93,427 $ - $ - $ (69,533 ) $ 23,894 Trade names and trademarks 5 - 10 591,081 - - (207,525 ) 383,556 Web addresses 5 130,000 - - (95,611 ) 34,389 Customer list 5 11,459,027 - - (4,256,070 ) 7,202,957 Software 4.5 9,771,195 452,002 1,625 (3,492,525 ) 6,732,297 Domain Name 5 - - 20,231 (2,037 ) 18,194 $ 22,044,730 $ 452,002 $ 21,856 $ (8,123,301 ) $ 14,395,287 December 31, 2018 Estimated Useful Life (Years) Gross Carrying Amount at December 31, 2017 Assets Acquired Pursuant to Business Combination (1) (2) Accumulated Amortization Net Book Value Database 5 $ 93,427 $ - $ (50,858 ) $ 42,569 Trade names and trademarks 5-10 125,000 466,081 (91,554 ) 499,527 Web addresses 5 130,000 - (69,625 ) 60,375 Customer list 5 3,154,578 8,304,449 (1,965,520 ) 9,493,507 Software 4.5 - 9,771,195 (1,263,095 ) 8,508,100 $ 3,503,005 $ 18,541,725 $ (3,440,652 ) $ 18,604,078 (1) On June 1, 2018, the Company acquired various assets of BioTrackTHC (See Note 5) (2) On August 3, 2018, the Company acquired various assets of Engeni (See Note 5) (3) On September 10, 2019, the Company acquired various assets of GTI (See Note 5) The Company uses the straight-line method to determine the amortization expense for its definite lived intangible assets. Amortization expense related to the purchased intangible assets was $4,682,649 and $2,979,906 for the years ended December 31, 2019 and 2018, respectively. The estimated future amortization expense for the next five years and thereafter is as follows: Years Ending December 31, Future amortization expense 2020 $ 4,773,348 2021 4,718,392 2022 4,036,485 2023 808,591 2024 39,669 Thereafter 18,802 Total $ 14,395,287 The following table summarizes the Company's goodwill as of December 31, 2019 and 2018: Total Goodwill Balance at December 31, 2017 $ 664,329 Impairment of goodwill (664,329 ) Goodwill attributable to Biotrack acquisition 39,135,007 Goodwill attributable to Engeni acquisition 778,552 Balance at December 31, 2018 $ 39,913,559 Goodwill attributable to Tan Security acquisition 821,807 Goodwill attributable to Green Tree acquisition 12,980,840 Balance at December 31, 2019 $ 53,716,207

Costs, Estimated Earnings and B

Costs, Estimated Earnings and Billings	12 Months Ended
	Dec. 31, 2019
Costs in Excess of Billings on Uncompleted Contracts or Programs [Abstract]
Costs, Estimated Earnings and Billings	8. Costs, Estimated Earnings and Billings Costs, estimated earnings and billings on uncompleted contracts are summarized as follows as of December 31, 2019 and 2018: December 31, 2019 2018 Costs incurred on uncompleted contracts $ 444,344 $ 89,700 Estimated earnings 150,355 50,512 Cost and estimated earnings earned on uncompleted contracts 594,699 140,212 Billings to date 501,543 252,535 Billings in excess of costs and costs in excess of billings on uncompleted contracts 93,156 (112,323 ) Costs in excess of billings $ 257,819 $ 42,869 Billings in excess of cost (164,663 ) (155,192 ) $ 93,156 $ (112,323 )

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	9. Accounts Payable and Accrued Expenses As of December 31, 2019 and 2018, accounts payable and accrued expenses consisted of the following: December 31, 2019 2018 Accounts payable $ 895,785 $ 842,389 Accrued compensation and related expenses 260,280 - Accrued expenses 1,733,371 847,560 Accrued interest - 12,764 Lease obligation - current 373,710 - Total $ 3,263,146 $ 1,702,713

Convertible Notes Payable, Net

Convertible Notes Payable, Net of Discount	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Convertible Notes Payable, net of discount	10. Convertible Notes Payable, net of discount December 31, 2019 2018 Note Five, 5% convertible promissory note, fixed secured, maturing November 16, 2019 $ - $ 187,177 Note Ten, 25% convertible promissory note, fixed secured, maturing March 1, 2020, net of debt discount for warrants 143,630 - Note Eleven, 10% convertible promissory note, fixed secured, maturing May 15, 2020, net of debt discount for warrants and legal fees 185,313 - Note Twelve, 10% convertible promissory note, fixed secured, maturing June 16, 2020, net of debt discount for warrants and legal fees 205,363 - Note Thirteen, 10% convertible promissory note, fixed secured, maturing July 11, 2020, net of debt discount for warrants and legal fees 206,091 - Note Fourteen, 12% convertible promissory note, fixed secured, maturing September 26, 2020, net of debt discount for warrants and legal fees 92,095 - Note Fifteen, 12% convertible promissory note, fixed secured, maturing November 15, 2021 385,000 - 1,217,492 187,177 Less: Current portion (832,492 ) (187,177 ) Long-term portion $ 385,000 $ - On May 16, 2018, the Company amended Note Five ("Second Amendment") with the First Investor. The Second Amendment states that Note Five shall have a maturity of November 16, 2018 and shall be pre-payable at any time at 120% of the unpaid principal and accrued interest balance. The principal amount as of the date of the Second Amendment was $112,305. In November 2018, the Company amended Note Five ("Third Amendment") with a second investor. The Third Amendment states that Note Five shall have a maturity of November 16, 2019. The principal amount as of the date of the Third Amendment was $115,136. During March 2019, the remaining principal of $112,305 was converted into 155,421 shares of common stock. The interest expense associated with Note Five was $936 and $10,724 for the years ended December 31, 2019 and 2018, respectively. On March 1, 2019, the Company entered into a $450,000 Secured Convertible Promissory Note ("Note Ten") with an independent investor (the "investor"). The investor provided the Company with $450,000 in cash proceeds, which was received by the Company during the period ended June 30, 2019. Note Ten will mature on March 1, 2020 and bear interest at a rate of 25% per annum, payable by the Company half in cash and half in kind on a quarterly basis. The principal balance of Note Ten is convertible at the election of the investor, in whole or in part, at any time or from time to time, into the Company's common stock at the lower of $0.90 per share or a 30% discount to the Company's 30-day weighted average listed price per share immediately before the date of conversion. In conjunction with Note Ten, the Company issued a warrant to the investor to purchase 160,715 shares of the Company's common stock at $1.40 per share. The Company evaluated Note Ten in accordance with ASC 480, Distinguishing Liabilities from Equity In addition, the company recorded a debt discount relating to the warrants issued in the amount of $355,847 based on the relative fair value of the warrants at inception of Note Ten. Debt discounts amortized to interest expense was $297,352 for the year ended December 31, 2019. The unamortized discount balance at December 31, 2019 was $58,495. In May, September, and December 2019, the Company issued 15,625, 16,568 and 19,401 restricted shares of common stock as paid-in-kind ("PIK") interest payments in the amount of $14,062, $14,063, and $12,029, respectively. Accrued interest expense associated with Note Ten was $3,542 as of December 31, 2019, which includes PIK interest payable. On August 15, 2019, the Company entered into a $400,000 Fixed Convertible Promissory Note ("Note Eleven") with the investor. The investor provided the Company with $380,000 in cash proceeds, which was received by the Company during the period ended September 30, 2019. The additional $20,000 was retained by the investor for due diligence and legal bills for the transaction and recorded as a debt discount. Note Eleven will mature on May 15, 2020 and bear interest at a rate of 10% per annum, payable by the Company in cash. The principal balance of Note Eleven is convertible at the election of the investor, in whole or in part, at any time or from time to time, into the Company's common stock at $0.90 per share for the first 6 months and thereafter at the lower of $0.90 per share or at 70% of the average of the five lowest daily VWAPs of the Company's common stock during the 15 consecutive trading days prior to the date on which the investor elects to convert all or part of Note Eleven. In conjunction with Note Eleven, the Company issued a warrant to the investor to purchase 25,000 shares of the Company's common stock at $1.00 per share. The Company evaluated Note Eleven in accordance with ASC 480, Distinguishing Liabilities from Equity In addition, the company recorded a debt discount of $38,543 relating to the warrants issued in the amount of $18,543 based on the relative fair value of the warrants themselves at inception of Note Eleven and $20,000 relating to legal fees. Debt discounts amortized to interest expense were $19,412 for the year ended December 31, 2019. The unamortized discount balance at December 31, 2019 was $19,131. Accrued interest expense associated with Note Eleven was $17,460 as of December 31, 2019. On September 16, 2019, the Company entered into a $450,000 Fixed Convertible Promissory Note ("Note Twelve") with the investor. The investor provided the Company with $427,500 in cash proceeds, which was received by the Company during the period ended December 31, 2019. The additional $22,500 was retained by the investor for due diligence and legal bills for the transaction and was recorded as a debt discount. Note Twelve will mature on June 16, 2020 and bear interest at a rate of 10% per annum, payable by the Company in cash. The principal balance of Note Twelve is convertible at the election of the investor, in whole or in part, at any time or from time to time, into the Company's common stock at $0.90 per share for the first 6 months and thereafter at the lower of $0.90 per share or at 70% of the average of the five lowest daily VWAPs of the Company's common stock during the 15 consecutive trading days prior to the date on which the investor elects to convert all or part of Note Twelve. In conjunction with Note Twelve, the Company issued a warrant to the investor to purchase 25,000 shares of the Company's common stock at $1.00 per share. The Company evaluated Note Twelve in accordance with ASC 480, Distinguishing Liabilities from Equity In addition, the company recorded a debt discount of $40,183 relating to the warrants issued in the amount of $17,683 based on the residual fair value of the warrants themselves at inception of Note Twelve and $22,500 relating to legal fees. Debt discounts amortized to interest expense were $15,545 for the year ended December 31, 2019. The unamortized discount balance at December 31, 2019 was $24,638. Accrued interest expense associated with Note Twelve was $18,285 as of December 31, 2019. On October 11, 2019, the Company entered into a $450,000 Fixed Convertible Promissory Note ("Note Thirteen") with the investor. The investor provided the Company with $427,500 in cash proceeds, which was received by the Company during the period ended December 31, 2019. The additional $22,500 was retained by the investor for due diligence and legal bills for the transaction and was recorded as a debt discount. Note Thirteen will mature on July 11, 2020 and bear interest at a rate of 10% per annum, payable by the Company in cash. The principal balance of Note Thirteen is convertible at the election of the investor, in whole or in part, at any time or from time to time, into the Company's common stock at $0.90 per share for the first 6 months and thereafter at the lower of $0.90 per share or at 70% of the average of the five lowest daily VWAPs of the Company's common stock during the 15 consecutive trading days prior to the date on which the investor elects to convert all or part of Note Thirteen. In conjunction with Note Thirteen, the Company issued a warrant to the investor to purchase 25,000 shares of the Company's common stock at $1.00 per share. The Company evaluated Note Thirteen in accordance with ASC 480, Distinguishing Liabilities from Equity In addition, the company recorded a debt discount of $33,943 relating to the warrants issued in the amount of $11,443 based on the residual fair value of the warrants themselves at inception of Note Thirteen and $22,500 relating to legal fees. Debt discounts amortized to interest expense were $10,034 for the year ended December 31, 2019. The unamortized discount balance at December 31, 2019 was $23,909. Accrued interest expense associated with Note Thirteen was $16,022 as of December 31, 2019. On December 26, 2019, the Company entered into a $210,526 Fixed Convertible Promissory Note ("Note Fourteen") with the investor. The investor provided the Company with $200,000 in cash proceeds, which was received by the Company during the period ended December 31, 2019. The additional $10,526 was retained by the investor for due diligence and legal bills for the transaction and was recorded as a debt discount. Note Fourteen will mature on September 26, 2020 and bear interest at a rate of 12% per annum, payable by the Company in cash. The principal balance of Note Fourteen is convertible at the election of the investor, in whole or in part, at any time or from time to time, into the Company's common stock at $0.90 per share for the first 6 months and thereafter at the lower of $0.90 per share or at 70% of the average of the five lowest daily VWAPs of the Company's common stock during the 15 consecutive trading days prior to the date on which the investor elects to convert all or part of Note Fourteen. In conjunction with Note Fourteen, the Company issued a warrant to the investor to purchase 12,500 shares of the Company's common stock at $1.00 per share. The Company evaluated Note Fourteen in accordance with ASC 480, Distinguishing Liabilities from Equity In addition, the company recorded a debt discount of $15,794 relating to the warrants issued in the amount of $5,268 based on the residual fair value of the warrants themselves at inception of Note Fourteen and $10,526 relating to legal fees. Debt discounts amortized to interest expense were $287 for the year ended December 31, 2019. The unamortized discount balance at December 31, 2019 was $15,507. Accrued interest expense associated with Note Fourteen was $463 as of December 31, 2019. On November 15, 2019, the Company entered into a $5,000,000 Unsecured Convertible Promissory Note ("Note Fifteen") with the investor. The investor provided the Company with $385,000 in cash proceeds, which was received by the Company during the period ended December 31, 2019. Note Fifteen will mature on November 15, 2021 and bear interest at a rate of 12% per annum, payable by the Company in cash. The principal balance of Note Fifteen is convertible at the election of the investor, in whole or in part, at any time or from time to time, into the Company's common stock at 70% of the average of the five lowest daily VWAPs of the Company's common stock during the 15 consecutive trading days prior to the date on which the investor elects to convert all or part of Note Fifteen. As of December 31, 2019, the balance of Note Fifteen was $385,000. Accrued interest expense associated with Note Fifteen was $5,239 as of December 31, 2019.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party Transactions Advances from Related Parties The Company had a loan outstanding from a former Company executive. The advance did not accrue interest and had no definite repayment terms. The loan balance was $0 and $45,250 for the years ended December 31, 2019 and 2018, respectively. Convertible Note Payable On March 11, 2016, the Company entered into an Unsecured Convertible Promissory Note ("Note Eight") with a Director of the Company (the "Related Party Holder"). The Related Party Holder provided the Company with $150,000 in cash, and the Company promised to pay the principal amount, together with interest at an annual rate of 7%, with principal and accrued interest on Note Eight due and payable on December 31, 2017 (unless converted under terms and provisions as set forth below). The principal balance of Note Eight was convertible at the election of the Related Party Holder, in whole or in part, at any time or from time to time, into the Company's common stock at a forty percent (40%) discount to the average market closing price for the previous five (5) trading days, preceding the date of conversion election. The Company evaluated Note Eight in accordance with ASC 480, Distinguishing Liabilities from Equity On February 20, 2018, the Company entered into an agreement to amend Note Eight (this "Amendment") with the Related Party Holder. The Company and the Related Party Holder desired to extend the maturity date of Note Eight to August 20, 2018. Note Eight was amended as follows. The Company promises to pay (i) all accrued interest on the unpaid principal amount through December 31, 2017 and (ii) $25,000 in principal within 5 business days of the date of the Amendment. The Company agrees to issue 15,000 shares of restricted Company common stock as an inducement for this amendment within 10 business days of the date of the Amendment. The principal amount of the note will be reduced to $125,000. Unless extended by the Company, converted or prepaid earlier, all unpaid principal and unpaid accrued interest on Note Eight shall be due and payable on August 20, 2018 (the "Maturity Date"). All provisions related to conversion of Note Eight into equity securities of the Company were terminated as part of this Amendment. As of February 20, 2018, the fair value of the liability was $239,343, however due to termination of the conversion of the note into equity securities, Note Eight will be valued in its principal amount of $125,000 and accordingly the Company recorded a credit regarding the change in fair value of $93,506 for the year ended December 31, 2018. The interest expense associated with Note Eight was $5,806 for the year ended December 31, 2018. Note Eight was paid in full on the Maturity Date. On March 1, 2019, the Company entered into a $1,500,000 Secured Convertible Promissory Note ("Note Nine") with Rose Capital Fund I, LP (the Related Party Holder"). A Managing Member of the Related Party Holder is also a Director of the Company. The Related Party Holder provided the Company with $1,475,000 in cash proceeds, which was received by the Company during the period ended December 31, 2019. The additional $25,000 was retained by the Related Party Holder for legal bills for the transaction. Note Nine will mature on March 1, 2020 and bear interest at a rate of 25% per annum, payable by the Company half in cash and half in kind on a quarterly basis. The principal balance of Note Nine is convertible at the election of the Related Party Holder, in whole or in part, at any time or from time to time, into the Company's common stock at the lower of $0.90 per share or a 30% discount to the Company's 30-day weighted average listed price per share immediately before the date of conversion. In conjunction with Note Nine, the Company issued a warrant to the Related Party Holder to purchase 535,715 shares of the Company's common stock at $1.40 per share. The Company evaluated Note Nine in accordance with ASC 480, Distinguishing Liabilities from Equity In addition, the company recorded a debt discount relating to the warrants issued in the amount of $1,186,153 based on the relative fair value of the warrants at inception of Note Nine. The additional $25,000 retained by the Related Party Holder for legal bills for the transaction will be recorded as a debt discount. Debt discounts amortized to interest expense were $1,012,059 for the year ended December 31, 2019, respectively. The unamortized discount balance at December 31, 2019 was $199,094. In May and October 2019, the Company issued 52,083 and 83,311 restricted shares of common stock as PIK interest payments in the amount of $46,875 and $45,821, respectively. Accrued interest expense associated with Note Nine was $93,750 as of December 31, 2019, which includes PIK interest payable. As of December 31, 2019, the balance of Note Nine, net of debt discount for warrants and legal bills was $1,584,360. Warrants On March 1, 2019, in connection with the issuance of Note Nine, the Company issued warrants, of which the value was derived and based off the fair value of Note Nine, to the investor to purchase 535,715 shares of the Company's common stock at $1.40 per share. Exercise of the purchase rights represented by the warrant may be made, in whole or in part, at any time or times on or after March 1, 2019 and on or before March 1, 2024, by delivery to the Company of the Notice of Exercise. The Company determined that the warrants associated with Note Nine are puttable for cash upon a fundamental transaction at the option of the holder and as such required classification as a liability pursuant to ASC 480, Distinguishing Liabilities from Equity

Promissory Notes

Promissory Notes	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Promissory Notes	12. Promissory Notes On August 29, 2018, the Company entered into an unsecured promissory note in the amount of $250,000. The unsecured promissory note has a fixed interest rate of 7% and is due and payable on July 31, 2019. As of December 31, 2018 the unsecured promissory note was paid off in full. The interest expense associated with the unsecured promissory note was $0 and $3,021 for the years ended December 31, 2019 and 2018, respectively. On January 3, 2019, the Company entered into an unsecured promissory note with the Related Party Holder in the amount of $280,000. The unsecured promissory note has a fixed interest rate of 10% and is due and payable on March 31, 2019. On March 2, 2019, the unsecured promissory note was paid off in full. On July 29, 2019, the Company entered into an unsecured promissory note with the Related Party Holder in the amount of $300,000. The unsecured promissory note has a fixed interest rate of 12% and is due and payable on January 29, 2020.

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Notes Payable	13. Notes Payable As of December 31, 2019 and December 31, 2018 Notes payable consisted of the following: December 31, 2019 2018 Vehicle financing loans payable, between 4.7% and 7.0% interest and maturing between June 2022 and July 2022 $ 52,507 $ 71,284 Loans Payable - Credit Union 5,385 5,075 Notes Payable 400,000 - Less: Current portion of loans payable (24,805 ) (24,805 ) Long-term portion of loans payable $ 433,087 $ 51,554 The interest expense associated with the notes payable was $5,874 and $5,281 for the years ended December 31, 2019 and 2018, respectively. In connection with the GTI Merger, the Company assumed a $400,000 Senior Secured Convertible Debenture (the "Convertible Debenture") (See Note 5). The Convertible Debenture will mature on July 31, 2021 and bears interest at a rate of 10% per annum, payable by the Company to the Lender. In the event that Lender elects to convert the Convertible Debenture into Helix common stock or in the event Helix required the lender to convert the Convertible Debenture into its common stock, the number of shares that shall be issuable upon full conversion of the Convertible Debenture at any time shall be equal to the outstanding principal of the Convertible Debenture divided by $1.00. Pursuant to the terms of the Convertible Debenture, Helix common stock can be transferred to the lender from Steve Janjic, as a shareholder of the Company who receives shares of Helix common stock at the closing, instead of via a new issuance of shares of Helix common stock by Helix to the lender, and the lender agrees to accept such transfer of shares from Mr. Janjic as the issuance of Helix common stock. In addition, the Company shall have the right to require the lender to convert the Convertible Debenture into Helix common stock at any time provided its common stock is listed on a stock exchange other than the U.S. OTCQB, the common stock would be fully traded up on conversion and the trading price of its common stock closes above $1.15 for 20 consecutive trading days on such exchange. The Convertible Debenture will be secured by a general security interest over all of the assets of GTI, however does not apply to those assets owned by Helix or Merger Sub prior to the closing of the GTI Merger.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Shareholders' Equity (Deficit)	14. Shareholders’ Equity Common Stock Subscription Agreements The table below reflect shares of restricted common stock issued in relation to Subscription Agreements during the year-ended December 31, 2018: Date of Sale Number of Total February 2018 222,222 $ 200,000 March 2018 500,000 450,000 April 2018 500,000 450,000 May 2018 244,444 219,999 July 2018 327,777 294,999 August 2018 327,777 294,999 August 2018 183,333 164,999 September 2018 577,778 520,000 October 2018 694,444 625,000 November 2018 150,000 135,000 December 2018 222,222 200,000 3,949,997 $ 3,554,996 Other Common Stock Issuances In June 2018, the Company issued 38,184,985 shares of common stock as part of the BioTrackTHC acquisition. In June and August of 2018, three selling shareholders of Security Grade exercised their right to purchase 212,633 and 14,189 shares of the Company’s common stock. In July 2018, the Company issued 200,000 shares of restricted common stock to a consultant per a consulting agreement. In August and December 2018, the Company issued 100,000 and 25,000 shares of restricted common stock as part of an agreement entered into with an investor relation consultant. In August 2018, the Company issued 366,700 shares of common stock as part of the Engeni US acquisition. In December 2018, the Company issued 100,000 shares of restricted common stock to a consultant as an inducement to enter into the agreement. In January 2019, the Company issued 20,000 shares of restricted common stock to a consultant per a consulting agreement and recorded shared based compensation expense of $27,400. In March and June 2019, the Company issued 1,255,222 and 166,667 shares of common stock as part of investment unit purchase agreements (see Note 16). In March and June 2019, certain option holders exercised their rights under the BioTrackTHC Stock Plan and were issued 62,847 and 47,084 shares of common stock, respectively, for no cash proceeds. In March and April 2019, certain option holders exercised their rights under the BioTrackTHC Stock Plan and were issued 6,082 and 57,461 shares of common stock for total proceeds of $4,805 and $21,808, respectively. In April 2019, the Company issued 250,000 shares of common stock as part of the Tan Security acquisition. In April 2019, a selling shareholder of Security Grade exercised their right to purchase 15,101 shares of the Company’s common stock. In April 2019, the Company issued 733,300 shares of common stock in satisfaction of the Engeni contingent consideration (see Note 5). In May, September, October and December 2019, the Company issued 51,594 and 135,394 restricted shares of common stock as PIK interest payments in the amount of $40,154 and $92,696, respectively (see Notes 10 and 11). In August 2019, the Company issued 16,765,727 shares of common stock as part of the GTI acquisition (see Note 5). In November 4, 2019, the Company issued 100,000 shares of restricted common stock resulting from a consulting agreement. Conversion of Convertible Note to Common Stock On February 15, 2018, March 12, 2018 and March 21, 2018, the holder of a 10% fixed secured convertible promissory note issued by the Company elected their option to partially convert $50,000, $50,000 and $75,000 in principal of the convertible note into 46,066, 63,963, and 95,945 shares of the Company’s common stock. On March 7, 2019 and March 28, 2019, the holder of a 10% fixed secured convertible promissory note issued by the Company elected its option to fully convert $75,882 and $42,055 in principal of the convertible note into 100,000 and 55,421 shares of the Company’s common stock. On October 18, 2019, the holder of a 10% fixed secured convertible promissory note issued by the Company elected its option to fully convert $20,000 in principal of the convertible note into 56,738 shares of the Company’s common stock. On November 15, 2019, the holder of a 10% fixed secured convertible promissory note issued by the Company elected its option to fully convert $20,000 in principal of the convertible note into 63,012 shares of the Company’s common stock. On November 7, 2019, the holder of a 10% fixed secured convertible promissory note issued by the Company elected its option to fully convert $40,000 in principal of the convertible note into 126,024 shares of the Company’s common stock. On November 11, 2019, the holder of a 10% fixed secured convertible promissory note issued by the Company elected its option to fully convert $100,000 in principal of the convertible note into 315,060 shares of the Company’s common stock. On November 19, 2019, the holder of a 10% fixed secured convertible promissory note issued by the Company elected its option to fully convert $100,000 in principal of the convertible note into 315,060 shares of the Company’s common stock. Amended Convertible Note On February 20, 2018, the Company entered into an agreement to amend a Convertible Promissory Note with the undersigned holder initially issued to such Holder and dated March 2016. The Company and Holders desired to extend the maturity date of the Note to August 20, 2018. The holder was issued 15,000 shares of the Company’s restricted common stock as part of the amendment. The Note was amended as follows. The Company promises to pay (i) all accrued interest on the unpaid principal amount through December 31, 2017 and (ii) $25,000 in principal within 5 business days of the date of the Amendment. The Company agrees to issue 15,000 shares of restricted Company common stock as an inducement for this amendment within 10 business days of the date of the Amendment. The principal amount of the note will be reduced to $125,000. Unless extended by the Company, converted or prepaid earlier, all unpaid principal and unpaid accrued interest on this Note shall be due and payable on August 20, 2018 (the “Maturity Date”). All provisions related to conversion of the Note into equity securities of the Company are hereby deleted. On May 16, 2018, the Company entered into a second amendment agreement of a Convertible Promissory Note with the holder of a 10% fixed secured convertible promissory note. The new Maturity Date is November 16, 2018. The new interest rate is 5%. The note is prepayable at 120% of the unpaid balance upon 10 business days’ notice to the holder, which has the option to convert, in whole or in part, during the notice period. The conversion price shall be equal to a 40% discount to the lowest one-day Volume Average Weighted Price (“VWAP”) during the 30 trading days preceding such conversion. 2017 Omnibus Incentive Plan The table below reflects shares issued under the 2017 Omnibus Incentive Plan during the year-ended December 31, 2019. Date of Sale Number of Total March 2019 250,000 $ 320,000 Ending Balance 250,000 $ 320,000 The table below reflects shares issued under the 2017 Omnibus Incentive Plan during the year-ended December 31, 2018. Date of Sale Number of Total January 2018 42,850 $ 173,014 March 2018 100,000 250,000 May 2018 133,900 223,774 July 2018 100,000 126,000 August 2018 10,000 10,600 August 2018 33,195 33,195 October 2018 20,000 20,400 November 2018 75,000 79,500 Ending Balance 514,945 $ 916,483 Series A convertible preferred stock In October 2015, the Company issued a total of 1,000,000 shares of its Class A Preferred Stock. The Class A Preferred Stock included super majority voting rights and were convertible into 60% of the Company’s common stock. During the third quarter of 2017, the Company modified the conversion rate on the Class A Preferred Stock to a 1:1 ratio. This modification reduced the amount of potentially dilutive Convertible Series A Stock by 15,746,127 shares to a total of 1,000,000 at September 30, 2017. Series B convertible preferred stock Series B Preferred Stock Purchase Agreement On May 17, 2017, the Company sold to accredited investors an aggregate of 5,781,426 Series B Preferred Shares for gross proceeds of $1,875,000 and converted a $500,000 Unsecured Convertible Promissory Note into 1,536,658 Series B Preferred Shares. This tranche of Series B Preferred Shares are convertible into 7,318,084 shares of common stock based on the current conversion price, at a purchase price of $0.325 per share. In connection with the Series B Preferred Stock Purchase Agreement, the Company is obligated to issue warrants to a third-party for services to purchase 462,195 shares of common stock at $0.325 per share. These warrants have been accounted for as an obligation to issue because as of the balance sheet date the Company did not deliver the warrants though incurred the obligation; accordingly, they were recognized as a liability on the unaudited condensed consolidated balance sheet and cost of issuance of Series B preferred shares on the unaudited condensed consolidated statement of shareholders’ equity. In accordance with the Certificate of Incorporation, there were 9,000,000 authorized Series B Preferred Stock at a par value of $ 0.001. On August 23, 2017 the Certificate of Designations was amended and restated to increase the number of shares of Series B Preferred Stock authorized to be 17,000,000. Conversion: Each Series B Preferred Share is convertible at the option of the holder into such number of shares of the Company’s common stock equal to the number of Series B Preferred Shares to be converted, multiplied by the Preferred Conversation Rate. The Preferred Conversion Rate shall be the quotient obtained by dividing the Preferred Stock Original Issue Price ($0.3253815) by the Preferred Stock Conversation Price in effect at the time of the conversion (the initial conversion price will be equal to the Preferred Stock Original Issue Price, subject to adjustment in the event of stock splits, stock dividends, and fundamental transactions). Based on the current conversion price, the Series B Preferred Shares are convertible into 13,784,201 shares of common stock. A fundamental transaction means: (i) our merger or consolidation with or into another entity, (ii) any sale of all or substantially all of our assets in one transaction or a series of related transactions, (iii) any reclassification of our Common Stock or any compulsory share exchange by which Common Stock is effectively converted into or exchanged for other securities, cash or property; or (iv) sale of shares below the preferred stock conversion price. Each Series B Preferred Share will automatically convert into common stock upon the earlier of (i) notice by the Company to the holders that the Company has elected to convert all outstanding Series B Preferred Shares at any time on or after May 12, 2018; or (ii) immediately prior to the closing of a firmly underwritten initial public offering (involving the listing of the Company’s Common Stock on an Approved Stock Exchange) pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale of the Common Stock for the account of the Company in which the net cash proceeds to the Company (before underwriting discounts, commissions and fees) are at least fifty million dollars ($50,000,000). Beneficial Conversion Feature – Series B Preferred Stock (deemed dividend): Each share of Series B Preferred Stock is convertible into shares of common stock, at any time at the option of the holder at any time on or after May 12, 2018. On May 17, 2017, the date of issuances of the Series B, the publicly traded common stock price was $3.98. Based on the guidance in ASC 470-20-20, the Company determined that a beneficial conversion feature exists, as the effective conversion price for the Series B preferred shares at issuance was less than the fair value of the common stock into which the preferred shares are convertible. A beneficial conversion feature based on the intrinsic value at the date of issuances for the Series B preferred shares is scheduled below. For the year ended December 31, 2018, the beneficial conversion amount of $22,202,194 was accreted back to the preferred stock as a deemed dividend and charged to additional paid in capital in the absence of earning as the beneficial conversion feature is amortized over time through the earliest conversion date, May 12, 2018. As of December 31, 2018, the beneficial conversion feature was fully amortized. Provided below is a schedule of the issuances of Series B preferred shares and the amount accredited to deemed dividend at December 31, 2018. For the Year Ended December 31, 2018 Issuance Date Beneficial Number of Fair Value Amount Amount accreted Unamortized May 17, 2017 12 7,318,084 $ 25,247,098 $ (15,779,436 ) $ (9,467,661 ) $ - July 29, 2017 9.5 1,680,000 6,804,000 (3,674,634 ) (3,129,366 ) - August 29, 2017 8.5 369,756 1,148,263 (556,190 ) (592,073 ) - September 15, 2017 8 462,195 1,435,329 (648,601 ) (786,728 ) - October 11, 2017 7 462,195 1,121,036 (426,309 ) (694,727 ) - October 31, 2017 6.5 1,042,337 1,735,641 (548,570 ) (1,187,071 ) - December 19, 2017 5 2,449,634 6,921,348 (576,780 ) (6,344,568 ) - Total 13,784,201 $ 44,412,715 $ (22,210,520 ) $ (22,202,194 ) $ - Dividends, Voting Rights and Liquidity Value: Pursuant to the Certificate of Designations, the Series B Preferred Shares shall bear no dividends, except that if the Board shall declare a dividend payable upon the then-outstanding shares of the Company’s common stock. The Series B Preferred Shares vote together with the common stock and all other classes and series of stock of the Company as a single class on all actions to be taken by the stockholders of the Company including, but not limited to, actions amending the certificate of incorporation of the Company to increase the number of authorized shares of the common stock. Upon any dissolution, liquidation or winding up, whether voluntary or involuntary, holders of Series B Preferred Shares are entitled to (i) first receive distributions out of our assets in an amount per share equal to the Stated Value plus all accrued and unpaid dividends, whether capital or surplus before any distributions shall be made on any shares of common stock and (ii) second, on an as-converted basis alongside the common stock. Classification: These Series B Preferred Shares are classified within permanent equity on the Company’s consolidated balance sheet as they do not meet the criteria that would require presentation outside of permanent equity under ASC 480, Distinguishing Liabilities from Equity

Stock Options

Stock Options	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock Options	15. Stock Options As part of the Membership Interest Purchase Agreement entered into between the Company and Security Grade, on June 2, 2017 (see Note 5), the Company granted to the selling Members the option to purchase up to 414,854 shares of the Company’s common stock at a price of $0.001 per share. Of the 414,854 options granted, 207,427 were vested at closing and equity classified. The vesting of the remaining 207,427 shares were subject to certain milestones being achieved and was initially recognized as contingent consideration, both a component of purchase price. As a result of the milestones being met during the third quarter of 2017, the remaining 207,427 shares have also vested. The options have an expiration date of 36 months from the closing date. The exercise price will be based on the fair market value of the share on the date of grant. On March 15, 2018 the Company awarded Zachary Venegas two options to purchase a total of 490,000 shares of the Company’s common stock at prices ranging from $1.90 to $2.09 per share. These options vested on June 28, 2018 and have expiration dates ranging from March 2023 to March 2028. On February 6, 2019 the Company awarded an executive an option to purchase a total of 100,000 shares of the Company’s common stock at an exercise price $1.51 per share. These options vested on May 6, 2019 and have an expiration date of February 6, 2024. On March 19, 2019 the Company awarded the Chief Financial Officer, two options to purchase a total of 300,000 shares of the Company’s common stock at prices ranging from $2.35 to $2.59 per share. These options shall vest over a three-year period from March 2020 to March 2022 and have expiration dates ranging from March 2024 to March 2029. On March 19, 2019 the Company awarded the Chief Executive Officer, two options to purchase a total of 500,000 shares of the Company’s common stock at prices ranging from $2.35 to $2.59 per share. These options shall vest over a three-year period from March 2020 to March 2022 and have expiration dates ranging from March 2024 to March 2029. On May 2, 2019, the Company awarded an investor an option to purchase a total of 125,000 shares of the Company’s common stock at an exercise price of $2.03 per share. 62,500 of the options shall vest immediately and 62,500 of the options shall vest on August 2, 2019 provided the marketing agreement between the Company and grantee has not been terminated. These options shall expire on May 1, 2024. In May and June 2019, the Company awarded five employees, options to purchase a total of 50,000and 170,000 shares of the Company’s common stock at prices ranging from $1.05 to $2.03 per share. These options shall vest over a period ranging from September 2019 to June 2020 and have expiration dates ranging from May 2024 to June 2024. On November 1, 2019, the Company awarded an investor an option to purchase a total of 50,000 shares of the Company’s common stock at an exercise price of $.435 per share. All of the options shall vest immediately. These options shall expire on November 1, 2022. On December 1, 2019, the Company awarded an investor an option to purchase a total of 50,000 shares of the Company’s common stock at an exercise price of $.535 per share. All of the options shall vest immediately. These options shall expire on December 1, 2022. On December 27, 2019, the Company awarded various BioTrackTHC employees options to purchase a total of 1,730,000 shares of the Company’s common stock at an exercise price of $.52 per share. 432,500 of the options shall vest immediately and 432,500 of the options shall vest on June 27, 2020, December 27, 2020 and June 27, 2021. These options shall expire on December 27, 2024. The fair value of the stock options was estimated using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgement. The assumptions at the inception date are as follows: December 31, March 28, Exercise Price $0.435 to $2.59 $ 1.90 to $2.09 Fair value of company’s common stock $0.435 to $2.35 $ 0.90 to $1.90 Dividend yield 0 0 Expected volatility 110% to 191% 186.64% to 253.52 Risk free interest rate 1.55% to 2.51% 2.35% to 2.59 Expected life (years) remaining 2.92 to 9.22 4.24 to 10.00 On March 6, 2018, the Company filed a lawsuit in the United States Court for the District of Colorado alleging violations in previously disclosed representations and warranties by the plaintiff as part of the Acquisition. Following the appointment of a registered Public Company Accounting Oversight Board (“PCAOB”) auditor, certain misrepresentations, primarily surrounding the misclassification of certain revenues as being recurring, were discovered, artificially inflating the price of the membership interest in Security Grade. As a result of the settlements with the selling shareholders, 79,486 options previously issued as part of the acquisition were cancelled. As part of the BioTrackTHC Merger Agreement entered into between the Company and BioTrackTHC, on June 1, 2018 (see Note 5), the Company assumed the BioTrackTHC Stock Plan, pursuant to which options exercisable at prices between $0.001 to $1.66 per share for 8,132,410 shares of Company common stock are outstanding so that the BioTrackTHC stockholders owned approximately 48% of the Company on a fully diluted basis as of the BioTrackTHC Closing Date. Stock option activity for the years ended December 31, 2019 and 2018 is as follows: Shares Underlying Weighted Weighted Outstanding at January 1, 2018 414,854 $ 0.001 2.42 Granted 490,000 $ 1.916 8.84 Options assumed pursuant to acquisition – BioTrackTHC Stock Plan 3,841,492 $ 0.790 1.84 Options assumed pursuant to acquisition – Management Awards 4,290,918 $ 0.439 2.34 Exercised (226,822 ) $ 0.001 1.50 Forfeited and expired (79,486 ) $ 0.001 0.00 Outstanding at January 1, 2019 8,730,956 $ 0.671 2.44 Granted 3,075,000 $ 1.161 5.56 Exercised (188,575 ) $ 0.261 0.57 Outstanding at December 31, 2019 11,617,381 $ 0.807 3.21 Vested options at December 31, 2019 9,339,881 $ 0.716 1.72

Warrant Liability

Warrant Liability	12 Months Ended
	Dec. 31, 2019
Warrants and Rights Note Disclosure [Abstract]
Warrant Liability	16. Warrant Liability During the year ended December 31, 2018, the Company entered into a Graduated Lock-Up Letter to induce the entering into of a consulting agreement in exchange for 50,000 shares of the Company's common stock and the granting of 575,000 warrants for the purchase of common stock of the Company. The company recognized compensation expense of $943,000 for the year ended December 31, 2018 relating to the granting of the warrants. On December 12, 2018, the Company sold an aggregate of 222,222 units (the "December 2018 Units") of the Company's securities to an investor at a purchase price of $0.90 per unit for total proceeds of $200,000. Each December 2018 Unit consists of one share of the Company's common stock and a warrant ("December Warrant") exercisable to purchase one half of one share of common stock of the Company. As of December 31, 2019, the warrants granted were not exercised. Each December Warrant is exercisable at any time on or after 90 days from the issuance date until the four-year anniversary issuance date. Each December Warrant is exercisable at a price of $1.25 per one half of one share of common stock (thereby requiring the exercise of two warrants to purchase one share of common stock). The Company determined that the December Warrants are puttable for cash upon a fundamental transaction at the option of the holder and as such required classification as a liability pursuant to ASC 480, Distinguishing Liabilities from Equity On March 1, 2019, in connection with the issuance of Note Ten, the Company issued warrants, of which the value was derived and based off the fair value of Note Ten, to the investor to purchase 160,715 shares of the Company's common stock at $1.40 per share. Exercise of the purchase rights represented by the warrant may be made, in whole or in part, at any time or times on or after March 1, 2019 and on or before March 1, 2024, by delivery to the Company of the Notice of Exercise. The Company determined that the warrants associated with Note Ten are puttable for cash upon a fundamental transaction at the option of the holder and as such required classification as a liability pursuant to ASC 480, Distinguishing Liabilities from Equity On January 10, 2019, the Company entered into an Investment Unit Purchase Agreement (the "First Investment Agreement") to issue and sell investment units to an investor, in which the investment units consist of one share of the common stock of the Company, and a warrant exercisable for one half share of common stock of the Company at an Exercise Price of $1.25 per share for cash at a price per investment unit of $0.90. On March 5, 2019, the Company sold an aggregate of 1,255,222 units of the Company's securities to an investor at a purchase price of $0.90 per unit for total proceeds of $1,129,700. In connection with the First Investment Agreement, the investor is entitled to purchase from the Company, at the Exercise Price, at any time on or after 90 days from the issuance date, 627,611 shares of the Company's common stock (the "March Warrant Shares"). The Company determined that the warrants are puttable for cash upon a fundamental transaction at the option of the holder and as such required classification as a liability pursuant to ASC 480, Distinguishing Liabilities from Equity The fair value of the March Warrant Shares at issuance on January 10, 2019 is in excess of the proceeds received, the warrant liability is required to be recorded at fair value with the excess of the fair value over the proceeds received recognized as a loss in earnings. The gross proceeds from the 1,255,222 investment units at $0.90 was $1,129,700. The fair value of the March Warrant Shares at issuance was $1,717,506. The amount to be recognized as a loss in earnings is calculated as follows: Proceeds from January investment units $ 1,129,700 Par value of common stock issues $ (1,255 ) Fair value of warrants $ (1,717,506 ) Loss on issuance of warrants (January 10, 2019 issuance) $ (589,061 ) As of December 31, 2019, the fair value of the warrant liability was $193,753 and the Company recorded a change in fair value of the warrant liability of $(1,523,753) for the year ended December 31, 2019. On March 11, 2019, the Company issued warrants to an investment bank to purchase a total of 100,000 restricted shares of the Company's common stock at a per share purchase price of $0.90. The warrants are exercisable at any time nine months after the issuance date within three years of issuance. The Company determined that the warrants are puttable for cash upon a fundamental transaction at the option of the holder and as such required classification as a liability pursuant to ASC 480, Distinguishing Liabilities from Equity On June 14, 2019, the Company entered into another Investment Unit Purchase Agreement (the "Second Investment Agreement") to issue and sell investment units to an investor (the "investor"), in which the investment units consist of one share of the common stock of the Company, and a warrant exercisable for one half share of common stock of the Company at an exercise price of $1.25 per share for cash at a price per investment unit of $0.90. On June 24, 2019, the Company sold an aggregate of 166,667 units of the Company's securities to an investor at a purchase price of $0.90 per unit for total proceeds of $150,000. In connection with the Second Investment Agreement, the investor is entitled to purchase from the Company, at the exercise price, at any time on or after 90 days from the issuance date, 83,333 shares of the Company's common stock (the "June Warrant Shares"). The gross proceeds from the 166,667 investment units at $0.90 was $150,000. The fair value of the June Warrant Shares at issuance was $83,586 while as of December 31, 2019, the fair value of the warrant liability was $26,881. Accordingly, the Company recorded a change in fair value of the warrant liability of $(56,705) related to the warrants for the year ended December 31, 2019. On August 15, 2019, in connection with the issuance of Note Eleven, the Company issued warrants, of which the value was derived and based off the fair value of Note Eleven, to the investor to purchase 25,000 shares of the Company's common stock at $1.00 per share. Exercise of the purchase rights represented by the warrant may be made, in whole or in part, at any time or times on or after August 15, 2019 and on or before August 15, 2024, by delivery to the Company of the Notice of Exercise. The Company determined that the warrants associated with Note Eleven are puttable for cash upon a fundamental transaction at the option of the holder and as such required classification as a liability pursuant to ASC 480, Distinguishing Liabilities from Equity On September 16, 2019, in connection with the issuance of Note Twelve, the Company issued warrants, of which the value was derived and based off the fair value of Note Twelve, to the investor to purchase 25,000 shares of the Company's common stock at $1.00 per share. Exercise of the purchase rights represented by the warrant may be made, in whole or in part, at any time or times on or after September 16, 2019 and on or before September 16, 2024, by delivery to the Company of the Notice of Exercise. The Company determined that the warrants associated with Note Twelve are puttable for cash upon a fundamental transaction at the option of the holder and as such required classification as a liability pursuant to ASC 480, Distinguishing Liabilities from Equity On October 11, 2019, in connection with the issuance of Note Thirteen, the Company issued warrants, of which the value was derived and based off the fair value of Note Thirteen, to the investor to purchase 25,000 shares of the Company's common stock at $1.00 per share. Exercise of the purchase rights represented by the warrant may be made, in whole or in part, at any time or times on or after October 11, 2019 and on or before October 11, 2024, by delivery to the Company of the Notice of Exercise. The Company determined that the warrants associated with Note Thirteen are puttable for cash upon a fundamental transaction at the option of the holder and as such required classification as a liability pursuant to ASC 480, Distinguishing Liabilities from Equity On November 1, 2019, the Company issued warrants to an institution to purchase a total of 100,000 restricted shares of the Company's common stock at a per share purchase price of $0.435. The warrants are exercisable at any time after the issuance date within five years of issuance. The Company determined that the warrants are puttable for cash upon a fundamental transaction at the option of the holder and as such required classification as a liability pursuant to ASC 480, Distinguishing Liabilities from Equity On December 26, 2019, in connection with the issuance of Note Fourteen, the Company issued warrants, of which the value was derived and based off the fair value of Note Fourteen, to the investor to purchase 12,500 shares of the Company's common stock at $1.00 per share. Exercise of the purchase rights represented by the warrant may be made, in whole or in part, at any time or times on or after December 26, 2019 and on or before December 26, 2024, by delivery to the Company of the Notice of Exercise. The Company determined that the warrants associated with Note Fourteen are puttable for cash upon a fundamental transaction at the option of the holder and as such required classification as a liability pursuant to ASC 480, Distinguishing Liabilities from Equity A summary of warrant activity is as follows: Warrant Shares Weighted Average Balance at January 1, 2018 2,732,073 $ 0.23 Warrants granted 686,111 $ 0.21 Balance at January 1, 2019 3,418,184 $ 0.23 Warrants granted 1,694,874 $ 1.17 Balance at December 31, 2019 5,113,058 $ 0.55 Warrant Obligations In connection with the Series B Preferred Stock Purchase Agreement (See Note 14), the Company is obligated to issue warrants to a third-party to purchase 812,073 shares of common stock at $0.325 per share for services rendered. These warrants have been accounted for as warrant obligations and are recognized as a liability on the consolidated balance sheets as of December 31, 2019 and 2018. For the years ended December 31, 2019 and 2018, the Company recorded a change in fair value of the warrant obligations of $(676,144) and $1,625,398, respectively, and is reflected in the consolidated statements of operations. Although the Company issued warrants during the first quarter of 2018, the rights entitled to the third-party holder of the warrants to purchase shares of the Company's common stock was not exercised. Upon exercising the right to purchase the Company's common stock by the third-party, the Company will de-recognize the liability for warrant obligations and reclassify the appropriate amount into equity. The fair value of the Company's obligation to issue warrants was calculated using the Black-Scholes model and the following assumptions: As of As of Fair value of company's common stock $ 0.60 $ 0.90 Dividend yield 0 % 0 % Expected volatility 45% - 140 % 175.0 % Risk Free interest rate 1.55% - 1.79 % 2.49 % Expected life (years) 2.83 1.65 Fair value of financial instruments - warrants $ 715,259 $ 896,171 The change in fair value of the financial instruments – warrants is as follows: Amount Balance as of January 1, 2018 $ 2,429,569 Change in fair value of liability to issue warrants (1,641,398 ) Balance as of December 31, 2018 $ 896,171 Fair value of warrants issued 3,632,065 Change in fair value of liability to issue warrants (3,812,977 ) Balance as of December 31, 2019 $ 715,259

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	17. Stock-Based Compensation 2017 Omnibus Incentive Plan The Company's 2017 Omnibus Incentive Plan (the "2017 Plan") was adopted by our Board of Directors and a majority of our voting securities on October 17, 2017. The 2017 Plan permits the granting of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and dividend equivalent rights to eligible employees, directors and consultants. We grant options to purchase shares of common stock under the 2017 Plan at no less than the fair value of the underlying common stock as of the date of grant. Options granted under the Plan have a maximum term of ten years. Under the Plan, a total of 5,000,000 shares of common stock are reserved for issuance, of which options to purchase 2,599,945 and 1,004,945 shares of common stock were granted as of December 31, 2019 and December 31, 2018, respectively. Bio-Tech Medical Software, Inc. 2014 Stock Incentive Plan On October 22, 2014, BioTrackTHC approved and adopted the BioTrackTHC Stock Plan. The BioTrackTHC Stock Plan set aside and reserved 600,000 shares of BioTrackTHC's common stock for grant and issuance in accordance with its terms and conditions. Persons eligible to receive awards from the BioTrackTHC Stock Plan include employees (including officers and directors) of BioTrackTHC or its affiliates and consultants who provide significant services to BioTrackTHC or its affiliates (the "Grantees"). The BioTrackTHC Stock Plan permits BioTrackTHC to issue to Grantees qualified and/or non-qualified options to purchase BioTrackTHC's common stock, restricted common stock, performance units, and performance shares. The term of each award under the BioTrackTHC Stock Plan shall be no more than ten years from the date of grant thereof. BioTrackTHC's Board of Directors or a committee designated by the Board of Directors is responsible for administration of the BioTrackTHC Stock Plan and has the sole discretion to determine which Grantees will be granted awards and the terms and conditions of the awards granted. The BioTrackTHC Stock Plan will annually increase the number of shares of common stock authorized for issuance thereunder to 15% of the Company's common stock outstanding as of the first day of each calendar year beginning January 1, 2016 (see Notes 5 and 15). BioTrackTHC Management Awards On September 1, 2015 and November 1, 2015, BioTrackTHC's Board approved individual employee option grants (the "Executive Grants") for three executives (the "Executives"). Pursuant to the Executive Grants, the Executives were each granted stock options to purchase 146,507 shares (totaling 439,521 shares) of BioTrackTHC's common stock (the "Option") at an exercise price equal to approximately $7.67. The options vest as to 25% of the shares subject to the Options, one year after the date of grant and then in equal quarterly installments for the three years thereafter, subject to the Executive's continued employment with BioTrackTHC (see Note 5 and 15).

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	18. Income Taxes No provision for U.S. federal or state income taxes has been recorded as the Company has incurred net operating losses since inception. Significant components of the Company’s net deferred income tax assets for the years ended December 31, 2019 and 2018 consist of income tax loss carryforwards. These amounts are available for carryforward for use in offsetting taxable income of future years through 2035. Realization of the future tax benefits is dependent on the Company’s ability to generate sufficient taxable income within the carry-forward period. Utilization of the net operating loss carry-forwards may be subject to a substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. Due to the Company’s history of operating losses, these deferred tax assets arising from the future tax benefits are currently not likely to be realized and are thus reduced to zero by an offsetting valuation allowance. As a result, there is no provision for income taxes. For the years ended December 31, 2019, and 2018, the Company has a net operating loss carry forwards of approximately $18,025,000 and $12,686,000, respectively. Utilization of these net loss carry forwards is subject to the limitations of Internal Revenue Code Section 382. The Company applied a 100% valuation reserve against the deferred tax benefit as the realization of the benefit is not certain.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	19. Commitments and Contingencies Under Topic 842, operating lease expense is generally recognized evenly on a straight-line basis. The Company has operating leases primarily consisting of facilities with remaining lease terms of one year to five years. The lease term represents the period up to the early termination date unless it is reasonably certain that the Company will not exercise the early termination option. Certain leases include rental payments that are adjusted periodically based on changes in consumer price and other indices. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company combines the lease and non-lease components in determining the lease liabilities and ROU assets. Activity related to the Company's leases was as follows: Year Ended Operating lease expense $ 513,008 Cash paid for amounts included in the measurement of operating lease liabilities $ 389,380 ROU assets obtained in exchange for operating lease obligations $ 1,499,752 The Company's lease agreements generally do not provide an implicit borrowing rate, therefore an internal incremental borrowing rate is determined based on information available at lease commencement date for purposes of determining the present value of lease payments. The Company used the incremental borrowing rate on December 31, 2018 for all leases that commenced prior to that date. ROU lease assets and lease liabilities for the Company's operating leases were recorded in the consolidated balance sheet as follows: As of Other assets $ 1,091,065 Accounts payable and accrued liabilities $ 373,710 Other long-term liabilities 783,230 Total lease liabilities $ 1,156,940 Weighted average remaining lease term (in years) 2.91 Weighted average discount rate 6.00 % The Company is obligated under operating lease agreements for office facilities in Colorado, Florida, Washington and Hawaii, which expire in February and March 2021. Rent expense incurred under the Company's operating leases amounted to $561,530 and $362,607 during the years ended December 31, 2019 and 2018, respectively. Future lease payments included in the measurement of lease liabilities on the consolidated balance sheet as of December 31, 2019, for the following five fiscal years and thereafter were as follows: As of 2020 $ 393,413 2021 248,223 2022 195,144 2023 200,944 2024 205,435 Thereafter - Total future minimum lease payments $ 1,243,159 Less imputed interest (86,219 ) Total $ 1,156,940 As of December 31, 2019, the Company had additional operating lease obligations for a lease with a future effective date of approximately $600,000. This operating lease will commence during the first quarter of fiscal 2022 with a lease term of three years. As of December 31, 2019 the future minimum lease payments, as defined under the previous lease accounting guidance of ASC 840, under noncancelable operating leases for the following five fiscal years and thereafter are as follows: Years Ending December 31, Future 2020 420,291 2021 275,223 2022 198,144 2023 199,144 2024 205,135 Thereafter - Total $ 1,297,937

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Segment Reporting	20. Segment Reporting FASB ASC 280-10-50 requires use of the “management approach” model for segment reporting. The management approach is based on the way a company’s management organized segments within the company for making operating decisions and assessing performance. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision–making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision–making group is composed of the Chief Executive Officer. The Company operates in three segments, Security and guarding, Systems installation and Software. Asset information by operating segment is not presented below since the chief operating decision maker does not review this information by segment. The reporting segments follow the same accounting policies used in the preparation of the Company’s consolidated financial statements. The following represents selected information for the Company’s reportable segments: For the Years Ended 2019 2018 Security and guarding Revenue $ 5,022,436 $ 4,889,472 Cost of revenue 4,004,881 3,618,173 Gross profit 1,017,555 1,271,299 Total operating expenses (1) 7,174,866 11,101,635 Loss from operations (6,157,311 ) (9,830,336 ) Total other income 553,612 3,029,392 Total net loss $ (5,603,699 ) $ (6,800,944 ) Systems installation Revenue $ 783,192 $ 499,138 Cost of revenue 854,801 531,567 Gross profit (71,609 ) (32,429 ) Total operating expenses 545,474 168,159 Loss from operations (617,083 ) (200,588 ) Total other income (expense) 88,903 (273,642 ) Total net loss $ (528,180 ) $ (474,230 ) Software Revenue $ 9,486,472 $ 4,174,963 Cost of revenue 3,318,455 1,819,299 Gross profit 6,168,017 2,355,664 Total operating expenses 9,616,488 3,046,390 Loss from operations (3,448,471 ) (690,726 ) Total other income 181 98 Total net loss $ (3,448,290 ) $ (690,628 ) (1) Total operating expenses for the years ended December 31, 2019 and 2018 contained certain corporate expenditures totaling $5,399,184 and $8,687,900, respectively, which benefit all segments of the business but are not specifically allocable to any one segment.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	21. Subsequent Events On February 10, 2020, the Company and Advantage Platform Services Inc. (“Advantage”) entered into an Agreement for the Purchase and Sale of Future Receipts (the “Future Receipts Agreement”). Pursuant to the terms and conditions of the Future Receipts Agreement, the Company sold to Advantage 15% of the proceeds of future sales made by the Company, up to $660,000 (“Future Sales Amount”), for an immediate cash payment by Advantage of $500,000 (“Purchase Price”). The Future Receipts Agreement includes an origination fee of $15,000, which was deducted from the Purchase Price, and weekly payments of $15,000 for eight weeks followed by weekly payments of $20,000 to be made by the Company to Advantage until the Future Sales Amount is paid in full. On February 14, 2020 John Audet filed a complaint in 15 th On March 6, 2020, Terence Ferraro resigned as a director of Helix TCS, Inc. (the “Company”). On the same date, the Company’s Board of Directors appointed Garvis Toler III as a director to fill the vacancy. TJ Ferraro’s resignation was not due to a disagreement with the Company’s Board of Directors or management or any matter relating to the Company’s operations, policies or procedures. During January and February 2020, the holder of a 25% fixed secured convertible promissory note issued by the Company elected its option to partially convert $140,000 in principal of the convertible note into 435,554 shares of the Company’s common stock. During March 2020, the holder of a 10% fixed secured convertible promissory note issued by the Company elected its option to partially convert $120,000 in principal of the convertible note into 1,084,186 shares of the Company’s common stock. On January 28, 2020, the Company entered into a securities purchase agreement pursuant to which the Company agreed to sell 270,270 shares of restricted common stock of the Company and 135,135 warrants to purchase shares of restricted common stock of the Company for an aggregate purchase price of $100,000. The warrants are exercisable at $.40 per warrant and expire four years after issuance. On February 29, 2020 the Company and Patrick Vo entered into a Separation Agreement and General Release (the “Separation Agreement”). As part of the Separation Agreement Patrick Vo forfeited 1,634,670 vested and unexercised stock options to purchase shares of the Company’s common stock.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, which include Helix TCS, LLC ("Helix TCS"), Security Consultants Group, LLC ("Security Consultants"), Boss Security Solutions, Inc. ("Boss Security"), Security Consultants Group Oregon, LLC ("Security Oregon"), Security Grade, BioTrackTHC (since June 1, 2018), Engeni US (since August 3, 2018), Tan Security (since April 1, 2019) and Green Tree International, Inc. (since September 10, 2019).
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Use of estimates includes the following: 1) allowance for doubtful accounts, 2) estimated useful lives of property, equipment and intangible assets, 3) intangibles impairment, 4) valuation of convertible notes payable and 5) revenue recognition. Actual results could differ from estimates.
Cash	Cash Cash consists of checking accounts. The Company considers all highly-liquid investments purchased with a maturity of three months or less at the time of purchase to be cash equivalents. The Company has no cash equivalents as of December 31, 2019 or 2018.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount, net of an allowance for doubtful accounts. The Company performs ongoing credit evaluations of its customers and adjusts credit limits based upon payment history and the customer's current credit worthiness, as determined by the review of their current credit information; and determines the allowance for doubtful accounts based on historical write-off experience, customer specific facts and economic conditions. Management charges balances off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company determines when receivables are past due, or delinquent based on how recently payments have been received. Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing accounts receivable. Allowance for doubtful accounts was $273,138 and $76,156 at December 31, 2019 and 2018, respectively.
Long-Lived Assets, Including Definite Lived Intangible Assets	Long-Lived Assets, Including Definite Lived Intangible Assets Long-lived assets, other than goodwill and other indefinite-lived intangibles, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable through the estimated undiscounted future cash flows derived from such assets. Definite-lived intangible assets primarily consist of non-compete agreements and customer relationships. For long-lived assets used in operations, impairment losses are only recorded if the asset's carrying amount is not recoverable through its undiscounted, probability-weighted future cash flows. The Company measures the impairment loss based on the difference between the carrying amount and the estimated fair value. When an impairment exists, the related assets are written down to fair value.
Goodwill	Goodwill Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value-based test. Helix reviews goodwill for possible impairment annually during the fourth quarter, or whenever events or circumstances indicate that the carrying amount may not be recoverable. The impairment model prescribes a two-step method for determining goodwill impairment. However, an entity is permitted to first assess qualitative factors to determine whether the two-step goodwill impairment test is necessary. The qualitative factors considered by Helix may include, but are not limited to, general economic conditions, Helix’s outlook, market performance of Helix’s industry and recent and forecasted financial performance. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that a reporting unit’s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. In the first step, Helix determines the fair value of its reporting unit using a discounted cash flow analysis. If the net book value of the reporting unit exceeds its fair value, Helix then performs the second step of the impairment test, which requires allocation of the reporting unit’s fair value to all of its assets and liabilities using the acquisition method prescribed under authoritative guidance for business combinations with any residual fair value being allocated to goodwill. An impairment charge is recognized when the implied fair value of Helix’s goodwill is less than its carrying amount. Assumptions and estimates used in the evaluation of impairment may affect the carrying value of long-lived assets, which could result in impairment charges in future periods. Such assumptions include projections of future cash flows and the current fair value of the asset. It was determined that during the first quarter of 2018, the Company’s entire amount of goodwill attributable to the Security Grade acquisition was impaired. See Note 7 for a further discussion on the impairment.
Accounting for Acquisitions	Accounting for Acquisitions In accordance with the guidance for business combinations, the Company determines whether a transaction or other event is a business combination, which requires that the assets acquired, and liabilities assumed constitute a business. Each business combination is then accounted for by applying the acquisition method. If the assets acquired are not a business, the Company accounts for the transaction or other event as an asset acquisition. Under both methods, the Company recognizes the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquired entity. In addition, for transactions that are business combinations, the Company evaluates the existence of goodwill or a gain from a bargain purchase. The Company capitalizes acquisition-related costs and fees associated with asset acquisitions and immediately expense acquisition-related costs and fees associated with business combinations.
Business Combinations	Business Combinations The Company accounts for its business combinations under the provisions of Accounting Standards Codification ("ASC") Topic 805-10, Business Combinations ("ASC 805-10"), which requires that the purchase method of accounting be used for all business combinations. Assets acquired and liabilities assumed, including non-controlling interests, are recorded at the date of acquisition at their respective fair values. ASC 805-10 also specifies criteria that intangible assets acquired in a business combination must meet to be recognized and reported apart from goodwill. Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from the business combinations and are expensed as incurred. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date and any changes in fair value after the acquisition date are accounted for as measurement-period adjustments. Changes in fair value of contingent consideration resulting from events after the acquisition date, such as earn-outs, are recognized as follows: 1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or 2) if the contingent consideration is classified as a liability, the changes in fair value are recognized in earnings. The estimated fair value of net assets acquired, including the allocation of the fair value to identifiable assets and liabilities, was determined using established valuation techniques. The estimated fair value of the net assets acquired was determined using the income approach to valuation based on the discounted cash flow method. Under this method, expected future cash flows of the business on a stand-alone basis are discounted back to a present value. The estimated fair value of identifiable intangible assets, consisting of software and trade name acquired were determined using the relief from royalty method. The most significant assumptions under the relief from royalty method used to value software and trade names include: estimated remaining useful life, expected revenue, royalty rate, tax rate, discount rate and tax amortization benefit. The discounted cash flow method used to value non-compete agreements includes assumptions such as: expected revenue, term of the non-compete agreements, probability and ability to compete, operating margin, tax rate and discount rate. Management has developed these assumptions on the basis of historical knowledge of the business and projected financial information of the Company. These assumptions may vary based on future events, perceptions of different market participants and other factors outside the control of management, and such variations may be significant to estimated values.
Revenue Recognition	Revenue Recognition Under FASB Topic 606, Revenue from Contacts with Customers The security services revenue is generated from performing armed and unarmed guarding which is contracted for on an hourly basis. Revenues associated with these contracted services are recognized under time-based arrangements as services are provided. Additionally, the Company provides transportation security services, which are generally contracted for on a per-run basis and sometimes additional fees and surcharges are also billed to the client depending on the length of the run. Revenues associated with these services are recognized as the transportation service is provided. The Company also generates revenue from developing and licensing seed to sale cannabis compliance software to both private-sector and public-sector (government agencies) businesses that are involved in cannabis related operations. The Company also generates revenue from on-going training, support and software customization services. Occasionally, the Company will enter into systems installation arrangements. Installation jobs are estimated based on the cost of equipment to be installed, the number of hours expected to be incurred to complete the job and other ancillary costs. Revenue associated with these services are recognized over the arrangement period. Lastly, the Company generates monthly recurring revenues from Cannalytics, its business intelligence and data tool for commercial customers. Revenue is recognized monthly.
Segment Information	Segment Information Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 280, Segment Reporting, establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company's chief operating decision maker is the Chief Executive Officer, who reviews the financial performance and the results of operations of the segments prepared in accordance with GAAP when making decisions about allocating resources and assessing performance of the Company. Asset information by operating segment is not presented since the chief operating decision maker does not review this information by segment. The reporting segments follow the same accounting policies used in the preparation of the Company's consolidated financial statements.
Expenses	Expenses Cost of Revenue The cost of revenues is the total cost incurred to obtain a sale and the cost of the goods or services sold. Cost of revenues primarily consisted of hourly compensation for security personnel and employees involved in the creation and development of licensing software. Operating Expenses Operating expenses encompass selling general and administrative expenses, salaries and wages, professional and legal fees and depreciation and amortization. Selling, general and administrative expenses consist primarily of rent/moving expenses, advertising and travel expenses. Salaries and wages is composed of non-revenue generating employees. Professional services are principally comprised of outside legal, audit, information technology consulting, marketing and outsourcing services as well as the costs related to being a publicly traded company. Other Income Other income consisted of a gain on the change in fair value of convertible notes, gain on the change in the fair value of warrant liability, loss on the change in fair value of convertible notes – related party, loss on the change in fair value of contingent consideration, loss on issuance of warrants and interest expense.
Property and Equipment	Property and Equipment Property and equipment are stated at cost and depreciated on a straight-line basis over their estimated useful lives. Useful lives are 3 years for vehicles and 5 years for furniture and equipment. Maintenance and repairs are expensed as incurred and major improvements are capitalized. When assets are sold, or retired, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is included in loss from operations.
Contingencies	Contingencies Occasionally, the Company may be involved in claims and legal proceedings arising from the ordinary course of its business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred, and the amount can be reasonably estimated. If these estimates and assumptions change or prove to be incorrect, it could have a material impact on the Company's consolidated financial statements. Contingencies are inherently unpredictable, and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions.
Advertising	Advertising Advertising costs are expensed as incurred and included in selling, general and administrative expenses and amounted to $378,233 and $96,420 for the years ended December 31, 2019 and 2018, respectively.
Foreign Currency	Foreign Currency The local currency is the functional currency for one entity's operations outside the United States. Assets and liabilities of these operations are translated to U.S. dollars at the exchange rate in effect at the end of each period. Income statement accounts are translated at the average exchange rate prevailing during the period. Translation adjustments arising from the use of differing exchange rates from period to period are included as a component of other comprehensive loss within shareholders' equity. Gains and losses from foreign currency transactions are included in net loss for the period.
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company has incurred net operating loss for financial-reporting and tax-reporting purposes. Accordingly, for Federal and state income tax purposes, the benefit for income taxes has been offset entirely by a valuation allowance against the related federal and state deferred tax asset for the years ended December 31, 2019 and 2018.
Comprehensive Loss	Comprehensive Loss Comprehensive loss consists of consolidated net loss and foreign currency translation adjustments. Foreign currency translation adjustments included in comprehensive loss were not tax-effected as investments in international affiliates are deemed to be permanent.
Distinguishing Liabilities from Equity	Distinguishing Liabilities from Equity The Company relies on the guidance provided by ASC Topic 480, Distinguishing Liabilities from Equity Once the Company determines that a financial instrument should not be classified as a liability, the Company determines whether the financial instrument should be presented between the liability section and the equity section of the balance sheet ("temporary equity"). The Company will determine temporary equity classification if the redemption of the financial instrument is outside the control of the Company (i.e. at the option of the holder). Otherwise, the Company accounts for the financial instrument as permanent equity. Initial Measurement The Company records its financial instruments classified as liability, temporary equity or permanent equity at issuance at the fair value, or cash received. Subsequent Measurement – Financial instruments classified as liabilities The Company records the fair value of its financial instruments classified as liabilities at each subsequent measurement date. The changes in fair value of its financial instruments classified as liabilities are recorded as other expense/income.
Share-based Compensation	Share-based Compensation The Company accounts for stock-based compensation to employees in conformity with the provisions of ASC Topic 718, Stock Based Compensation The Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC Topic 718, based upon the fair-value of the underlying instrument. The equity instruments are valued using the Black-Scholes valuation model. The measurement of stock-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense over the period which services are received. The Company calculates the fair value of option grants utilizing the Black-Scholes pricing model and estimates the fair value of the stock based upon the estimated fair value of the common stock. The amount of stock-based compensation recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. The resulting stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight- line basis over the requisite service period of the award.
Fair Value of Financial Instruments	Fair Value of Financial Instruments ASC Topic 820, Fair Value Measurements and Disclosures ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC Topic 820 are described as follows: ● Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date. ● Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. ● Level 3 – Inputs that are unobservable for the asset or liability. Certain assets and liabilities of the Company are required to be recorded at fair value either on a recurring or non-recurring basis. Fair value is determined based on the price that would be received for an asset or paid to transfer a liability in an orderly transaction based on market participants. The following section describes the valuation methodologies that the Company used to measure, for disclosure purposes, its financial instruments at fair value. Convertible notes payable The fair value of the Company's convertible notes payable, approximated the carrying value as of December 31, 2019 and 2018. Factors that the Company considered when estimating the fair value of its debt included market conditions and the term of the debt. The level of the debt would be considered as Level 2. Additional Disclosures Regarding Fair Value Measurements The carrying value of cash, accounts receivable, prepaid expenses, deposits, accounts payable and accrued liabilities, advances from shareholders and obligation pursuant to acquisition approximate their fair value due to the short-term maturity of those items.
Earnings (Loss) per Share	Earnings (Loss) per Share The Company follows ASC 260, Earnings Per Share Basic net loss per share is based on the weighted average number of common and common-equivalent shares outstanding. Potential common shares includable in the computation of fully-diluted per share results are not presented in the consolidated financial statements for the years ended December 31, 2019 and 2018 as their effect would be anti-dilutive. The anti-dilutive shares of common stock outstanding for years ended December 31, 2019 and 2018 were as follows: For the Years Ended 2019 2018 Potentially dilutive securities: Convertible notes payable 5,994,838 124,784 Convertible Preferred A Stock 1,000,000 1,000,000 Convertible Preferred B Stock 13,784,201 13,784,201 Warrants 5,113,058 3,418,184 Stock options 11,617,381 8,729,463
Reclassifications	Reclassifications Certain reclassifications have been made to the prior period financial statements to conform to the current period financial statement presentation. These reclassifications had no effect on net earnings or cash flows as previously reported.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-.02, Leases (Topic 842) The Company adopted the new standard on January 1, 2019 and used the modified retrospective approach with the effective date as the date of initial application. Consequently, prior period balances and disclosures have not been restated. The Company elected certain practical expedients, which among other things, allowed us to carry forward prior conclusions about lease identification and classification. Adoption of the standard resulted in the balance sheet recognition of additional lease assets and lease liabilities of approximately $1,500,000. The new standard also provides practical expedients for an entity's ongoing accounting. The Company currently has elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in separate lease and non-lease components for all our leases. For additional information regarding the Company's leases, see Note 19 in the notes to condensed consolidated financial statements. In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception In February 2018, the FASB issued ASU 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220); Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (ASC 718): Improvements to Nonemployee Share-Based Payment Accounting In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (ASC 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact on the Company's consolidated financial statements and related disclosures effective for public companies for the reporting periods beginning after December 15, 2019.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Schedule of anti-dilutive shares of common stock outstanding	For the Years Ended 2019 2018 Potentially dilutive securities: Convertible notes payable 5,994,838 124,784 Convertible Preferred A Stock 1,000,000 1,000,000 Convertible Preferred B Stock 13,784,201 13,784,201 Warrants 5,113,058 3,418,184 Stock options 11,617,381 8,729,463

Revenue Recognition (Tables)

Revenue Recognition (Tables)	12 Months Ended
	Dec. 31, 2019
Revenue Recognition [Abstract]
Schedule of disaggregation of revenue	For the Years Ended 2019 2018 Types of Revenues: Security and Guarding $ 5,022,436 $ 4,889,472 Systems Installation 783,192 499,138 Software 9,486,472 4,174,963 Total revenues $ 15,292,100 $ 9,563,573

Business Combination (Tables)

Business Combination (Tables)	12 Months Ended
	Dec. 31, 2019
BioTrackTHC Acquisition [Member]
Schedule of allocation of the purchase price	Base Price - Common Stock $ 44,905,542 Base Price - Stock Options 12,646,491 Total Purchase Price $ 57,552,033
Schedule of assets acquired and liabilities assumed	Weighted Average Useful Life Description Fair Value (in years) Assets acquired: Cash $ 448,697 Accounts receivable 128,427 Prepaid expenses 351,615 Property, plant and equipment, net 72,252 Goodwill 39,135,007 Customer list 8,304,449 5 Software 9,321,627 4.5 Tradename 466,081 4.5 Total assets acquired $ 58,228,155 Liabilities assumed: Accounts payable $ 223,581 Other liabilities 452,541 Total liabilities assumed 676,122 Estimated fair value of net assets acquired $ 57,552,033
Engeni Acquisition Member [Member]
Schedule of allocation of the purchase price	Base Price - Common Stock $ 388,702 Contingent Consideration - Common Stock 777,298 Total Purchase Price $ 1,166,000
Schedule of assets acquired and liabilities assumed	Weighted Average Useful Life Description Fair Value (in years) Assets acquired: Cash $ 5,609 Accounts receivable and other assets 30,479 Property, plant and equipment, net 57,830 Software 449,568 3.3 Goodwill 778,552 Total assets acquired $ 1,322,038 Liabilities assumed: Accounts payable $ 56,038 Total liabilities assumed 56,038 Estimated fair value of net assets acquired $ 1,266,000
Tan's International Security [Member]
Schedule of allocation of the purchase price	Base Price – Cash at closing $ 25,000 Base Price – Deferred cash payment (including $25,000 to be made on the 4,8 and 12-month anniversaries of closing) 75,000 Base Price – Common Stock 710,000 Total Purchase Price $ 810,000
Schedule of assets acquired and liabilities assumed	Description Fair Value Assets acquired: Cash $ 2,940 Accounts receivable 7,635 Goodwill 821,807 Total assets acquired $ 832,382 Liabilities assumed: Accounts payable $ 12,526 Other liabilities 9,856 Total liabilities assumed 22,382 Estimated fair value of net assets acquired $ 810,000
Green Tree International,Inc [Member]
Schedule of allocation of the purchase price	Base Price - Common Stock $ 12,909,611 Total Purchase Price $ 12,909,611
Schedule of assets acquired and liabilities assumed	Description Fair Value Weighted Average Useful Life Assets acquired: Note Receivable, net $ 135,000 Property, Plant and Equipment, Net 12,142 Software 452,002 4.5 Goodwill 12,980,840 Total assets acquired $ 13,579,984 Liabilities assumed: Accounts Payable 43,717 Notes Payable 400,000 Other Liabilities 226,656 Total liabilities assumed: 670,373 Estimated fair value of net assets acquired: $ 12,909,611
Security Grade Acquisition [Member]
Schedule of allocation of the purchase price	Base Price - Cash $ 2,100,373 Base Price - Stock Options 916,643 Contingent Consideration - Stock Options 916,643 Total Purchase Price $ 3,933,659
Schedule of assets acquired and liabilities assumed	Weighted Average Useful Life Description Fair Value (in years) Assets acquired: Cash $ 14,137 Accounts receivable 53,792 Costs & earnings in excess of billings 96,898 Property, plant and equipment, net 27,775 Trademarks 25,000 10 Customer lists 3,154,578 5 Web address 5,000 5 Goodwill 664,329 Other assets 3,880 Total assets acquired $ 4,045,389 Liabilities assumed: Billings in excess of costs $ 23,967 Loans payable 18,414 Credit card payable and other liabilities 69,349 Total liabilities assumed 111,730 Estimated fair value of net assets acquired $ 3,933,659

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of property and equipment, net	December 31, 2019 2018 Furniture and equipment $ 262,167 $ 264,659 Software equipment 561,964 - Vehicles 201,066 202,700 Total 1,025,197 467,359 Less: Accumulated depreciation (219,518 ) (117,841 ) Property and equipment, net $ 805,679 $ 349,518

Intangible Assets, Net and Go_2

Intangible Assets, Net and Goodwill (Tables)	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets, net and goodwill	December 31, 2019 Estimated Useful Life (Years) Gross Carrying Amount Assets Acquired Pursuant to Business Combination (2) Assets Acquired Accumulated Amortization Net Book Value Database 5 $ 93,427 $ - $ - $ (69,533 ) $ 23,894 Trade names and trademarks 5 - 10 591,081 - - (207,525 ) 383,556 Web addresses 5 130,000 - - (95,611 ) 34,389 Customer list 5 11,459,027 - - (4,256,070 ) 7,202,957 Software 4.5 9,771,195 452,002 1,625 (3,492,525 ) 6,732,297 Domain Name 5 - - 20,231 (2,037 ) 18,194 $ 22,044,730 $ 452,002 $ 21,856 $ (8,123,301 ) $ 14,395,287 December 31, 2018 Estimated Useful Life (Years) Gross Carrying Amount at December 31, 2017 Assets Acquired Pursuant to Business Combination (1) (2) Accumulated Amortization Net Book Value Database 5 $ 93,427 $ - $ (50,858 ) $ 42,569 Trade names and trademarks 5-10 125,000 466,081 (91,554 ) 499,527 Web addresses 5 130,000 - (69,625 ) 60,375 Customer list 5 3,154,578 8,304,449 (1,965,520 ) 9,493,507 Software 4.5 - 9,771,195 (1,263,095 ) 8,508,100 $ 3,503,005 $ 18,541,725 $ (3,440,652 ) $ 18,604,078 (1) On June 1, 2018, the Company acquired various assets of BioTrackTHC (See Note 5) (2) On August 3, 2018, the Company acquired various assets of Engeni (See Note 5) (3) On September 10, 2019, the Company acquired various assets of GTI (See Note 5)
Schedule of estimated future amortization expense	Years Ending December 31, Future amortization expense 2020 $ 4,773,348 2021 4,718,392 2022 4,036,485 2023 808,591 2024 39,669 Thereafter 18,802 Total $ 14,395,287
Schedule of goodwill	Total Goodwill Balance at December 31, 2017 $ 664,329 Impairment of goodwill (664,329 ) Goodwill attributable to Biotrack acquisition 39,135,007 Goodwill attributable to Engeni acquisition 778,552 Balance at December 31, 2018 $ 39,913,559 Goodwill attributable to Tan Security acquisition 821,807 Goodwill attributable to Green Tree acquisition 12,980,840 Balance at December 31, 2019 $ 53,716,207

Costs, Estimated Earnings and_2

Costs, Estimated Earnings and Billings (Tables)	12 Months Ended
	Dec. 31, 2019
Costs in Excess of Billings on Uncompleted Contracts or Programs [Abstract]
Schedule of costs, estimated earnings and billings on uncompleted contracts	December 31, 2019 2018 Costs incurred on uncompleted contracts $ 444,344 $ 89,700 Estimated earnings 150,355 50,512 Cost and estimated earnings earned on uncompleted contracts 594,699 140,212 Billings to date 501,543 252,535 Billings in excess of costs and costs in excess of billings on uncompleted contracts 93,156 (112,323 ) Costs in excess of billings $ 257,819 $ 42,869 Billings in excess of cost (164,663 ) (155,192 ) $ 93,156 $ (112,323 )

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Schedule of accounts payable and accrued expenses	December 31, 2019 2018 Accounts payable $ 895,785 $ 842,389 Accrued compensation and related expenses 260,280 - Accrued expenses 1,733,371 847,560 Accrued interest - 12,764 Lease obligation - current 373,710 - Total $ 3,263,146 $ 1,702,713

Convertible Notes Payable, Ne_2

Convertible Notes Payable, Net of Discount (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Schedule of convertible note payable	December 31, 2019 2018 Note Five, 5% convertible promissory note, fixed secured, maturing November 16, 2019 $ - $ 187,177 Note Ten, 25% convertible promissory note, fixed secured, maturing March 1, 2020, net of debt discount for warrants 143,630 - Note Eleven, 10% convertible promissory note, fixed secured, maturing May 15, 2020, net of debt discount for warrants and legal fees 185,313 - Note Twelve, 10% convertible promissory note, fixed secured, maturing June 16, 2020, net of debt discount for warrants and legal fees 205,363 - Note Thirteen, 10% convertible promissory note, fixed secured, maturing July 11, 2020, net of debt discount for warrants and legal fees 206,091 - Note Fourteen, 12% convertible promissory note, fixed secured, maturing September 26, 2020, net of debt discount for warrants and legal fees 92,095 - Note Fifteen, 12% convertible promissory note, fixed secured, maturing November 15, 2021 385,000 - 1,217,492 187,177 Less: Current portion (832,492 ) (187,177 ) Long-term portion $ 385,000 $ -

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Schedule of notes payable	December 31, 2019 2018 Vehicle financing loans payable, between 4.7% and 7.0% interest and maturing between June 2022 and July 2022 $ 52,507 $ 71,284 Loans Payable - Credit Union 5,385 5,075 Notes Payable 400,000 - Less: Current portion of loans payable (24,805 ) (24,805 ) Long-term portion of loans payable $ 433,087 $ 51,554

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Schedule of restricted common stock issued in relation to subscription agreements	Date of Sale Number of Total February 2018 222,222 $ 200,000 March 2018 500,000 450,000 April 2018 500,000 450,000 May 2018 244,444 219,999 July 2018 327,777 294,999 August 2018 327,777 294,999 August 2018 183,333 164,999 September 2018 577,778 520,000 October 2018 694,444 625,000 November 2018 150,000 135,000 December 2018 222,222 200,000 3,949,997 $ 3,554,996
Schedule of number of shares issued under 2017 omnibus incentive plan	The table below reflects shares issued under the 2017 Omnibus Incentive Plan during the year-ended December 31, 2019. Date of Sale Number of Total March 2019 250,000 $ 320,000 Ending Balance 250,000 $ 320,000 The table below reflects shares issued under the 2017 Omnibus Incentive Plan during the year-ended December 31, 2018. Date of Sale Number of Total January 2018 42,850 $ 173,014 March 2018 100,000 250,000 May 2018 133,900 223,774 July 2018 100,000 126,000 August 2018 10,000 10,600 August 2018 33,195 33,195 October 2018 20,000 20,400 November 2018 75,000 79,500 Ending Balance 514,945 $ 916,483
Schedule of the issuances of Series B preferred shares	For the Year Ended December 31, 2018 Issuance Date Beneficial Number of Fair Value Amount Amount accreted Unamortized May 17, 2017 12 7,318,084 $ 25,247,098 $ (15,779,436 ) $ (9,467,661 ) $ - July 29, 2017 9.5 1,680,000 6,804,000 (3,674,634 ) (3,129,366 ) - August 29, 2017 8.5 369,756 1,148,263 (556,190 ) (592,073 ) - September 15, 2017 8 462,195 1,435,329 (648,601 ) (786,728 ) - October 11, 2017 7 462,195 1,121,036 (426,309 ) (694,727 ) - October 31, 2017 6.5 1,042,337 1,735,641 (548,570 ) (1,187,071 ) - December 19, 2017 5 2,449,634 6,921,348 (576,780 ) (6,344,568 ) - Total 13,784,201 $ 44,412,715 $ (22,210,520 ) $ (22,202,194 ) $ -

Stock Options (Tables)

Stock Options (Tables)	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Schedule of assumptions used	December 31, March 28, Exercise Price $0.435 to $2.59 $ 1.90 to $2.09 Fair value of company’s common stock $0.435 to $2.35 $ 0.90 to $1.90 Dividend yield 0 0 Expected volatility 110% to 191% 186.64% to 253.52 Risk free interest rate 1.55% to 2.51% 2.35% to 2.59 Expected life (years) remaining 2.92 to 9.22 4.24 to 10.00
Schedule of stock option activity	Shares Underlying Weighted Weighted Outstanding at January 1, 2018 414,854 $ 0.001 2.42 Granted 490,000 $ 1.916 8.84 Options assumed pursuant to acquisition – BioTrackTHC Stock Plan 3,841,492 $ 0.790 1.84 Options assumed pursuant to acquisition – Management Awards 4,290,918 $ 0.439 2.34 Exercised (226,822 ) $ 0.001 1.50 Forfeited and expired (79,486 ) $ 0.001 0.00 Outstanding at January 1, 2019 8,730,956 $ 0.671 2.44 Granted 3,075,000 $ 1.161 5.56 Exercised (188,575 ) $ 0.261 0.57 Outstanding at December 31, 2019 11,617,381 $ 0.807 3.21 Vested options at December 31, 2019 9,339,881 $ 0.716 1.72

Warrant Liability (Tables)

Warrant Liability (Tables)	12 Months Ended
	Dec. 31, 2019
Warrants and Rights Note Disclosure [Abstract]
Schedule of recognized as a loss in earnings	Proceeds from January investment units $ 1,129,700 Par value of common stock issues $ (1,255 ) Fair value of warrants $ (1,717,506 ) Loss on issuance of warrants (January 10, 2019 issuance) $ (589,061 )
Schedule of warrant activity	Warrant Shares Weighted Average Balance at January 1, 2018 2,732,073 $ 0.23 Warrants granted 686,111 $ 0.21 Balance at January 1, 2019 3,418,184 $ 0.23 Warrants granted 1,694,874 $ 1.17 Balance at December 31, 2019 5,113,058 $ 0.55
Schedule of fair value of the Company's warrant liability using the Black-Scholes model	As of As of Fair value of company's common stock $ 0.60 $ 0.90 Dividend yield 0 % 0 % Expected volatility 45% - 140 % 175.0 % Risk Free interest rate 1.55% - 1.79 % 2.49 % Expected life (years) 2.83 1.65 Fair value of financial instruments - warrants $ 715,259 $ 896,171
Schedule of fair value of the financial instruments - warrants	The change in fair value of the financial instruments – warrants is as follows: Amount Balance as of January 1, 2018 $ 2,429,569 Change in fair value of liability to issue warrants (1,641,398 ) Balance as of December 31, 2018 $ 896,171 Fair value of warrants issued 3,632,065 Change in fair value of liability to issue warrants (3,812,977 ) Balance as of December 31, 2019 $ 715,259

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of activity related to the Company's leases	Year Ended Operating lease expense $ 513,008 Cash paid for amounts included in the measurement of operating lease liabilities $ 389,380 ROU assets obtained in exchange for operating lease obligations $ 1,499,752
Schedule of ROU lease assets and lease liabilities	As of Other assets $ 1,091,065 Accounts payable and accrued liabilities $ 373,710 Other long-term liabilities 783,230 Total lease liabilities $ 1,156,940 Weighted average remaining lease term (in years) 2.91 Weighted average discount rate 6.00 %
Schedule of future lease payments included in the measurement of lease liabilities	As of 2020 $ 393,413 2021 248,223 2022 195,144 2023 200,944 2024 205,435 Thereafter - Total future minimum lease payments $ 1,243,159 Less imputed interest (86,219 ) Total $ 1,156,940
Schedule of future minimum lease payments	Years Ending December 31, Future 2020 420,291 2021 275,223 2022 198,144 2023 199,144 2024 205,135 Thereafter - Total $ 1,297,937

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Schedule of represents selected information reportable segments	For the Years Ended 2019 2018 Security and guarding Revenue $ 5,022,436 $ 4,889,472 Cost of revenue 4,004,881 3,618,173 Gross profit 1,017,555 1,271,299 Total operating expenses (1) 7,174,866 11,101,635 Loss from operations (6,157,311 ) (9,830,336 ) Total other income 553,612 3,029,392 Total net loss $ (5,603,699 ) $ (6,800,944 ) Systems installation Revenue $ 783,192 $ 499,138 Cost of revenue 854,801 531,567 Gross profit (71,609 ) (32,429 ) Total operating expenses 545,474 168,159 Loss from operations (617,083 ) (200,588 ) Total other income (expense) 88,903 (273,642 ) Total net loss $ (528,180 ) $ (474,230 ) Software Revenue $ 9,486,472 $ 4,174,963 Cost of revenue 3,318,455 1,819,299 Gross profit 6,168,017 2,355,664 Total operating expenses 9,616,488 3,046,390 Loss from operations (3,448,471 ) (690,726 ) Total other income 181 98 Total net loss $ (3,448,290 ) $ (690,628 ) (1) Total operating expenses for the years ended December 31, 2019 and 2018 contained certain corporate expenditures totaling $5,399,184 and $8,687,900, respectively, which benefit all segments of the business but are not specifically allocable to any one segment.

Description of Business (Detail

Description of Business (Details Narrative) - shares	Sep. 10, 2019	Aug. 03, 2018	Oct. 01, 2015	Jun. 01, 2018	Apr. 02, 2019
Business Acquisition [Line Items]
Exchanged percentage of Helix TCS			100.00%
Business acquisition, description			Effective October 1, 2015, for accounting purposes, as part of an acquisition amounting to a reorganization dated December 21, 2015, Helix Opportunities LLC exchanged 100% of Helix TCS, LLC and its wholly-owned subsidiaries, Security Consultants Group, LLC and Boss Security Solutions, Inc. to the Company in exchange for 20 million common shares and 1 million convertible preferred shares of the Company.	The Company issued 38,184,985 unregistered shares of its common stock to BioTrackTHC stockholders, of which 1,852,677 shares were held back to satisfy indemnification obligations in the BioTrackTHC Merger Agreement, if necessary. The Company also assumed the Bio-Tech Medical Software, Inc. 2014 Stock Incentive Plan (“BioTrackTHC Stock Plan”), pursuant to which options exercisable in the amount of 8,132,410 shares of common stock are outstanding. As a result, BioTrackTHC stockholders owned approximately 48% of the Company on a fully diluted basis as of the BioTrackTHC Closing Date.
Merger Agreement		In connection with closing the Engeni Merger Agreement, the Company issued 366,700 shares of Company common stock to Engeni US members. Furthermore, the Company subsequently issued Engeni US members 733,300 shares of Company common stock on April 2, 2019.
Amercanex Merger Agreement [Member] | GTI Shareholders [Member]
Business Acquisition [Line Items]
Number of unregistered shares issued	16,765,727
Number of shares repurchased during the year	4,140,274
Tan Security Acquisition Agreement [Member]
Business Acquisition [Line Items]
Exchanged percentage of Helix TCS					100.00%

Going Concern Uncertainty, Fi_2

Going Concern Uncertainty, Financial Condition and Management's Plans (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Going Concern Uncertainty, Financial Condition and Management's Plans [Abstract]
Working capital deficit	$ 3,416,501	$ 2,233,652
Increase of working capital	$ 1,182,849

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Potentially dilutive securities:
Convertible notes payable	5,994,838	124,784
Convertible Preferred A Stock	1,000,000	1,000,000
Convertible Preferred B Stock	13,784,201	13,784,201
Warrants	5,113,058	3,418,184
Stock options	11,617,381	8,729,463

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Allowance for doubtful accounts	$ 273,138	$ 76,156
Lease agreements, description	Adoption of the standard resulted in the balance sheet recognition of additional lease assets and lease liabilities of approximately $1,500,000. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company currently has elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in separate lease and non-lease components for all our leases.
Advertising costs	$ 378,233	$ 96,420
Furniture and equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives	5 years
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives	3 years

Revenue Recognition (Details)

Revenue Recognition (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Total revenues	$ 15,292,100	$ 9,563,573
Security and Guarding [Member]
Total revenues	5,022,436	4,889,472
Systems Installation [Member]
Total revenues	783,192	499,138
Software [Member]
Total revenues	$ 9,486,472	$ 4,174,963

Revenue Recognition (Details Na

Revenue Recognition (Details Narrative)	12 Months Ended
	Dec. 31, 2019
Revenue Recognition [Abstract]
System installation invoice, percentage	60.00%
Sales team members commissions, description	The Company provides sales team members with commissions at 0-6%.

Business Combination (Details)

Business Combination (Details)	12 Months Ended
	Dec. 31, 2019USD ($)
Security Grade Acquisition [Member]
Business Acquisition [Line Items]
Base Price - Cash	$ 2,100,373
Base Price - Stock Options	916,643
Contingent Consideration - Stock Options	916,643
Total Purchase Price	3,933,659
BioTrackTHC Acquisition [Member]
Business Acquisition [Line Items]
Base Price - Common Stock	44,905,542
Base Price - Stock Options	12,646,491
Total Purchase Price	57,552,033
Engeni SA Acquisition [Member]
Business Acquisition [Line Items]
Base Price - Common Stock	388,702
Contingent Consideration - Common Stock	777,298
Total Purchase Price	1,166,000
Tan’s International Security [Member]
Business Acquisition [Line Items]
Base Price - Cash	25,000
Base Price - Deferred cash payment (including $25,000 to be made on the 4,8 and 12-month anniversaries of closing)	75,000
Base Price - Common Stock	710,000
Total Purchase Price	810,000
Green Tree International, Inc. [Member]
Business Acquisition [Line Items]
Base Price - Common Stock	12,909,611
Total Purchase Price	$ 12,909,611

Business Combination (Details 1

Business Combination (Details 1)	12 Months Ended
	Dec. 31, 2019USD ($)
Security Grade Acquisition [Member]
Assets acquired:
Cash	$ 14,137
Accounts receivable	53,792
Costs & earnings in excess of billings	96,898
Property, plant and equipment, net	27,775
Trademarks	25,000
Customer list	3,154,578
Web address	5,000
Goodwill	664,329
Other assets	3,880
Total assets acquired	4,045,389
Liabilities assumed:
Billings in excess of costs	23,967
Loans payable	18,414
Credit card payable and other liabilities	69,349
Total liabilities assumed	111,730
Estimated fair value of net assets acquired	$ 3,933,659
Security Grade Acquisition [Member] | Trademarks [Member]
Liabilities assumed:
Weighted Average Useful Life (in years)	10 years
Security Grade Acquisition [Member] | Customer Lists [Member]
Liabilities assumed:
Weighted Average Useful Life (in years)	5 years
Security Grade Acquisition [Member] | Web Addresses [Member]
Liabilities assumed:
Weighted Average Useful Life (in years)	5 years
BioTrackTHC Acquisition [Member]
Assets acquired:
Cash	$ 448,697
Accounts receivable	128,427
Prepaid expenses	351,615
Property, plant and equipment, net	72,252
Customer list	8,304,449
Goodwill	39,135,007
Software	9,321,627
Tradename	466,081
Total assets acquired	58,228,155
Liabilities assumed:
Accounts payable	223,581
Other liabilities	452,541
Total liabilities assumed	676,122
Estimated fair value of net assets acquired	$ 57,552,033
BioTrackTHC Acquisition [Member] | Customer Lists [Member]
Liabilities assumed:
Weighted Average Useful Life (in years)	5 years
BioTrackTHC Acquisition [Member] | Software [Member]
Liabilities assumed:
Weighted Average Useful Life (in years)	4 years 6 months
BioTrackTHC Acquisition [Member] | Tradename [Member]
Liabilities assumed:
Weighted Average Useful Life (in years)	4 years 6 months
Engeni SA Acquisition [Member]
Assets acquired:
Cash	$ 5,609
Accounts receivable and other assets	30,479
Property, plant and equipment, net	57,830
Goodwill	778,552
Software	449,568
Total assets acquired	1,322,038
Liabilities assumed:
Accounts payable	56,038
Total liabilities assumed	56,038
Estimated fair value of net assets acquired	$ 1,266,000
Engeni SA Acquisition [Member] | Software [Member]
Liabilities assumed:
Weighted Average Useful Life (in years)	3 years 3 months 19 days
Tan's International Security [Member]
Assets acquired:
Cash	$ 2,940
Accounts receivable	7,635
Goodwill	821,807
Total assets acquired	832,382
Liabilities assumed:
Accounts payable	12,526
Other liabilities	9,856
Total liabilities assumed	22,382
Estimated fair value of net assets acquired	810,000
Green Tree International, Inc. [Member]
Assets acquired:
Note Receivable, net	135,000
Property, plant and equipment, net	12,142
Goodwill	12,980,840
Software	452,002
Total assets acquired	13,579,984
Liabilities assumed:
Accounts payable	43,717
Notes Payable	400,000
Other liabilities	226,656
Total liabilities assumed	670,373
Estimated fair value of net assets acquired	$ 12,909,611
Weighted Average Useful Life (in years)	4 years 6 months

Business Combination (Details N

Business Combination (Details Narrative) - USD ($)	Sep. 10, 2019	Apr. 02, 2019	Oct. 01, 2015	Jun. 01, 2018	Mar. 31, 2018	Jun. 02, 2017	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Aug. 03, 2018
Business Acquisition [Line Items]
Business acquisition, description			Effective October 1, 2015, for accounting purposes, as part of an acquisition amounting to a reorganization dated December 21, 2015, Helix Opportunities LLC exchanged 100% of Helix TCS, LLC and its wholly-owned subsidiaries, Security Consultants Group, LLC and Boss Security Solutions, Inc. to the Company in exchange for 20 million common shares and 1 million convertible preferred shares of the Company.	The Company issued 38,184,985 unregistered shares of its common stock to BioTrackTHC stockholders, of which 1,852,677 shares were held back to satisfy indemnification obligations in the BioTrackTHC Merger Agreement, if necessary. The Company also assumed the Bio-Tech Medical Software, Inc. 2014 Stock Incentive Plan (“BioTrackTHC Stock Plan”), pursuant to which options exercisable in the amount of 8,132,410 shares of common stock are outstanding. As a result, BioTrackTHC stockholders owned approximately 48% of the Company on a fully diluted basis as of the BioTrackTHC Closing Date.
Liability pursuant to agreement							$ 0	$ 0	$ 101,667
Fair value of contingent consideration						$ 916,643
Total acquisition costs								116,624
Selling, general and administrative								4,111,085	2,491,518
Gain on reduction of obligation pursuant									$ 607,415
Option issued of acquisition							9,339,881	9,339,881
Tan’s International Security [Member]
Business Acquisition [Line Items]
Business acquisition, description								Pursuant to the Tan Security Acquisition Agreement, Helix purchased all membership interests and capital stock of Tan Security and collectively holds 100% of the interests of Tan Security. The purchase price of $100,000 in cash plus 250,000 shares of the Company's restricted common stock will be paid to Rocky Tan as follows:     ● 250,000 shares of Helix Stock at closing.         ● $25,000 at closing         ● $25,000 on the 4-month anniversary of the Tan Security Closing Date         ● $25,000 on the 8-month anniversary of the Tan Security Closing Date         ● $25,000 on the 12-month anniversary of the Tan Security Closing Date
Deferred cash payment								$ 25,000
Engeni SA Acquisition [Member]
Business Acquisition [Line Items]
Business acquisition, description								The Company issued 366,700 shares of Company common stock to Engeni US members. Furthermore, the Company may also issue Engeni US members 366,700 and 366,600 shares of Parent common stock upon the achievement of specific objectives. If applicable, the Company will pay Engeni US members the aggregate amount of $100,000, on a pro rata basis, if Engeni SA reaches financial breakeven on or before December 31, 2018, as determined by the Company's Chief Financial Officer and Scott Zienkewicz.
Fair value of contingent consideration										$ 777,298
Change in fair value of contingent consideration					$ 100,000
Common stock shares issued		733,300
Green Tree International,Inc [Member] | Amercanex Merger Agreement [Member]
Business Acquisition [Line Items]
Business acquisition, description								Pursuant to the Amercanex Merger Agreement, the Company issued to the GTI stockholders an amount of unregistered shares of the Company’s common stock equal to $15 million, based on the average closing price of the Company’s common stock over the forty-five (45) trading day period ending three (3) trading days prior to the GTI Closing Date. If revenues of GTI in the second 12 month period following the GTI Closing Date exceed $5 million and are less than or equal to $10 million, the Company shall issue to the GTI shareholders a number of unregistered Helix shares (whether issued or reserved for issuance) equal to the quotient of (a) $5 million divided by (b) Helix share price multiplied by the quotient of (c) the revenues of GTI in the second 12 month period following the GTI Closing Date less $5 million divided by (d) $5 million. To secure the indemnification obligations of the GTI shareholders to the Company under the GTI Merger Agreement, 4,140,274 of the Company shares issued to the GTI shareholders were held back and the Company is entitled to retain such number of the holdback shares as necessary to satisfy those indemnification obligations. 50% of the holdback shares that remain after satisfaction of any indemnification obligations will be released 12 months after the GTI Closing Date of the merger, and the remainder 24 months after the GTI Closing Date of the merger. Additionally, if in the first 12 months following the closing GTI generates less than $1.5 million of revenues, 100% of the holdback shares shall be returned to the Company.
Total acquisition costs								$ 83,324
Revenues							$ 73,644
Green Tree International,Inc [Member] | Amercanex Merger Agreement [Member] | Unregistered Shares [Member]
Business Acquisition [Line Items]
Revenues							$ 0
Common stock shares issued	16,765,727
Number of shares repurchased during the year	4,140,274
Security Grade Protective Services, Ltd. [Member]
Business Acquisition [Line Items]
Business acquisition, description						The Company entered into a Membership Interest Purchase Agreement (the “Agreement”) in which the Company purchased all issued and outstanding Units of Security Grade Protective Services, Ltd. (“Security Grade”), which comprised of 800,000 Class A Units and 200,000 Class B Units. At closing, the Company delivered $800,000 in cash and 207,427 non-qualified stock options (the “Initial Stock Options”).
Business combination, contractual relationship, description						Provided that, within the first 60 days following the closing, no material customer identified in the Agreement terminates its contractual relationship with the Company and that all contracts with such material customers are in full force and effect without default or cancellation as of the 60th day following the closing, on the 61st day following the closing, the Company shall deliver an additional $800,000 in cash and issue 207,427 additional stock options (the "Additional Stock Options"). In the event of termination, cancellation or default of any contract with one or more material customer identified in the Agreement within the first 60 days following the closing, the stock options received by the acquiree shall be reduced and/or forfeited to the extent necessary (pro rata based upon their ownership interest in the Company immediately preceding the closing) by a percentage equal to the revenue received by the Company from the terminating customer(s) in the 180 days immediately preceding such termination divided by the revenue received by the Company from all material customers identified in the Agreement in the 180 days immediately preceding such termination.
BioTrackTHC Acquisition [Member]
Business Acquisition [Line Items]
Business acquisition, description								The Company issued 38,184,985 unregistered shares of Company common stock to BioTrackTHC stockholders, of which 1,852,677 shares were held back to satisfy indemnification obligations in the BioTrackTHC Merger Agreement, if necessary. The Company also assumed the BioTrackTHC Stock Plan, pursuant to which options exercisable for 8,132,410 shares of Company common stock are outstanding so that the BioTrackTHC stockholders owned approximately 48% of the Company on a fully diluted basis as of the BioTrackTHC Closing Date.

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Total	$ 1,025,197	$ 467,359
Less: Accumulated depreciation	(219,518)	(117,841)
Property and equipment, net	805,679	349,518
Furniture and equipment [Member]
Property, Plant and Equipment [Line Items]
Total	262,167	264,659
Software equipment [Member]
Property, Plant and Equipment [Line Items]
Total	561,565
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Total	$ 201,066	$ 202,700

Property and Equipment, Net (_2

Property and Equipment, Net (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 95,685	$ 106,625

Intangible Assets, Net and Go_3

Intangible Assets, Net and Goodwill (Details) - USD ($)		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount		$ 22,044,730	$ 3,503,005
Assets Acquired Pursuant to Business Combination	[1]	452,002	18,541,725	[2]
Assets Acquired		21,856
Accumulated Amortization		(8,123,301)	(3,440,652)
Net Book Value		$ 14,395,287	$ 18,604,078
Database [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)		5 years	5 years
Gross Carrying Amount		$ 93,427	$ 93,427
Assets Acquired Pursuant to Business Combination	[1]			[2]
Assets Acquired
Accumulated Amortization		(69,533)	(50,858)
Net Book Value		23,894	42,569
Trade names and trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount		591,081	125,000
Assets Acquired Pursuant to Business Combination	[1]		466,081	[2]
Assets Acquired
Accumulated Amortization		(207,525)	(91,554)
Net Book Value		$ 383,556	$ 499,527
Trade names and trademarks [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)		5 years	5 years
Trade names and trademarks [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)		10 years	10 years
Web addresses [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)		5 years	5 years
Gross Carrying Amount		$ 130,000	$ 130,000
Assets Acquired Pursuant to Business Combination	[1]			[2]
Assets Acquired
Accumulated Amortization		(95,611)	(69,625)
Net Book Value		$ 34,389	$ 60,375
Customer list [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)		5 years	5 years
Gross Carrying Amount		$ 11,459,027	$ 3,154,578
Assets Acquired Pursuant to Business Combination	[1]		8,304,449	[2]
Assets Acquired
Accumulated Amortization		(4,256,070)	(1,965,520)
Net Book Value		$ 7,202,957	$ 9,493,507
Software [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)		4 years 6 months	4 years 6 months
Gross Carrying Amount		$ 9,771,195
Assets Acquired Pursuant to Business Combination	[1]	452,002	9,771,195	[2]
Assets Acquired		1,625
Accumulated Amortization		(3,492,525)	(1,263,095)
Net Book Value		$ 6,732,297	$ 8,508,100
Domain Name [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)		5 years
Gross Carrying Amount
Assets Acquired Pursuant to Business Combination	[1]
Assets Acquired		20,231
Accumulated Amortization		(2,037)
Net Book Value		$ 18,194
[1]	On August 3, 2018, the Company acquired various assets of Engeni (See Note 5)
[2]	On June 1, 2018, the Company acquired various assets of BioTrackTHC (See Note 5)

Intangible Assets, Net and Go_4

Intangible Assets, Net and Goodwill (Details 1)	Dec. 31, 2019USD ($)
Future amortization expense
2020	$ 4,773,348
2021	4,718,392
2022	4,036,485
2023	808,591
2024	39,669
Thereafter	18,802
Total	$ 14,395,287

Intangible Assets, Net and Go_5

Intangible Assets, Net and Goodwill (Details 2) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Balance	$ 39,913,559	$ 664,329
Impairment of goodwill		(664,329)
Goodwill attributable to Biotrack acquisition		39,135,007
Goodwill attributable to Engeni acquisition		778,552
Goodwill attributable to Tan Security acquisition	821,807
Goodwill attributable to Green Tree acquisition	12,980,840
Balance	$ 53,716,207	$ 39,913,559

Intangible Assets, Net and Go_6

Intangible Assets, Net and Goodwill (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense related to intangible assets	$ 4,682,649	$ 2,979,906

Costs, Estimated Earnings and_3

Costs, Estimated Earnings and Billings (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Costs in Excess of Billings on Uncompleted Contracts or Programs [Abstract]
Costs incurred on uncompleted contracts	$ 444,344	$ 89,700
Estimated earnings	150,355	50,512
Cost and estimated earnings earned on uncompleted contracts	594,699	140,212
Billings to date	501,543	252,535
Billings in excess of costs and costs in excess of billings on uncompleted contracts	93,156	(112,323)
Costs in excess of billings	257,819	42,869
Billings in excess of cost	(164,663)	(155,192)
Total	$ 93,156	$ (112,323)

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Accounts payable	$ 895,785	$ 842,389
Accrued compensation and related expenses	260,280
Accrued expenses	1,733,371	847,560
Accrued interest		12,764
Lease obligation - current	373,710
Total	$ 3,263,146	$ 1,702,713

Convertible Notes Payable, Ne_3

Convertible Notes Payable, Net of Discount (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Short-term Debt [Line Items]
Convertible note payable	$ 1,217,492	$ 187,177
Less: Current portion	(832,492)	(187,177)
Long-term portion	385,000
Note Five, 5% convertible promissory note, fixed secured, maturing November 16, 2019 [Member]
Short-term Debt [Line Items]
Convertible note payable		187,177
Note Ten, 25% convertible promissory note, fixed secured, maturing March 1, 2020, net of debt discount for warrants [Member]
Short-term Debt [Line Items]
Convertible note payable	143,630
Note Eleven, 10% convertible promissory note, fixed secured, maturing May 15, 2020, net of debt discount for warrants and legal fees [Member]
Short-term Debt [Line Items]
Convertible note payable	185,313
Note Twelve, 10% convertible promissory note, fixed secured, maturing June 16, 2020, net of debt discount for warrants and legal fees [Member]
Short-term Debt [Line Items]
Convertible note payable	205,363
Note Thirteen, 10% convertible promissory note, fixed secured, maturing July 11, 2020, net of debt discount for warrants and legal fees [Member]
Short-term Debt [Line Items]
Convertible note payable	206,091
Note Fourteen, 12% convertible promissory note, fixed secured, maturing September 26, 2020, net of debt discount for warrants and legal fees [Member]
Short-term Debt [Line Items]
Convertible note payable	92,095
Note Fifteen, 12% convertible promissory note, fixed secured, maturing November 15, 2021 [Member]
Short-term Debt [Line Items]
Convertible note payable	$ 385,000

Convertible Notes Payable, Ne_4

Convertible Notes Payable, Net of Discount (Details Narrative)

May 16, 2018USD ($)

Dec. 26, 2019USD ($)$ / sharesshares

Sep. 30, 2019USD ($)shares

May 31, 2019USD ($)shares

Nov. 30, 2018USD ($)shares

Jun. 30, 2019USD ($)

Dec. 31, 2019USD ($)TradingDays$ / sharesshares

Dec. 31, 2018USD ($)$ / shares

Oct. 11, 2019USD ($)

Sep. 16, 2019USD ($)

Aug. 15, 2019USD ($)

Mar. 02, 2019USD ($)

Dec. 31, 2017$ / shares

Short-term Debt [Line Items]

Warrants exercise price | $ / shares

$ 0.55

$ 0.23

$ 0.23

Gain to change in fair value

$ 496,790

$ 450,216

Note Ten [Member]

Short-term Debt [Line Items]

Interest expense on convertible debt

3,542

Unamortized discount

58,495

Warrants issued amount

355,847

Debt discounts amortized to interest expense

297,352

Principal amount of notes

280,000

Fair value of notes

202,125

Gain to change in fair value

$ 32,125

Restricted shares of common stock | shares

16,568

15,625

19,401

Restricted shares of common stock value

$ 14,063

$ 14,062

$ 12,029

Converted into shares of common stock | shares

875,894

Note Ten [Member] | Investor [Member]

Short-term Debt [Line Items]

Discount on debt conversion, description

30% discount

Trading days related to conversion of debt | TradingDays

30

Conversion rate, per share | $ / shares

$ 0.90

Cash proceeds from investors

$ 450,000

Principal amount of notes

$ 450,000

Maturity date

Mar. 1, 2020

Interest rate

25.00%

Note Ten [Member] | Investor [Member] | Common Stock [Member]

Short-term Debt [Line Items]

Warrant issued to purchase shares of common stock | shares

160,715

Warrants exercise price | $ / shares

$ 1.40

Note Five [Member] | Second investor [Member]

Short-term Debt [Line Items]

Principal amount of notes

$ 115,136

Maturity date

Nov. 16, 2019

Converted into shares of common stock | shares

155,421

Interest expense

$ 936

$ 10,724

Note Five [Member] | First Investor [Member]

Short-term Debt [Line Items]

Principal amount of notes

$ 112,305

Maturity date

Nov. 16, 2018

Unpaid principal and accrued interest balance

120.00%

Note Eleven [Member] | Investor [Member]

Short-term Debt [Line Items]

Fair value of liability

$ 18,543

Convertible preferred stock, terms of conversion, description

Common stock at $0.90 per share for the first 6 months and thereafter at the lower of $0.90 per share or at 70% of the average of the five lowest daily VWAPs of the Company’s common stock during the 15 consecutive trading days prior to the date on which the investor elects to convert all or part of Note Eleven.

Warrant issued to purchase shares of common stock | shares

25,000

Warrants exercise price | $ / shares

$ 1

Unamortized discount

$ 19,131

Warrants issued amount

38,543

Value of debt

17,460

Debt discounts amortized to interest expense

19,412

Cash proceeds from investors

380,000

Principal amount of notes

$ 400,000

Fair value of notes

204,444

Gain to change in fair value

$ 195,556

Maturity date

May 15, 2020

Interest rate

10.00%

Due diligence and legal bills

$ 20,000

Legal fees

20,000

Note Twelve [Member] | Investor [Member] | Common Stock [Member]

Short-term Debt [Line Items]

Fair value of liability

$ 17,683

Conversion rate, per share | $ / shares

$ 0.90

Convertible preferred stock, terms of conversion, description

Common stock at $0.90 per share for the first 6 months and thereafter at the lower of $0.90 per share or at 70% of the average of the five lowest daily VWAPs of the Company’s common stock during the 15 consecutive trading days prior to the date on which the investor elects to convert all or part of Note Twelve.

Warrant issued to purchase shares of common stock | shares

25,000

Warrants exercise price | $ / shares

$ 1

Unamortized discount

$ 24,638

Warrants issued amount

40,183

Value of debt

18,285

Debt discounts amortized to interest expense

15,545

Cash proceeds from investors

427,500

Principal amount of notes

$ 450,000

Fair value of notes

230,000

Gain to change in fair value

$ (220,000)

Maturity date

Jun. 16, 2020

Interest rate

10.00%

Due diligence and legal bills

$ 22,500

Legal fees

22,500

Note Thirteen [Member] | Investor [Member] | Common Stock [Member]

Short-term Debt [Line Items]

Fair value of liability

$ 11,443

Conversion rate, per share | $ / shares

$ 0.90

Convertible preferred stock, terms of conversion, description

Common stock at $0.90 per share for the first 6 months and thereafter at the lower of $0.90 per share or at 70% of the average of the five lowest daily VWAPs of the Company's common stock during the 15 consecutive trading days prior to the date on which the investor elects to convert all or part of Note Thirteen.

Warrant issued to purchase shares of common stock | shares

25,000

Warrants exercise price | $ / shares

$ 1

Unamortized discount

$ 23,909

Warrants issued amount

33,943

Value of debt

16,022

Debt discounts amortized to interest expense

10,034

Cash proceeds from investors

427,500

Principal amount of notes

$ 450,000

Fair value of notes

230,000

Gain to change in fair value

$ (220,000)

Maturity date

Jul. 11, 2020

Interest rate

10.00%

Due diligence and legal bills

$ 22,500

Legal fees

22,500

Note Fourteen [Member]

Short-term Debt [Line Items]

Warrant issued to purchase shares of common stock | shares

12,500

Warrants exercise price | $ / shares

$ 1

Note Fourteen [Member] | Investor [Member] | Common Stock [Member]

Short-term Debt [Line Items]

Fair value of liability

$ 5,268

Conversion rate, per share | $ / shares

$ 0.90

Convertible preferred stock, terms of conversion, description

Common stock at $0.90 per share for the first 6 months and thereafter at the lower of $0.90 per share or at 70% of the average of the five lowest daily VWAPs of the Company's common stock during the 15 consecutive trading days prior to the date on which the investor elects to convert all or part of Note Fourteen.

Warrant issued to purchase shares of common stock | shares

12,500

Warrants exercise price | $ / shares

$ 1

Unamortized discount

$ 15,507

Warrants issued amount

15,794

Value of debt

463

Debt discounts amortized to interest expense

287

Cash proceeds from investors

200,000

Principal amount of notes

$ 210,526

Fair value of notes

102,924

Gain to change in fair value

$ 102,924

Maturity date

Sep. 26, 2020

Interest rate

12.00%

Due diligence and legal bills

$ 10,526

Legal fees

$ 10,526

Unsecured Convertible Promissory Note [Member] | Investor [Member] | Common Stock [Member]

Short-term Debt [Line Items]

Convertible preferred stock, terms of conversion, description

Common stock at 70% of the average of the five lowest daily VWAPs of the Company's common stock during the 15 consecutive trading days prior to the date on which the investor elects to convert all or part of Note Fifteen.

Unamortized discount

$ 5,239

Value of debt

5,239

Cash proceeds from investors

$ 385,000

Principal amount of notes

$ 5,000,000

Maturity date

Nov. 15, 2021

Interest rate

12.00%

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	Mar. 11, 2016USD ($)TradingDays	Oct. 31, 2019USD ($)shares	May 31, 2019USD ($)shares	Feb. 20, 2018USD ($)	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017$ / sharesshares
Debt Instrument [Line Items]
Related party loan balance						$ 32,489
Ffair value of warrant liability				$ 239,343
Common stock per share | $ / shares					$ 0.55	$ 0.23	$ 0.23
Warrants to purchase shares | shares					5,113,058	3,418,184	2,732,073
Note Nine [Member]
Debt Instrument [Line Items]
Principal amount					$ 1,500,000
Maturity date					Mar. 1, 2020
Annual rate of interest					25.00%
Change in fair value of convertible note - related party					$ 283,454
Interest expense					93,750
Total proceeds					$ 1,475,000
Common stock per share | $ / shares					$ 1.40
Warrants to purchase shares | shares					535,715
Fair value of liability after period end					$ 1,713,828
Restricted shares of common stock | shares		83,311	52,083
Restricted shares of common stock value		$ 45,821	$ 46,875
Legal fees					25,000
Debt discounts amortized to interest expense					1,012,059
Note Eight [Member]
Debt Instrument [Line Items]
Principal amount				125,000
Change in fair value of convertible note - related party						$ 93,506
Interest expense						$ 5,806
Note Eight [Member] | Related Party Holder [Member]
Debt Instrument [Line Items]
Principal amount	$ 150,000
Maturity date	Dec. 31, 2017
Promissory note, description	Forty percent (40%) discount to the average market closing price.
Annual rate of interest	7.00%
Trading days related to conversion of debt | TradingDays	5
Note [Member]
Debt Instrument [Line Items]
Principal amount				$ 125,000
Maturity date				Aug. 20, 2018
Promissory note, description				The Company promises to pay (i) all accrued interest on the unpaid principal amount through December 31, 2017 and (ii) $25,000 in principal within 5 business days of the date of the Amendment. The Company agrees to issue 15,000 shares of restricted Company common stock as an inducement for this amendment within 10 business days of the date of the Amendment. The principal amount of the note will be reduced to $125,000. Unless extended by the Company, converted or prepaid earlier, all unpaid principal and unpaid accrued interest on Note Eight shall be due and payable on August 20, 2018 (the "Maturity Date"). All provisions related to conversion of Note Eight into equity securities of the Company were terminated as part of this Amendment.
Warrant [Member] | Note Nine [Member]
Debt Instrument [Line Items]
Principal amount					1,186,153
Ffair value of warrant liability					182,065
Change in fair value of convertible note - related party					$ 1,004,088
Common stock per share | $ / shares					$ 1.40
Warrants to purchase shares | shares					535,715
Fair value of liability after period end					$ 1,186,153
Net of debt discount for warrants and legal bills					1,584,360
Unamortized discount					$ 199,094

Promissory Notes (Details)

Promissory Notes (Details) - USD ($)	1 Months Ended		11 Months Ended	12 Months Ended
	Jul. 29, 2019	Aug. 29, 2018	Jan. 03, 2019	Dec. 31, 2019	Dec. 31, 2018
Promissory Notes (Textual)
Interest expense on unsecured promissory note				$ 5,874	$ 5,281
Unsecured Promissory Note Two [Member]
Promissory Notes (Textual)
Unsecured promissory note		$ 250,000
Fixed interest rate of unsecured promissory note		7.00%
Interest expense on unsecured promissory note				0	$ 3,021
Promissory note due, description		Due and payable on July 31, 2019.
Convertible Notes Payable [Member]
Promissory Notes (Textual)
Unsecured promissory note			$ 280,000
Fixed interest rate of unsecured promissory note			10.00%
Interest expense on unsecured promissory note				$ 0
Promissory note due, description			Due and payable on March 31, 2019.
Unsecured Promissory Note One [Member]
Promissory Notes (Textual)
Unsecured promissory note	$ 300,000
Fixed interest rate of unsecured promissory note	12.00%
Promissory note due, description	Due and payable on January 29, 2020.

Notes Payable (Details)

Notes Payable (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Loans Payable - Credit Union	$ 5,385	$ 5,075
Convertible Note Payable	300,000
Less: Current portion of loans payable	(24,805)	(24,805)
Long-term portion of loans payable	433,087	51,554
Vehicle Financing Loans Payable [Member]
Vehicle financing loans payable, between 4.7% and 7.0% interest and maturing between June 2022 and July 2022	$ 55,127	$ 71,284

Notes Payable (Details Textual)

Notes Payable (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Notes Payable [Line Items]
Interest expense associated with notes payable	$ 5,874	$ 5,281
Debt Description	In connection with the Merger, the Company assumed a $400,000 Senior Secured Convertible Debenture (the "Convertible Debenture") (See Note 5). The Convertible Debenture will mature on July 31, 2021 and bears interest at a rate of 10% per annum, payable by the Company to the Lender. In the event that Lender elects to convert the Convertible Debenture into Helix Common Stock or in the event Helix required the Lender to convert the Convertible Debenture into its Common Stock, the number of shares that shall be issuable upon full Conversion of the Convertible Debenture at any time shall be equal to the outstanding principal of the Convertible Debenture divided by $1.00.
Vehicle Financing Loans Payable [Member] | Minimum [Member]
Notes Payable [Line Items]
Loans payable, interest rate	4.70%
Maturity date, description	June 2022
Vehicle Financing Loans Payable [Member] | Maximum [Member]
Notes Payable [Line Items]
Loans payable, interest rate		7.00%
Maturity date, description		July 2022

Shareholders' Equity (Details)

Shareholders' Equity (Details) - Subscription Agreements [Member]	12 Months Ended
	Dec. 31, 2018USD ($)shares
Class of Stock [Line Items]
Number of Shares Sold | shares	3,949,997
Total Proceeds | $	$ 3,554,996
February 2018 [Member]
Class of Stock [Line Items]
Number of Shares Sold | shares	222,222
Total Proceeds | $	$ 200,000
March 2018 [Member]
Class of Stock [Line Items]
Number of Shares Sold | shares	500,000
Total Proceeds | $	$ 450,000
April 2018 [Member]
Class of Stock [Line Items]
Number of Shares Sold | shares	500,000
Total Proceeds | $	$ 450,000
May 2018 [Member]
Class of Stock [Line Items]
Number of Shares Sold | shares	244,444
Total Proceeds | $	$ 219,999
July 2018 [Member]
Class of Stock [Line Items]
Number of Shares Sold | shares	327,777
Total Proceeds | $	$ 294,999
August 2018 [Member]
Class of Stock [Line Items]
Number of Shares Sold | shares	327,777
Total Proceeds | $	$ 294,999
August 2018 [Member]
Class of Stock [Line Items]
Number of Shares Sold | shares	183,333
Total Proceeds | $	$ 164,999
September 2018 [Member]
Class of Stock [Line Items]
Number of Shares Sold | shares	577,778
Total Proceeds | $	$ 520,000
October 2018 [Member]
Class of Stock [Line Items]
Number of Shares Sold | shares	694,444
Total Proceeds | $	$ 625,000
November 2018 [Member]
Class of Stock [Line Items]
Number of Shares Sold | shares	150,000
Total Proceeds | $	$ 135,000
December 2018 [Member]
Class of Stock [Line Items]
Number of Shares Sold | shares	222,222
Total Proceeds | $	$ 200,000

Shareholders' Equity (Details 1

Shareholders' Equity (Details 1) - Omnibus Incentive Plan [Member] - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Class of Stock [Line Items]
Number of Shares Issued	250,000	514,945
Total Expense	$ 320,000	$ 916,483
March 2019 [Member]
Class of Stock [Line Items]
Number of Shares Issued	250,000
Total Expense	$ 320,000

Shareholders' Equity (Details 2

Shareholders' Equity (Details 2) - Omnibus Incentive Plan [Member] - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Class of Stock [Line Items]
Number of Shares Issued	250,000	514,945
Total Expense	$ 320,000	$ 916,483
January 2018 [Member]
Class of Stock [Line Items]
Number of Shares Issued		42,850
Total Expense		$ 173,014
March 2018 [Member]
Class of Stock [Line Items]
Number of Shares Issued		100,000
Total Expense		$ 250,000
May 2018 [Member]
Class of Stock [Line Items]
Number of Shares Issued		133,900
Total Expense		$ 223,774
July 2018 [Member]
Class of Stock [Line Items]
Number of Shares Issued		100,000
Total Expense		$ 126,000
August 2018 [Member]
Class of Stock [Line Items]
Number of Shares Issued		10,000
Total Expense		$ 10,600
August 2018 [Member]
Class of Stock [Line Items]
Number of Shares Issued		33,195
Total Expense		$ 33,195
October 2018 [Member]
Class of Stock [Line Items]
Number of Shares Issued		20,000
Total Expense		$ 20,400
November 2018 [Member]
Class of Stock [Line Items]
Number of Shares Issued		75,000
Total Expense		$ 79,500

Shareholders' Equity (Details 3

Shareholders' Equity (Details 3) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Class of Stock [Line Items]
Fair Value of Beneficial Conversion Feature	$ 22,202,194
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Number of shares	13,784,201	13,784,201
Fair Value of Beneficial Conversion Feature	$ 44,412,715
Amount accreted as a deemed dividend	$ (22,202,194)	$ (22,210,520)
Series B Preferred Stock [Member] | May 17, 2017 [Member]
Class of Stock [Line Items]
Issuance Date	May 17, 2017
Beneficial Conversion Feature Term (months)	12 months
Number of shares	7,318,084
Fair Value of Beneficial Conversion Feature	$ 25,247,098
Amount accreted as a deemed dividend	(9,467,661)	(15,779,436)
Unamortized Beneficial Conversion Feature
Series B Preferred Stock [Member] | July 29, 2017 [Member]
Class of Stock [Line Items]
Issuance Date	Jul. 29, 2017
Beneficial Conversion Feature Term (months)	9 years 6 months
Number of shares	1,680,000
Fair Value of Beneficial Conversion Feature	$ 6,804,000
Amount accreted as a deemed dividend	(3,129,366)	(3,674,634)
Unamortized Beneficial Conversion Feature
Series B Preferred Stock [Member] | August 29, 2017 [Member]
Class of Stock [Line Items]
Issuance Date	Aug. 29, 2017
Beneficial Conversion Feature Term (months)	8 years 6 months
Number of shares	369,756
Fair Value of Beneficial Conversion Feature	$ 1,148,263
Amount accreted as a deemed dividend	(592,073)	(556,190)
Unamortized Beneficial Conversion Feature
Series B Preferred Stock [Member] | September 15, 2017 [Member]
Class of Stock [Line Items]
Issuance Date	Sep. 15, 2017
Beneficial Conversion Feature Term (months)	8 months
Number of shares	462,195
Fair Value of Beneficial Conversion Feature	$ 1,435,329
Amount accreted as a deemed dividend	(786,728)	(648,601)
Unamortized Beneficial Conversion Feature
Series B Preferred Stock [Member] | October 11, 2017 [Member]
Class of Stock [Line Items]
Issuance Date	Oct. 11, 2017
Beneficial Conversion Feature Term (months)	7 months
Number of shares	462,195
Fair Value of Beneficial Conversion Feature	$ 1,121,036
Amount accreted as a deemed dividend	(694,727)	(426,309)
Unamortized Beneficial Conversion Feature
Series B Preferred Stock [Member] | October 31, 2017 [Member]
Class of Stock [Line Items]
Issuance Date	Oct. 31, 2017
Beneficial Conversion Feature Term (months)	6 years 6 months
Number of shares	1,042,337
Fair Value of Beneficial Conversion Feature	$ 1,735,641
Amount accreted as a deemed dividend	(1,187,071)	(548,570)
Unamortized Beneficial Conversion Feature
Series B Preferred Stock [Member] | December 19, 2017 [Member]
Class of Stock [Line Items]
Issuance Date	Dec. 19, 2017
Beneficial Conversion Feature Term (months)	5 months
Number of shares	2,449,634
Fair Value of Beneficial Conversion Feature	$ 6,921,348
Amount accreted as a deemed dividend	(6,344,568)	$ (576,780)
Unamortized Beneficial Conversion Feature

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative) - USD ($)	Nov. 15, 2019	Nov. 11, 2019	Nov. 07, 2019	Nov. 04, 2019	Mar. 07, 2019	Mar. 12, 2018	Dec. 31, 2019	Nov. 19, 2019	Oct. 31, 2019	Oct. 18, 2019	Sep. 30, 2019	Aug. 31, 2019	Jun. 30, 2019	May 31, 2019	May 31, 2019	Apr. 30, 2019	Mar. 31, 2019	Mar. 28, 2019	Jan. 31, 2019	Dec. 31, 2018	Aug. 31, 2018	Jul. 31, 2018	Jun. 30, 2018	Mar. 21, 2018	Feb. 15, 2018	Dec. 31, 2019
Note Ten [Member]
Subsidiary or Equity Method Investee [Line Items]
Shares of restricted common stock											16,568			15,625												19,401
Restricted shares of common stock value											$ 14,063			$ 14,062												$ 12,029
Note Nine [Member]
Subsidiary or Equity Method Investee [Line Items]
Shares of restricted common stock									83,311						52,083
Restricted shares of common stock value									$ 45,821						$ 46,875
Principal amount							$ 1,500,000																			1,500,000
Other Common Stock Issuances [Member]
Subsidiary or Equity Method Investee [Line Items]
Restricted shares of common stock value																										$ 16,568
Common stock, shares issued													166,667				1,255,222				366,700
Other Common Stock Issuances [Member] | Note Ten [Member]
Subsidiary or Equity Method Investee [Line Items]
Shares of restricted common stock															51,594
Other Common Stock Issuances [Member] | Note Nine [Member]
Subsidiary or Equity Method Investee [Line Items]
Shares of restricted common stock							135,394
Restricted shares of common stock value							$ 92,696
Other Common Stock Issuances [Member] | Biotrack Acquisition [Member]
Subsidiary or Equity Method Investee [Line Items]
Shares of restricted common stock																							38,184,985
Common stock, shares issued												16,765,727
Stock exercised during period, shares																57,461	6,082
Proceeds from stock options exercised																$ 21,808	$ 4,805
Stock issued during period, shares, acquisitions																250,000
Other Common Stock Issuances [Member] | Security Grade Acquisition [Member]
Subsidiary or Equity Method Investee [Line Items]
Stock exercised during period, shares																15,101
Other Common Stock Issuances [Member] | Engeni Contingent Consideration [Member]
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares issued																733,300
Other Common Stock Issuances [Member] | Investor [Member]
Subsidiary or Equity Method Investee [Line Items]
Shares of restricted common stock																			20,000
Common stock, shares issued													47,084				62,847
Shared based compensation expense																			$ 27,400
Other Common Stock Issuances [Member] | Three Selling Shareholder Of Security [Member]
Subsidiary or Equity Method Investee [Line Items]
Shares of restricted common stock																					14,189		212,633
Other Common Stock Issuances [Member] | Consulting Agreement [Member]
Subsidiary or Equity Method Investee [Line Items]
Shares of restricted common stock				100,000																		200,000
Other Common Stock Issuances [Member] | Investor relation consultant [Member]
Subsidiary or Equity Method Investee [Line Items]
Shares of restricted common stock																				25,000	100,000
Other Common Stock Issuances [Member] | Inducement to Enter into Agreement [Member]
Subsidiary or Equity Method Investee [Line Items]
Shares of restricted common stock																				100,000
Convertible Note to Common Stock [Member]
Subsidiary or Equity Method Investee [Line Items]
Shares of restricted common stock										40,154	135,394
Principal amount	$ 20,000	$ 100,000	$ 40,000		$ 75,882	$ 50,000		$ 100,000		$ 20,000								$ 42,055						$ 75,000	$ 50,000
Convertible note into conversion shares common stock	63,012	315,060	126,024		100,000	63,963		315,060		56,738								55,421						95,945	46,066
Convertible note, percentage	10.00%	10.00%	10.00%		10.00%	10.00%		10.00%		10.00%								10.00%						10.00%	10.00%

Shareholders' Equity (Details_2

Shareholders' Equity (Details Narrative 1) - USD ($)	May 16, 2018	Feb. 20, 2018	May 17, 2017	Dec. 31, 2019
Amended Convertible Note [Member]
Subsidiary or Equity Method Investee [Line Items]
Preferred stock majority voting rights, description		(i) all accrued interest on the unpaid principal amount through December 31, 2017 and (ii) $25,000 in principal within 5 business days of the date of the Amendment. The Company agrees to issue 15,000 shares of restricted Company common stock as an inducement for this amendment within 10 business days of the date of the Amendment. The principal amount of the note will be reduced to $125,000. Unless extended by the Company, converted or prepaid earlier, all unpaid principal and unpaid accrued interest on this Note shall be due and payable on August 20, 2018 (the "Maturity Date"). All provisions related to conversion of the Note into equity securities of the Company are hereby deleted.
Shares of restricted common stock		15,000
Series B Preferred Shares [Member]
Subsidiary or Equity Method Investee [Line Items]
Preferred conversion, description				Based on the current conversion price, the Series B Preferred Shares are convertible into 13,784,201 shares of common stock. A fundamental transaction means: (i) our merger or consolidation with or into another entity, (ii) any sale of all or substantially all of our assets in one transaction or a series of related transactions, (iii) any reclassification of our Common Stock or any compulsory share exchange by which Common Stock is effectively converted into or exchanged for other securities, cash or property; or (iv) sale of shares below the preferred stock conversion price. Each Series B Preferred Share will automatically convert into common stock upon the earlier of (i) notice by the Company to the holders that the Company has elected to convert all outstanding Series B Preferred Shares at any time on or after May 12, 2018; or (ii) immediately prior to the closing of a firmly underwritten initial public offering (involving the listing of the Company's Common Stock on an Approved Stock Exchange) pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale of the Common Stock for the account of the Company in which the net cash proceeds to the Company (before underwriting discounts, commissions and fees) are at least fifty million dollars ($50,000,000).
Gross proceeds from sold on shares			$ 1,875,000
Unsecured convertible promissory note			$ 500,000
Convertible preferred shares			1,536,658
Preferred shares are convertible into common stock			7,318,084
Price, per share			$ 0.325
Accredited investors an aggregate shares			5,781,426
Class A Preferred Stock [Member]
Subsidiary or Equity Method Investee [Line Items]
Preferred conversion, description				The Company issued a total of 1,000,000 shares of its Class A Preferred Stock. The Class A Preferred Stock included super majority voting rights and were convertible into 60% of the Company’s common stock. During the third quarter of 2017, the Company modified the conversion rate on the Class A Preferred Stock to a 1:1 ratio. This modification reduced the amount of potentially dilutive Convertible Series A Stock by 15,746,127 shares to a total of 1,000,000 at September 30, 2017.
Series B Preferred Stock Purchase Agreement [Member]
Subsidiary or Equity Method Investee [Line Items]
Price, per share			$ 0.325
Warrants issue			462,195
Second Amendment Agreement [Member]
Subsidiary or Equity Method Investee [Line Items]
Preferred conversion, description	Convertible Promissory Note with the holder of a 10% fixed secured convertible promissory note. The new Maturity Date is November 16, 2018. The new interest rate is 5%. The note is prepayable at 120% of the unpaid balance upon 10 business days' notice to the holder, which has the option to convert, in whole or in part, during the notice period. The conversion price shall be equal to a 40% discount to the lowest one-day Volume Average Weighted Price ("VWAP") during the 30 trading days preceding such conversion.

Shareholders' Equity (Details_3

Shareholders' Equity (Details Narrative 2) - USD ($)	1 Months Ended		12 Months Ended
	May 17, 2017	Oct. 31, 2015	Dec. 31, 2019	Dec. 31, 2018	Aug. 23, 2017	May 12, 2017
Subsidiary or Equity Method Investee [Line Items]
Debt description			In connection with the Merger, the Company assumed a $400,000 Senior Secured Convertible Debenture (the "Convertible Debenture") (See Note 5). The Convertible Debenture will mature on July 31, 2021 and bears interest at a rate of 10% per annum, payable by the Company to the Lender. In the event that Lender elects to convert the Convertible Debenture into Helix Common Stock or in the event Helix required the Lender to convert the Convertible Debenture into its Common Stock, the number of shares that shall be issuable upon full Conversion of the Convertible Debenture at any time shall be equal to the outstanding principal of the Convertible Debenture divided by $1.00.
Series B Preferred Stock [Member]
Subsidiary or Equity Method Investee [Line Items]
Preferred stock, shares authorized					17,000,000	9,000,000
Preferred stock, par value						$ 0.001
Preferred stock original issue price			$ 0.3253815
Net cash proceeds				$ 50,000,000
Traded common stock, price	$ 3.98
Beneficial conversion feature				$ 22,202,194
Debt description		The Company issued a total of 1,000,000 shares of its Class A Preferred Stock. The Class A Preferred Stock included super majority voting rights and were convertible into 60% of the Company’s common stock. During the third quarter of 2017, the Company modified the conversion rate on the Class A Preferred Stock to a 1:1 ratio. This modification reduced the amount of potentially dilutive Convertible Series A Stock by 15,746,127 shares to a total of 1,000,000 at September 30, 2017.

Stock Options (Details)

Stock Options (Details) - $ / shares	9 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2019
Dividend yield	0.00%	0.00%
Maximum [Member]
Exercise Price	$ 2.09	$ 2.59
Fair value of company's common stock	$ 1.90	$ 2.35
Expected volatility	253.52%	191.00%
Risk Free interest rate	2.59%	2.51%
Expected life (years) remaining	10 years	9 years 2 months 19 days
Minimum [Member]
Exercise Price	$ 1.90	$ 0.435
Fair value of company's common stock	$ 0.90	$ 0.435
Expected volatility	186.64%	110.00%
Risk Free interest rate	2.35%	1.55%
Expected life (years) remaining	4 years 2 months 27 days	2 years 11 months 1 day

Stock Options (Details 1)

Stock Options (Details 1) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Shares Underlying Options
Beginning Outstanding, Shares Underlying Options	8,730,956	414,854
Granted, Shares Underlying Options	3,075,000	490,000
Options assumed pursuant to acquisition – BioTrackTHC Stock Plan		3,841,492
Options assumed pursuant to acquisition – Management Awards		4,290,918
Exercised, Shares Underlying Options	(188,575)	(226,822)
Forfeited and expired, Shares Underlying Options		(79,486)
Ending Outstanding, Shares Underlying Options	11,617,381	8,730,956
Vested options, Shares Underlying Options	9,339,881
Weighted Average Exercise Price
Beginning Outstanding, Weighted Average Exercise Price	$ 0.671	$ 0.001
Granted, Weighted Average Exercise Price	2.106	1.916
Options pursuant to acquisition, Weighted Average Exercise Price		0.790
Options assumed pursuant to acquisition – Management Awards, Weighted Average Exercise Price		0.439
Exercised, Weighted Average Exercise Price	0.261	0.001
Forfeited and expired, Weighted Average Exercise Price		0.001
Ending Outstanding, Weighted Average Exercise Price	0.807	$ 0.671
Vested options, Weighted Average Exercise Price	$ 0.716
Weighted Average Remaining Contractual Term
Outstanding, Weighted Average Remaining Contractual Term (in years)	2 years 5 months 9 days	2 years 5 months 1 day
Granted, Weighted Average Remaining Contractual Term (in years)	5 years 6 months 21 days	8 years 10 months 3 days
Options assumed pursuant to acquisition, Weighted Average Remaining Contractual Term (in years)		1 year 10 months 3 days
Options assumed pursuant to acquisition – Management Awards, Weighted Average Remaining Contractual Term (in years)		2 years 4 months 2 days
Exercised, Weighted Average Remaining Contractual Term (in years)	6 months 25 days	1 year 6 months
Outstanding, Weighted Average Remaining Contractual Term (in years)	3 years 2 months 16 days	2 years 5 months 9 days
Vested options, Weighted Average Remaining Contractual Term (in years)	1 year 8 months 19 days

Stock Options (Details Narrativ

Stock Options (Details Narrative) - $ / shares

Dec. 02, 2019

Nov. 01, 2019

May 02, 2019

Mar. 15, 2019

Feb. 06, 2019

Jun. 01, 2018

Mar. 06, 2018

Jun. 02, 2017

Dec. 27, 2019

Jun. 30, 2019

Jun. 30, 2019

May 31, 2019

Mar. 19, 2019

Sep. 30, 2017

Options to purchase on shares

100,000

414,854

Common stock at price per share

$ 1.51

$ 0.001

Options to purchase issued shares

207,427

Vesting of remaining shares

207,427

207,427

Options term, description

These options vested on May 6, 2019 and have an expiration date of February 6, 2024.

The options have an expiration date of 36 months from the closing date. The exercise price will be based on the fair market value of the share on the date of grant.

These options shall vest over a period ranging from September 2019 to June 2020 and have expiration dates ranging from May 2024 to June 2024.

Options granted shares

414,854

Previously issued options cancelled

79,486

Investor [Member]

Options to purchase on shares

50,000

50,000

125,000

Common stock at price per share

$ 0.535

$ 0.435

$ 2.03

Vesting of remaining shares

62,500

Options term, description

These options shall expire on December 1, 2022.

These options shall expire on November 1, 2022.

The options shall vest immediately and 62,500 of the options shall vest on August 2, 2019 provided the marketing agreement between the Company and grantee has not been terminated. These options shall expire on May 1, 2024.

BioTrackTHC [Member]

Options to purchase on shares

1,730,000

Common stock at price per share

$ 0.52

Options to purchase issued shares

8,132,410

Vesting of remaining shares

432,500

Options term, description

The options shall vest immediately and 432,500 of the options shall vest on June 27, 2020, December 27, 2020 and June 27, 2021. These options shall expire on December 27, 2024.

Equity ownership percentage

48.00%

Minimum [Member]

Common stock at price per share

$ 1.05

$ 1.05

Minimum [Member] | BioTrackTHC [Member]

Pursuant to options exercisable price per share

0.001

Maximum [Member]

Common stock at price per share

$ 2.03

$ 2.03

Maximum [Member] | BioTrackTHC [Member]

Pursuant to options exercisable price per share

1.66

Chief Financial Officer [Member]

Options to purchase on shares

300,000

Options term, description

These options shall vest over a three-year period from March 2020 to March 2022 and have expiration dates ranging from March 2024 to March 2029.

Chief Financial Officer [Member] | Minimum [Member]

Common stock at price per share

$ 2.35

Chief Financial Officer [Member] | Maximum [Member]

Common stock at price per share

$ 2.59

Zachary Venegas [Member]

Options to purchase on shares

490,000

500,000

Options term, description

These options vested on June 28, 2018 and have expiration dates ranging from March 2023 to March 2028.

These options shall vest over a three-year period from March 2020 to March 2022 and have expiration dates ranging from March 2024 to March 2029.

Zachary Venegas [Member] | Minimum [Member]

Common stock at price per share

$ 1.90

$ 2.35

Zachary Venegas [Member] | Maximum [Member]

Common stock at price per share

$ 2.09

$ 2.59

Employee One [Member]

Options to purchase on shares

170,000

50,000

Warrant Liability (Details)

Warrant Liability (Details) - USD ($)	Jan. 10, 2019	Dec. 31, 2019	Dec. 31, 2018
Par value of common stock issues		$ 0.001	$ 0.001
Warrant [Member]
Proceeds from January investment units	$ 1,129,700
Par value of common stock issues	$ (1,255)
Fair value of warrants	$ (1,717,506)
Warrant [Member] | January 10, 2019 Issuance [Member]
Total loss on issuance of warrants	$ (589,061)

Warrant Liability (Details 1)

Warrant Liability (Details 1) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Summary of warrant activity
Warrant Shares, Balance	3,418,184	2,732,073
Warrant Shares, Warrants granted	1,694,874	686,111
Warrant Shares, Balance	5,113,058	3,418,184
Weighted Average Exercise Price, Balance at beginning	$ 0.23	$ 0.23
Weighted Average Exercise Price, Warrants granted	1.17	0.21
Weighted Average Exercise Price, Balance at ending	$ 0.55	$ 0.23

Warrant Liability (Details 2)

Warrant Liability (Details 2) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Fair value of company's common stock	$ 0.60	$ 0.90
Dividend yield	0.00%	0.00%
Expected volatility		175.00%
Risk free interest rate		2.49%
Expected life (years)	2 years 9 months 29 days	1 year 7 months 24 days
Fair value of financial instruments - warrants	$ 715,259	$ 896,171
Minimum [Member]
Expected volatility	45.00%
Risk free interest rate	1.55%
Maximum [Member]
Expected volatility	140.00%
Risk free interest rate	1.79%

Warrant Liability (Details 3)

Warrant Liability (Details 3) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Summary of warrants
Beginning Balance	$ 896,171	$ 2,429,569
Fair value of warrants issued	3,632,065
Change in fair value of liability to issue warrants	(3,812,977)	(1,641,398)
Ending Balance	$ 715,259	$ 896,171

Warrant Liability (Details Narr

Warrant Liability (Details Narrative) - USD ($)

Nov. 02, 2019

Oct. 11, 2019

Sep. 16, 2019

Aug. 15, 2019

Jun. 14, 2019

Mar. 05, 2019

Mar. 02, 2019

Jan. 10, 2019

Dec. 12, 2018

Dec. 26, 2019

Jun. 24, 2019

Mar. 31, 2019

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Warrants exercise price

$ 0.55

$ 0.23

$ 0.23

Fair value of the warrant liability

$ 715,259

$ 896,171

Change in fair value of warrant liability

(3,812,977)

(1,533,398)

Compensation expense

1,783,939

$ 3,002,648

Second Investment Agreement [Member]

Fair value of the warrant liability

26,881

Change in fair value of warrant liability

(56,705)

Investment unit purchase agreement, description

The Company sold an aggregate of 166,667 units of the Company’s securities to an investor at a purchase price of $0.90 per unit for total proceeds of $150,000. In connection with the Second Investment Agreement, the investor is entitled to purchase from the Company, at the exercise price, at any time on or after 90 days from the issuance date, 83,333 shares of the Company’s common stock (the “June Warrant Shares”).

Stock issued

$ 150,000

Stock issued, shares

166,667

Purchase price per share

$ 0.90

Fair value warrant shares at issuance

$ 83,586

Investment Unit Purchase Agreement [Member]

Investment unit purchase agreement, description

The Company entered into another Investment Unit Purchase Agreement (the “Second Investment Agreement”) to issue and sell investment units to an investor (the “investor”), in which the investment units consist of one share of the common stock of the Company, and a warrant exercisable for one half share of common stock of the Company at an exercise price of $1.25 per share for cash at a price per investment unit of $0.90

Note Eleven [Member]

Fair value of the warrant liability

$ 18,542

9,130

Change in fair value of warrant liability

(9,412)

Stock issued

$ 25,000

Purchase price per share

$ 1

Description of warrant exercise term

Exercise of the purchase rights represented by the warrant may be made, in whole or in part, at any time or times on or after August 15, 2019 and on or before August 15, 2024, by delivery to the Company of the Notice of Exercise.

Note Twelve [Member]

Fair value of the warrant liability

$ 17,683

9,194

Change in fair value of warrant liability

(8,489)

Stock issued

$ 25,000

Purchase price per share

$ 1

Description of warrant exercise term

Exercise of the purchase rights represented by the warrant may be made, in whole or in part, at any time or times on or after September 16, 2019 and on or before September 16, 2024, by delivery to the Company of the Notice of Exercise.

Note Thirteen [Member]

Fair value of the warrant liability

$ 11,443

9,236

Change in fair value of warrant liability

$ (2,207)

Stock issued

$ 25,000

Purchase price per share

$ 1

Description of warrant exercise term

Exercise of the purchase rights represented by the warrant may be made, in whole or in part, at any time or times on or after October 11, 2019 and on or before October 11, 2024, by delivery to the Company of the Notice of Exercise.

Note Fourteen [Member]

Warrant issued to purchase shares of common stock

12,500

Warrants exercise price

$ 1

Warrants, description

At inception, November 1, 2019, the fair value of the warrant liability was $37,889, which was recognized as a loss in earnings for the year ended December 31, 2019. As of December 31, 2019, the fair value of the warrant liability was $40,063 and the Company recorded a change in fair value of the warrant liability of $2,174 related to the warrants for the year ended December 31, 2019.

Description of warrant exercise term

Exercise of the purchase rights represented by the warrant may be made, in whole or in part, at any time or times on or after December 26, 2019 and on or before December 26, 2024, by delivery to the Company of the Notice of Exercise.

Note Fiftteen [Member]

Warrants, description

At inception, December 26, 2019, the fair value of the warrant liability was $5,268 while as of December 31, 2019, the fair value of the warrant liability was $4,687. Accordingly, the Company recorded a change in fair value of the warrant liability of $(581) related to Note Fourteen for the year ended December 31, 2019.

Warrant [Member]

Warrant issued to purchase shares of common stock

575,000

Warrant exercisable, description

A warrant exercisable for one half share of common stock of the Company at an Exercise Price of $1.25 per share for cash at a price per investment unit of $0.90.

Warrant is exercisable at any time on or after 90 days from the issuance date until the four-year anniversary issuance date. Each December Warrant is exercisable at a price of $1.25 per one half of one share of common stock (thereby requiring the exercise of two warrants to purchase one share of common stock).

Warrants, description

The Company sold an aggregate of 1,255,222 units of the Company’s securities to an investor at a purchase price of $0.90 per unit for total proceeds of $1,129,700. In connection with the First Investment Agreement, the investor is entitled to purchase from the Company, at the Exercise Price, at any time on or after 90 days from the issuance date, 627,611 shares of the Company’s common stock (the “March Warrant Shares”).

The gross proceeds from the 1,255,222 investment units at $0.90 was $1,129,700. The fair value of the March Warrant Shares at issuance was $1,717,506. The amount to be recognized as a loss in earnings is calculated as follows:

The Company sold an aggregate of 222,222 units (the “December 2018 Units”) of the Company’s securities to an investor at a purchase price of $0.90 per unit for total proceeds of $200,000. Each December 2018 Unit consists of one share of the Company’s common stock and a warrant (“December Warrant”) exercisable to purchase one half of one share of common stock of the Company. As of December 31, 2019, the warrants granted were not exercised.

At inception, December 12, 2018, the fair value of the warrant liability was $108,000 while as of December 31, 2019 and 2018, the fair value of the warrant liability was $33,100 and $92,000, respectively. Accordingly, the Company recorded a change in fair value of the warrant liability of $(58,900) and $(16,000) related to the warrants for the years ended December 31, 2019 and 2018, respectively.

Issued warrants to purchase restricted shares

100,000

Warrant purchase price

$ 0.90

Fair value of the warrant liability

$ 198,148

$ 193,753

Consulting agreement shares of common stock

50,000

Compensation expense

$ 943,000

Warrant [Member] | Note Ten [Member]

Warrant issued to purchase shares of common stock

100,000

160,715

Warrants exercise price

$ 0.435

$ 1.40

Warrants, description

At inception, March 1, 2019, the fair value of the warrant liability was $355,847 while as of December 31, 2019, the fair value of the warrant liability was $54,620. Accordingly, the Company recorded a change in fair value of the warrant liability of $(301,227) related to Note Ten for the year ended December 31, 2019.

Change in fair value of warrant liability

$ (1,523,753)

Warrant [Member] | Note Fourteen [Member]

Warrant issued to purchase shares of common stock

812,073

Warrants exercise price

$ 0.325

Change in fair value of warrant liability

$ 676,144

$ 1,625,398

Warrant [Member]

Fair value of the warrant liability

24,504

Change in fair value of warrant liability

$ (173,644)

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - shares	Nov. 01, 2015	Sep. 01, 2015	Oct. 17, 2017	Oct. 22, 2014	Dec. 31, 2019	Dec. 31, 2018
Defined Benefit Plan Disclosure [Line Items]
Granted, weighted average remaining contractual term (in years)					5 years 6 months 21 days	8 years 10 months 3 days
Stock options granted					3,075,000	490,000
Biotrackthc [Member]
Defined Benefit Plan Disclosure [Line Items]
Reserved for issuance of common stock				600,000
Stock option, description	BioTrackTHC’s Board approved individual employee option grants (the “Executive Grants”) for three executives (the “Executives”). Pursuant to the Executive Grants, the Executives were each granted stock options to purchase 146,507 shares (totaling 439,521 shares) of BioTrackTHC’s common stock (the “Option”) at an exercise price equal to approximately $7.67. The options vest as to 25% of the shares subject to the Options, one year after the date of grant and then in equal quarterly installments for the three years thereafter, subject to the Executive’s continued employment with BioTrackTHC	BioTrackTHC’s Board approved individual employee option grants (the “Executive Grants”) for three executives (the “Executives”). Pursuant to the Executive Grants, the Executives were each granted stock options to purchase 146,507 shares (totaling 439,521 shares) of BioTrackTHC’s common stock (the “Option”) at an exercise price equal to approximately $7.67. The options vest as to 25% of the shares subject to the Options, one year after the date of grant and then in equal quarterly installments for the three years thereafter, subject to the Executive’s continued employment with BioTrackTHC		BioTrackTHC approved and adopted the BioTrackTHC Stock Plan. The BioTrackTHC Stock Plan set aside and reserved 600,000 shares of BioTrackTHC's common stock for grant and issuance in accordance with its terms and conditions.
2017 Omnibus Incentive Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Reserved for issuance of common stock			5,000,000
Granted, weighted average remaining contractual term (in years)			10 years
Stock options granted					2,599,945	1,004,945

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Tax carryforward, description	These amounts are available for carryforward for use in offsetting taxable income of future years through 2035.
Percentage of valuation reserve deferred tax benefit	100.00%
Net operating loss carry forward	$ 18,025,000	$ 12,686,000

Commitments and Contingencies_2

Commitments and Contingencies (Details)	12 Months Ended
	Dec. 31, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
Operating lease expense	$ 513,008
Cash paid for amounts included in the measurement of operating lease liabilities	389,380
ROU assets obtained in exchange for operating lease obligations	$ 1,499,752

Commitments and Contingencies_3

Commitments and Contingencies (Details 1) - Operating Lease [Member]	12 Months Ended
	Dec. 31, 2019USD ($)
Other assets	$ 1,091,065
Accounts payable and accrued liabilities	373,710
Other long-term liabilities	783,230
Total lease liabilities	$ 1,156,940
Weighted average remaining lease term (in years)	2 years 10 months 28 days
Weighted average discount rate	6.00%

Commitments and Contingencies_4

Commitments and Contingencies (Details 2) - Operating Lease Liability [Member]	Dec. 31, 2019USD ($)
2020	$ 393,413
2021	248,223
2022	195,144
2023	200,944
2024	205,435
Thereafter
Total future minimum lease payments	1,243,159
Less imputed interest	(86,219)
Total	$ 1,156,940

Commitments and Contingencies_5

Commitments and Contingencies (Details 3) - Noncancelable operating leases [Member]	Dec. 31, 2019USD ($)
2020	$ 420,291
2021	275,223
2022	198,144
2023	199,144
2024	205,135
Thereafter
Total	$ 1,297,937

Commitments and Contingencies_6

Commitments and Contingencies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Operating lease, rent expense	$ 561,530	$ 362,607
Lease agreement expires date	Mar. 31, 2022
Additional operating lease obligations	$ 600,000
Lease term	3 years

Segment Reporting (Details)

Segment Reporting (Details) - USD ($)		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018
Cost of revenue		$ 8,178,137	$ 5,969,039
Gross profit		7,113,963	3,594,534
Total operating expenses		17,336,828	14,316,184
Total other income		642,696	2,755,848
Total net loss		(9,580,169)	(7,965,802)
Security and guarding [Member]
Revenue		5,022,436	4,889,472
Cost of revenue		4,004,881	3,618,173
Gross profit		1,017,555	1,271,299
Total operating expenses	[1]	7,174,866	11,101,635
Loss from operations		(6,157,311)	(9,830,336)
Total other income		553,612	3,029,392
Total net loss		(5,603,699)	(6,800,944)
Systems installation [Member]
Revenue		783,192	499,138
Cost of revenue		854,801	531,567
Gross profit		(71,609)	(32,429)
Total operating expenses		545,474	168,159
Loss from operations		(617,083)	(200,588)
Total other income		88,903	(273,642)
Total net loss		(528,180)	(474,230)
Software [Member]
Revenue		9,486,472	4,174,963
Cost of revenue		3,318,455	1,819,299
Gross profit		6,168,017	2,355,664
Total operating expenses		9,616,488	3,046,390
Loss from operations		(3,448,471)	(690,726)
Total other income		181	98
Total net loss		$ (3,448,290)	$ (690,628)
[1]	Total operating expenses for the years ended December 31, 2019 and 2018 contained certain corporate expenditures totaling $5,399,184 and $8,687,900, respectively, which benefit all segments of the business but are not specifically allocable to any one segment.

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)	Feb. 10, 2020	Mar. 31, 2020	Feb. 29, 2020	Jan. 28, 2020
Forfeited vested and unexercised stock options			1,634,670
Securities Purchase Agreement [Member]
Shares of restricted common stock issued				270,270
Warrants to purchase shares of restricted common stock				135,135
Aggregate purchase price				$ 100,000
Warrants exercisable price				$ 0.40
Expire maturity date, description				The warrants are exercisable at $.40 per warrant and expire four years after issuance.
Secured Convertible Promissory Note [Member]
Principal amount		$ 120,000	$ 140,000
Issued shares of common stock		1,084,186	435,554
Percentage of fixed secured convertible promissory note		10.00%	25.00%
Future Receipts Agreement [Member]
Subsequent events, description	Pursuant to the terms and conditions of the Future Receipts Agreement, the Company sold to Advantage 15% of the proceeds of future sales made by the Company, up to $660,000 (“Future Sales Amount”), for an immediate cash payment by Advantage of $500,000 (“Purchase Price”). The Future Receipts Agreement includes an origination fee of $15,000, which was deducted from the Purchase Price, and weekly payments of $15,000 for eight weeks followed by weekly payments of $20,000 to be made by the Company to Advantage until the Future Sales Amount is paid in full.